Expression and regulation of zinc-alphaâ‚‚-glycoprotein in rodent adipose tissue by Tzanavari, Theodora
Expression and regulation o f zinc-alpha2-glycoprotein 
in rodent adipose tissue
Thesis submitted in accordance with the requirements o f the University o f Liverpool 
for the degree o f Doctor in Philosophy by Theodora Tzanavari.
January 2007
" Copyright © and Moral Rights for this thesis and any 
accompanying data (where applicable) are retained by the 
author and/or other copyright owners. A copy can be 
downloaded for personal non-commercial research or study, 
without prior permission or charge. This thesis and the 
accompanying data cannot be reproduced or quoted 
extensively from without first obtaining permission in 
writing from the copyright holder/s. The content of the 
thesis and accompanying research data (where applicable) 
must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the 
copyright holder/s. When referring to this thesis and any 
accompanying data, full bibliographic details must be given, 
e.g. Thesis: Author (Year of Submission) "Full thesis title", 
University of Liverpool, name of the University Faculty or 
School or Department, PhD Thesis, pagination."
Declaration
I declare that the research reported in this thesis has been carried out by myself at the 
Division of Cellular and Metabolic Medicine, University o f Liverpool, and help which 
was received for any part o f the work has been duly acknowledged. I believe that the 
contents o f this thesis are wholly original, except where references are made. The work 
reported in this thesis has not been presented for any other degree.
Theodora Tzanavari 




I would like to thank the following people for their assistance in completing this work:
My supervisors Dr Chen Bing and Professor Paul Trayhurn for providing the required 
resources and unlimited supervision and patience during the practical and written part o f 
this thesis.
Dr. Stuart Wood for his practical support and advice.
Mr. Leif Hunter for his continued practical advice and patience.
Andy for his help and the staff o f the Bioresources Unit for their work in providing and 
maintaining animals.
Dr. Bohan Wang for her advice and the kind donation o f tissues.
Dr. Sarah Dutton for her useful advice and friendship throughout this work.
All the members o f my group for making this work a big pleasure and for the useful 
conversations.
Dr Nikos Migas for his support and his help with the final editing o f this thesis.
My family for their love and support.
i l l
Abbreviations
a-M SH a-melanocyte-stimulating hormone
ACE angiotensin-converting enzyme
AGT angiotensinogen
ASP acylation stimulating protein
BAT brown adipose tissue
BCA bicinchoninic acid
BMI body mass index
BSA bovine serum albumin
cAMP cyclic adenosine monophosphate
C/EBP CCAAT/enhancer binding proteins
CN S central nervous system
C N TF ciliary neurotrophic factor
CO X cyclooxygenase
CPE carboxypeptidase E
CRBP cellular retinol binding protein
CRP c-reactive protein
D IT diet induced thermogenesis
DM EM dulbecco’s modified eagle’s medium
DNA deoxyribonucleic acid
D T T dithiothreitol
ECL enhanced chemiluminescence
ED TA ethlyenediaminetetraacetic acid
EGF epidermal growth factor
FCS foetal calf serum
F FA free fatty acid
FGF fibroblast growth factor




HEPES (4-(2-hydroxyethyl)piperazine-1 -ethanesulphonic acid)
HIF-1 hypoxia-inducible factor-1
hMADs human multipotent adipose-derived stem cells
HRP horse radish peroxidase
HSL hormone sensitive lipase
IBM X 3-isobutyl- 1-methylxan thine
IFN-y interferon-y
IGF-1 insulin-like growth factor-1
IGFBPs insulin-like growth factor binding proteins
IL- interleukin-
JAK/STAT janus kinase/ signal transducer and activator o f transcription
LD L low-density lipoprotein
LIF leukaemia-inhibitory factor
LMF lipid mobilizing factor
LPL lipoprotein lipase
LPS lipopolysaccharide
M C4R melanocortin 4 receptor
MCP-1 chemokine monocyte chemoattractant protein 1
M H C major histocompatibility complex
MIF macrophage migration inhibitory factor
M SH melanocyte-stimulating hormone
M T metallothionein
NCBI national center for biotechnology information
NEAT nonexercise activity thermogenesis
NGF nerve growth factor
NPY neuropeptide Y
N ST non-shivering thermogenesis
PAI-1 plasminogen activator inhibitor-1
PBS phosphate buffered saline
PCR polymerase chain reaction
V
PG- prostaglandin-
PIF proteolysis inducing factor
PKA protein kinase A
PPAR peroxisome proliferator activated receptor
PO M C pro-opiomelanocortin
RAR retinoic acid receptor
RAS renin-angiotensinogen system
RBP retinol binding protein
REE resting energy expenditure
RNA ribonucleic acid
RT reverse transcription
SAA serum amyloid A
SDS sodium dodecyl sulphate
SEM standard error o f the mean





TGF-ß transforming growth factor-ß
T  ris-HCl trizma hydrochloride; tris [hydroxymethyl]-aminomethane 
hydrochloride
T Z D thiazolidinedione
TN F- tumour necrosis factor­
UCP uncoupling protein
u v ultra violet
VEGF vascular endothelial factor







Table o f contents vii
List o f  figures xii
List o f tables X V
Abstract xvi
Chapter  l In tr o d u ctio n 1
1.1 Adipose tissue anatomy 2
l . l . l Adipose tissue morphology 2
1.1.2 Adipocyte differentiation and development 3
1.1.3 Function o f WAT 6
1.1.3.1 WAT metabolism: lipolysis and lipogenesis 6
1.1.4 BAT function 8
1.1.5 Adipose tissue and adipocyte studies 9
1.2 Energy balance 11
1.2.1 Obesity 12
1.2.1.1 Epidemiology of obesity 12
1.2.1.2 Obesity as a medical problem 13
1.2.1.3 Obesity as an inflammatory state 14
1.2.1.4 Study of obesity: Genetic models 15
1.2.2 Cancer cachexia 17
1.2.2.1 Pathogenesis of cancer cachexia 17
1.2.2.2 Pathogenesis of cancer cachexia in adipose tissue 19
1.2.2.3 Mediators of cancer cachexia 19
1.3 Endocrine function o f adipose tissue 22
1.3.1 Free fatty acids and steroid secretions o f WAT 22
1.3.2 Leptin 24
1.3.2.1 Regulation of leptin expression and production 24
1.3.2.2 Functions of leptin 26
1.3.2.3 Leptin receptor 26
1.3.3 Insulin sensitivity and insulin resistance 27
1.3.3.1 Adiponectin 27
1.3.3.1.1 Expression, regulation and function of adiponectin 27




1.3.4.1 Tumour necrosis factor aa (TNFa) 30
1.3.4.2 Interleukins 31
1.3.5 Chemokines 32
1.3.6 Growth factors 33
1.3.7 Haemostatic factors 34
1.3.8 Acute-phase proteins 36
vn
1.3.9 Prostaglandins 37
1.3.9.1 Prostaglandin synthesis 37
1.3.9.2 Prostaglandin receptors 38
1.3.9.3 Prostaglandins in WAT 40
1.3.10 Proteins o f lipid and lipoprotein metabolism 41
1.4 Zinc-<X2-glycoprotein (ZAG) 42
1.4.1 ZAG expression 43
1.4.2 Biological functions o f ZAG 43
1.4.3 ZAG is involved in body weight regulation and is expressed in
adipose tissue 44
1.5 Aims o f this thesis 45
C hapter  2 Materials &  M eth o d s o 47
2.1 Reagents and Equipment 48
2.1.1 Chemical reagents 48
2.1.2 Commercial kits 50
2.1.3 Equipment 50
2.1.4 Software 51




2.3 Mature adipocytes and stromal vascular cell fractionation 56
2.3.1 Reagents 56
2.3.2 Fractionation with collagenase digestion method 57
2.4 3T3-L1 adipocyte cell culture 58
2.4.1 Reagents 58
2.4.2 Cell storage 59
2.4.2.1 Cell generation and maintenance 59
2.4.2.2 Cell passaging and plating 60
2.4.2.3 Cell differentiation 60
2.4.2.4 Cell treatment 60
2.4.2.5 Cell and media collection 61
2.4.3 Light microscopy 61
2.5 Total RNA isolation from cells and tissues using the Trizol - Reagent
method 61
2.5.1 Reagents 61
2.5.2 Trizol - Reagent RNA extraction method 62
2.5.3 TU R BO  DNase treatment o f RNA 63
2.5.3.1 Reagents 63
2.5.3.2 Method 63
2.5.4 RNA quantification 64
2.6 Reverse-transcription polymerase chain reaction (RT-PCR) 64




2.6.2 Polymerase Chain Reaction (PCR) 65
2.6.2.1 PCR primer design 66
2.6.2.2 PCR primer optimization 67
2.6.2.3 Reagents 69
2.6.2.4 Method 69
2.6.3 Agarose gel electrophoresis 69
2.6.3.1 Reagents 70
2.6.3.2 Method 70
2.7 Real-time Polymerase chain reaction (qPCR) -  Taqman system 70
2.7.1 Taqman system description 71
2.7.2 Primers and Taqman probes design and optimisation 73
2.7.3 Preparation of 96 well plates for real-time PCR 76
2.7.3.1 Reagents 76
2.73.2 Method 76
2.7.4 Taqman system real-time PCR machine setup 77
2.7.5 Analysis o f real-time PCR data 78
2.8 Protein detection using western blotting method 78
2.8.1 Protein Isolation 81
2.8.1.1 Protein isolation from frozen tissues 81
2.8.1.1.1 Reagents 81
2.8.1.1.2 Method 81
2.8.1.2 Protein Isolation from TRizol reagent 81
2.8.1.2.1 Reagents 81
2.8.1.2.2 Method 82
2.8.1.3 Protein isolation from 3T3-L1 adipocyte media using TCA precipitation 82
2.8.1.3.1 Reagents 82
2.8.1.3.2 Method 83
2.8.2 Protein quantification by the BCA method 83
2.8.2.1 Reagents and equipment 83
2.8.2.2 Method 83






2.8.4.1 Reagents and equipment 87
2.8.5 Immunological detection of proteins 88
2.8.5.1 Reagents and Equipment 88
2.8.5.2 Ponceau S staining 89
2.8.5.3 Detection method 89
2.8.5.4 Determination of optimal primary antibody dilution 90
2.8.6 Protein quantification from western blotting 91
2.9 Statistical analysis 91
C hapter  3 ZAG E X P R E S S IO N  IN  R O D E N T  A D IP O S E  T IS S U E  A N D  G E N E T IC




3.2.1 Animals and tissues 95
3.2.2 RT-PCR and real-time PCR 96
3.2.3 Western blotting 97
3.2.4 Statistical analysis 97
3.3 Results 97
3.3.1 ZAG expression in adult rodent adipose tissue 97
3.3.1.1 ZAG expression in mouse adipose tissue 97
3.3.1.2 ZAG expression in mature adipocytes and the stromal vascular (SV) fraction
of WAT depots 99
3.3.1.3 ZAG expression in rat adipose tissue 104
3.3.2 ZAG expression levels in rodent models o f obesity 106
3.3.2.1 ZAG gene expression in WAT of lean and ob/ob mice 106
3.3.2.2 ZAG expression in WAT of lean and fa/fa Zucker rats 108
3.4 Discussion 108
C hapter  4 Regulation  of ZAG expression in  m ouse adipose t issu e :




4.2.2 RT-PCR and real-time PCR 118
4.2.3 Western blotting 119
4.2.4 Statistical analysis 119
4.3 Results 120
4.3.1 Effects o f I6h-fasting on ZAG expression in mouse adipose tissue
depots 120
4.3.2 Effects o f high-fat diet on ZAG expression in mouse adipose tissue
depots 128
4.4 Discussion 131
C hapter  5 ZAG expression in 3T3-L1 adipocytes: Regulation  by h o rm o n es ,
INFLAMMATORY CYTOKINES AND PROSTAGLANDINS 135
5.1 Introduction 136
5.2 Methods 138
5.2.1 Cell culture 138
5.2.2 RT-PCR and real-time PCR 139
5.2.3 Statistical analysis 139
5.3 Results 140
5.3.1 ZAG gene expression in 3T3-L1 cells 140
5.3.2 Regulation of ZAG gene expression in 3T3-L1 adipocytes 140
5.3.2.1 Effects of sympathetic agonists on ZAG gene expression 143
5.3.2.2 Effects of peripheral hormones and rosiglitazone on ZAG gene expression 143
5.3.2.3 Effects of inflammatory regulators on ZAG gene expression 147
5.3.3 Regulation of ZAG gene expression by prostaglandins in 3T3-L1
x
adipocytes 147
5.3.3.1 Effects ofPGD 2 and E-series prostaglandins on ZdG gene expression 147
5.3.3.2 Effects of PGE2, PGF2a and PGI2 on ZAG gene expression 151
5.4 Discussion 157




6.2.2 RT-PCR and real-time PCR 167
6.2.3 Western blotting 168
6.2.4 Statistical analysis 168
6.3 Results 169
6.3.1 ZAG expression in the early postnatal period 169
6.3.2 Total body weight and adipose tissue depots during early postnatal
development 172
6.3.3 ZAG expression patterns in adipose tissue postnatally 172
6.3.4 Postnatal expression of ZAG in the liver o f rat neonates 177
6.3.5 Expression patterns o f several adipokines in adipose tissue postnatally 177
6.3.5.1 Gene expression pattern of leptin in rat adipose tissue during postnatal
development 177
63.5.2 Gene expression pattern of adiponectin in rat adipose tissue during postnatal
development 180
63 .53 Gene expression pattern of NGF in rat adipose tissue during postnatal
development 180
63.5.4 Gene expression pattern of MCP-1 in rat adipose tissue during postnatal
development 180
63.5.5 Gene expression pattern of IL-6 in rat adipose tissue during postnatal
development 184
6 3 .6 Comparison o f ZAG mRNA levels in different adipose depots at days
1, 21 and 32 postnatally 184
6.4 Discussion 190
C hapter  7 G eneral D iscussion 196
7.1 Introduction 197
7.2 Previous work 197
7.3 Current study 198
7.4 ZAG expression in adipose tissue 200
7.5 Regulation of ZAG expression in adipose tissue 202
7.6 Future work 205
i n Concluding remarks 207
REFERENCES 208
List of figures
Figure 1.1 Stages o f adipocyte differentiation 5
Figure 1.2 Pathogenesis o f cancer cachexia 21
Figure 1.3 Proteins secreted from white adipose tissue 23
Figure 1.4 Prostaglandin synthetic pathway 39
Figure 2.1 The principle ofTaqm an assay 71
Figure 2.2 Default baseline plot-log and linear view 79
Figure 2.3 Schematic diagram o f protein detection 85
Figure 2.4 Standard curve for protein concentration estimation 80
Figure 3.1 ZAG gene expression in adipose tissue depots o f mice 98
Figure 3.2 Leptin gene expression adipose tissue depots o f mice 100
Figure 3.3 ZAG protein expression in adipose tissue depots o f mice 101
Figure 3.4 ZAG mRNA levels in mature adipocytes and stromal vascular fraction
o f white adipose tissue depots 102
Figure 3.5 ZAG protein expression in mature adipocytes and stromal vascular
fraction of subcutaneous white adipose tissue in mice 103
Figure 3.6 Tissue distribution o f ZAG gene and protein in rat 105
Figure 3.7 ZAG gene expression in white adipose tissue depots o f lean and
ob/ob mice 107
Figure 3.8 ZAG gene expression in white adipose tissue o f lean and obese (fa/fa)
Zucker rats 109
Figure 3.9 ZAG protein expression in retroperitoneal white adipose tissue of
lean and fa /fa  Zucker rats 110
Figure 4.1 Body weight and adipose tissue weight o f mice fasted for 16 h 121
Figure 4.2 ZAG mRNA levels in adipose tissue depots o f mice fasted for 16 h 122
Figure 4.3 ZAG protein expression in epididymal WAT o f mice fasted for 16 h 123
Figure 4.4 ZAG protein expression in perirenal WAT o f mice fasted for 16 h 124
Figure 4.5 ZAG mRNA levels in liver o f mice fasted for 16 h 125
Figure 4.6 Leptin mRNA levels in adipose tissue depots o f mice fasted for 16 h 126
Figure 4.7 Adiponectin mRNA levels in adipose tissue depots o f mice fasted
for 16h 127
Figure 4.8 Effects o f high-fat diet on ZAG mRNA levels 129
Figure 4.9 Effects o f high-fat diet on ZAG protein levels 130
Figure 5.1 Time course o f ZAG gene expression in 3T3-L1 adipocytes 141
xii
Figure 5.2 Time course o f ZAG mRNA levels in 3T3-L1 adipocytes 142
Figure 5.3 Effect o f noradrenaline, isoprenaline and BRL 37344 on ZAG
mRNA levels in 3T3-L1 adipocytes 144
Figure 5.4 Effect o f Insulin and Adiponectin on ZAG mRNA levels in 3T3-L1
adipocytes 145
Figure 5.5 Effect o f rosiglitazone on ZAG mRNA levels in 3T3-L1 adipocytes 146
Figure 5.6 Effect o f Leptin on ZAG mRNA levels in 3T3-L1 adipocytes 148
Figure 5.7 Effect o f LPS, IL-6 and T N F-a on ZAG mRNA levels in 3T3-L1
adipocytes 149
Figure 5.8 Effect o f PGD 2 and J 2 - series prostaglandins on ZAG mRNA levels
in 3T3-L1 adipocytes 150
Figure 5.9 Dose response of AI2-PGj2 on ZAG mRNA levels in 3T3-L1 adipocytes 152
Figure 5.10 Dose response o f PGE2 on ZAG mRNA levels in 3T3-L1 adipocytes 153
Figure 5.11 Dose response o f PGE2 on adiponectin and IL-6 mRNA levels in
3T3-L1 adipocytes 154
Figure 5.12 Dose response o f PGF2a on ZAG mRNA levels in 3T3-L1 adipocytes 155
Figure 5.13 Effect o f PG Lon ZAG mRNA levels in 3T3-L1 adipocytes 156
Figure 6.1 ZAG is expressed in rat adipose tissue at day 1 postnatally and onwards 170
Figure 6.2 Gene expression of leptin and adiponectin in WAT depots and BAT
o f rat neonates 171
Figure 6.3 Developmental changes in body weight and weight o f adipose tissue
depots in rat neonates 173
Figure 6.4 Developmental changes in weight o f WAT depots and BAT relative to
body weight in rat neonates 174
Figure 6.5 ZAG gene expression in adipose tissue depots o f neonatal rats 175
Figure 6.6 ZAG protein levels in adipose tissue depots o f rat neonates 176
Figure 6.7 ZAG gene expression in the liver o f rat neonates 178
Figure 6.8 Leptin gene expression in adipose tissue depots o f neonatal rats 179
Figure 6.9 Adiponectin gene expression in adipose tissue depots o f neonatal rats 181
Figure 6.10 N G F  gene expression in adipose tissue depots o f neonatal rats 182
Figure 6.11 MCP-1 gene expression in adipose tissue depots o f neonatal rats 183
Figure 6.12 IL-6  gene expression in adipose tissue depots o f neonatal rats 185
Figure 6.13 Depot differences in ZAG gene expression in adipose tissue of
neonatal rats 186
Xl l l
Figure 6.14 Depot differences in leptin gene expression in adipose tissue o f 
neonatal rats
Figure 6.15 Depot differences o f adiponectin gene expression in adipose tissue of 
neonatal rats
List of tables
Table 2.1 Sequences o f the primers and the PCR conditions
Table 2.2 Sequences o f primers and Taqman probes o f mouse target genes and 
working conditions for real-time PCR
Table 2.3 Sequences o f primer and Taqman probe sequences o f rat target genes 






Adipose tissue is now recognised as a significant endocrine organ which plays a key role 
in energy balance and metabolic regulation through the secretion o f hormones and other 
protein factors, known as adipokines. The work in this thesis examined the regulation of 
zinc-a2-glycoprotein (ZAG), a novel adipokine, expression in adipose tissue, using a 
combination o f in vivo and cell culture (3T3-L1 adipocytes) approaches.
ZAG, both mRNA and protein, was detected in BAT and in all major white adipose 
tissue (WAT) depots; visceral fat, especially omental, was the main adipose tissue site of 
ZAG synthesis in adult mice. Following collagenase digestion, ZAG was equally detected 
both in mature adipocytes and the stromal vascular fraction o f mouse subcutaneous, 
epididymal and perirenal WAT. Obesity was found to be associated with decreased ZAG 
expression in two rodent models o f genetic obesity (the obi ob mouse and the fa !fa  rat). 
Fasting (I6h) led to a decrease in ZAG mRNA levels in mouse epididymal WAT. ZAG 
was found to be differentially regulated in WAT depots o f mice kept on a high-fat diet 
for 12 weeks; ZAG mRNA levels were increased in epididymal WAT, while decreased in 
the subcutaneous depot, and no changes were found in perirenal WAT. The findings 
suggest that ZAG expression in adipose tissue is subject to dietary regulation with a 
depot-specific pattern.
In vitro, rosiglitazone, a selective PPARy agonist with anti-inflammatory properties, 
induced a dose-dependent increase in ZAG gene expression. Isoprenaline, a ß- 
adrenoreceptor agonist and BRL37344, a selective ß3-adrenoreceptor agonist, were also 
both found to have a small inducing effect on ZAG gene expression; however there 
appears to be only a limited role for the sympathetic system in ZAG regulation. 
Adiponectin led to a 5-fold increase in ZAG gene expression. On the other hand, ZAG 
was downregulated by leptin, while inflammatory agents, such as LPS, T N F a  and IL-6 
had no effect on ZAG expression. The possible role o f prostaglandins on ZAG gene 
expression was also investigated in vitro. While prostaglandin PG D 2 had no effect, the 
PGD 2 metabolites, PGJ2 , 9-deoxy-A9,A12,13,I4-dihydro-PGj2 (A12-PGJ2) and 15-deoxy-
xvi
A12,i4_pGj2 (15d-PGj2), a PPARy ligand and potent anti-inflammatory agent, induced 
major increases in ZAG gene expression; A12-PGJ2 induced a major, dose-dependent 
increase in ZAG expression. In marked contrast, the pro-inflammatory prostaglandins 
PGE2 , which is also known for its antilipolytic properties, and PGF2a induced a 
substantial dose-dependent decrease in ZAG expression in the adipocytes.
Finally, the ontogenic pattern o f ZAG expression in WAT and BAT during early 
postnatal development was examined in female Wistar rats aged 1 to 32 days. Before 
weaning at day 21, white fat was predominantly subcutaneous, the amount increasing 
rapidly after birth. The perirenal and gonadal fat depots were evident by around day 5 
and were increased significantly at weaning. ZAG mRNA and protein were detected from 
day 1 in subcutaneous WAT, which appears to be a key source for its synthesis during the 
suckling period. The relative mRNA and protein levels were unchanged in WAT depots 
until day 21, when both were significantly reduced. ZAG was also detected in BAT at 
day 1, while the expression levels were reduced from day 3 onwards. The downregulation 
o f ZAG expression in WAT depots at weaning and thereafter, when fat mass is expanded 
substantially, suggests that ZAG might be involved in the postnatal development of 
adipose tissue mass
In conclusion, these studies indicate that WAT and BAT synthesize ZAG, and provide 
evidence that the adipokine might be involved in the lipolytic process taking place within 
the tissue. The levels o f ZAG are also influenced under various conditions where energy 
flux changes and by several agents, particularly rosiglitazone and prostaglandins. Finally, 
there is evidence that ZAG is involved in the inflammatory response o f WAT, its role 




1.1 Adipose tissue anatomy
Mammals have two types o f adipocytes, namely white and brown adipocytes, which have 
distinct anatomy and function. These are in turn organized into white and brown adipose 
tissue (WAT and BAT), both tissue types comprising the adipose organ (Cind 2001).
Histologically, white and brown adipocytes are quite distinct. Although both types o f 
adipocytes are spherical, brown adipocytes range in diameter from 10 to 25 pm, while 
white adipocytes can vary from 15 to 150 pm, due to their ability to accumulate different 
amounts o f triglyceride that form a single vacuole in the jaloplasm. In brown adipocytes, 
which are multilocular in terms o f lipid droplets, the nucleus is spherical and situated in 
the centre o f the cell. The cytoplasm is rich in mitochondria, which account for the 
tissue’s brown colour, with well-developed cristae and the lipids are organized in 
numerous vacuoles. In contrast, in white adipocytes, which are unilocular and also 
possess fewer and less-developed mitochondria, the nucleus is located peripherally (Cinti, 
2001).
Apart from morphological changes, there are numerous quantitative differences between 
the two tissues. In contrast to WAT, BAT is characterized by high sympathetic 
innervation and respiratory activity, but has a lower lipid content (30-40%) compared to 
WAT (up to 90%). Furthermore, although most genes which are expressed in WAT are 
also expressed in BAT, the abundance and physiological regulation o f gene products and 
their activity can vary considerably between the two tissues (Klaus, 2001). For example, 
the response o f the two tissues to environmental or nutritional stress can be quite 
opposite, as is the regulation o f the activity and gene expression o f lipoprotein lipase 
(LPL) (Klaus, 2001).
1.1.1 Adipose tissue morphology
The two types o f adipose tissue are organized in discrete depots throughout the body, 
which can broadly be categorized as subcutaneous and visceral. In rodents, the main 
visceral depots are perirenal, mesenteric, omental, retroperitoneal, and epididymal.
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Adipocytes exhibiting the white phenotype can also be found in or around many other 
organs, including the skin, lymph nodes, bone marrow, pancreas, thymus and blood 
vessels (Cinti, 2001). Although specific depots are predominantly white or brown, some 
depots contain both types o f adipocytes, the relative amount o f each type depending on 
age, strain, as well as the nutritional and environmental conditions to which the animal is 
exposed (Cinti, 2001). This concominant existence o f both cell types may reflect the 
ability o f mature adipocytes to transdifferentiate between the two forms, the effect being 
possibly mediated by changes in fb-adrenoreceptor expression level (Cinti, 2005).
However, only 50% o f WAT is composed o f mature adipocytes (Hausman, 1985), the 
rest o f the tissue being the stromal vascular fraction, which consists o f numerous cell 
types, including pre-adipocytes, fibroblasts, histiocytes, mast cells, and capillary 
endothelial cells (Cinti, 2001).
In rats, white adipocytes appear in the perinatal period and the biggest white depot in 
newborns is the subcutaneous depot, visceral fat mass substantially increasing after 
weaning (around day 20) in rodents (Cinti, 2001), as it will be discussed in more detail 
in Chapter 6. In contrast to most mammals, including rodents, where WAT is 
predominantly developed postnatally and is usually below 3% o f body weight at birth, 
human newborns have large amounts o f WAT mainly in the subcutaneous regions. There 
are currently three main explanations for this. The first is that fat compensates for the 
lack o f insulating fur. It has also been suggested that large amounts o f fat may represent 
the increased energy requirements by the brain or that fat is needed by the newborn as it 
is forced to mobilize fat at birth to compensate for the disruption in flow of maternal 
nutritional support at parturition before lactation is established (Klaus, 2001).
1.1.2 Adipocyte differentiation and development
When energy intake exceeds energy expenditure, WAT undergoes an increment. White 
adipocytes enlarge, thus becoming hypertrophic, and subsequently hyperplastic by 
developing more adipocytes from the precursor pool. It is believed that adipocytes can 
only enlarge up to a certain maximal size, which is genetically determined and specific for
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each depot (Girolamo et al., 1998), and that once adipocytes have reached that size, 
hyperplasia is triggered (Faust et al., 1978; Bjorntorp, 1991). Contrary to other cell types, 
the ability to increase the quantity o f fat cells is retained into adulthood (Gregoire, 2001). 
On the other hand, when energy expenditure is greater than energy intake, adipocytes 
release their triacyglycerols in the form of free fatty acids and glycerol. During extreme 
fasting conditions, they give up all stored lipid and can no longer be distinguished from 
preadipocytes, a condition known as hypotrophy (Schling &  Löffler, 2002). There has 
been an ongoing debate on whether totally slimmed-down adipocytes undergo apoptosis 
or not, with the latest report indicating that this is not the case (Cinti, 2005).
Adipocyte differentiation (adipogenesis), the process during which functioning 
adipocytes develop from fibroblast-like cells called adipoblasts, is a multi-step, tightly 
controlled and irreversible process (Ailhaud, 2001). Once adipose tissue is formed, 
adipocytes represent between one-third and two-thirds o f the total number o f cells. As 
illustrated in Figure 1.1, there are many factors involved in each step of the adipogenic 
process, and every step following adipoblasts reaching confluence is characterized by the 
presence o f specific markers. Adipogenesis is triggered by the production of two key 
transcription factors, CCAAT/ enhancer-binding protein a  (CEBPa) and peroxisome 
proliferator-activated receptor y (PPARy), which are responsible for inducing the 
expression o f adipocyte-specific genes (Warne, 2003). Creation of new adipocytes is 
always accompanied by development o f blood vessels and average blood flow to WAT 
can vary from 3 to 30 ml'min'1 ' 100 g tissue'1 (Schling &  Löffler, 2002).
Numerous factors trigger adipocyte differentiation. Dexamethasone, a synthetic 
glucocorticoid increases the production o f prostacyclin, a potent adipogenic factor, and 
glucocorticoids also repress at a transcriptional level the expression of preadipocyte factor- 
1 (pref-1), thus allowing the differentiation process to proceed. Insulin-like growth 
hormone 1 (IGF-1) has also been shown to stimulate adipogenesis together with insulin­
like growth factor binding proteins (IGFBPs). Insulin, which is known for its role in
4
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Schematic representation of multiple stages o f adipocyte differentiation. This is based on 
data obtained from 3T3-L1 and 3T3-F442A adipocytes (adapted from Ailhaud, 2001).
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lipogenesis, as discussed in the following section, also triggers adipogenesis. Furthermore, 
prostaglandin I2 (PGI2) rapidly upregulates the expression o f early transcription factors, 
such as C/EBPP and CEBP5, through activation o f its cell surface receptor (Ailhaud, 
2001) .
In contrast to the above, various factors have been identified which inhibit or abolish 
differentiation o f adipose precursor cells, such as platelet-derived growth factor (PDGF), 
transforming growth factor-p (TGF-P), most possibly fibroblast growth factor (FGF) and 
epidermal growth factor (EGF), retinoids, fat-soluble vitamins and prostaglandin F2a 
(PGF2a) (Ailhaud, 2001).
1.1.3 Function o f WAT
WAT plays several important roles in mammalian physiology, and is essential in the 
maintenance o f energy homeostasis. The classical view o f WAT is that it serves as an 
energy storage site that is mobilized during periods o f food deprivation to release fatty 
acids for oxidation in other organs. WAT also provides thermal insulation, this trait 
being particularly evident in the case o f the blubber o f marine mammals such as seals and 
whales (Trayhurn 6C Beattie, 2001). Fat stores also serve as a source o f water (metabolic 
water), which is important in the case o f some desert and marine mammals (Klaus, 
2001). However, this traditional view of WAT changed in 1994 with the discovery of 
leptin (Zhang et al., 1994). Since then more than fifty WAT protein secreted factors have 
been identified, the number constantly increasing, which are involved in the regulation of 
energy balance and other physiological processes, thus making WAT a very important 
endocrine organ. The major products o f adipose tissue and their functions will be 
discussed later in this chapter.
1.1.3.1 WA T  metabolism: lipolysis and lipogenesis
The two major metabolic processes o f adipose tissue are lipolysis and lipogenesis, fat 
accumulation being determined by the balance between them. In a restricted sense, 
lipogenesis, which takes place in the adipose tissue and the liver, is the de novo synthesis 
o f fatty acids, but in a broader sense, it is the acylation of glycerol with free fatty acids to
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form triacylglycerols (TAGs), which can then be either stored in the adipocyte or 
incorporated into more complex structures such as lipoproteins. LPL is a key enzyme for 
the regulation o f lipogenesis. In adipose tissue, LPL is the rate-limiting enzyme for the 
import o f triglyceride-derived fatty acids into the adipocytes for storage. LPL levels are 
higher in adipose tissue of women compared to men, but the fact that its activity is 
higher in the gluteo-femoral than the abdominal region, explains the difference in fat 
distribution observed between the sexes. Lipogenesis is directly promoted by insulin in 
part by increasing LPL activity in adipose tissue. Insulin which acts through binding to 
its receptor at the surface o f the membrane also stimulates glucose transport into the 
adipocyte by increasing the number o f G LU T4 transporters in the plasma membrane. 
Glucocorticoids, such as cortisol that act though a specific glucocorticoid receptor (GR), 
also stimulate LPL activity, as well, in vitro in the presence o f insulin. Elevated cortisol 
levels can lead to increased accumulation of fat in visceral adipose tissue. However, this 
combined effect o f insulin and cortisol on LPL activity can be totally inhibited by growth 
hormone (GH). Leptin, which will be discussed later, may also contribute to lipogenesis. 
Finally, lipogenesis is very responsive to changes in the diet. While high-fat diets decrease 
lipogenesis, carbohydrates increase lipogenesis in both adipose tissue and liver. LPL 
activity in obesity is increased. Apart from nutrition, exercise and aging also play a role in 
lipogenesis (Boschmann, 2001; Kersten, 2001).
Lipolysis is the process by which triglycerides are broken down into glycerol and non- 
esterified fatty acids (Tisdale, 2002). Lipolysis largely occurs in adipose tissue for the 
mobilization o f fatty acids to serve as a fuel in the body, as well as a precursor for the 
synthesis o f ketone bodies. TAG mobilization is mainly achieved by hormone-sensitive 
lipase (HSL), a key enzyme in the process, located inside the adipocyte. H SL hydrolyzes 
TAGs first into diacylglycerol, then monoacylglycerol and finally glycerol and the 
respective free fatty acids (FFA). FFAs are then transported through blood to the organs 
o f respective destination, mainly liver and muscle. It is believed that the sympathetic 
nervous system (SNS) is the most important mechanism for controlling lipolysis in 
adipose tissue and that neuronal signals derived from it are mediated to the adipocyte and 
the surrounding blood vessels via specific receptors. Catecholamines, including both
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epinephrine and norepinephrine act as physiological receptor-binding ligands and there 
are two types o f catecholamine-binding adrenergic receptors, also called adrenoreceptors, 
the a- and P- adrenergic receptors. All their subtypes (a, (X2, Pi, P2 and P3) are expressed in 
white adipocytes. The P3-adrenoreceptor shares 40-50% amino acid sequence homology 
with the Pi and P2 subtypes (Howe, 1993). All three mediate lipolysis in white adipose 
tissue in mice and rats (Arch et al., 1984), and thermogenesis in BAT (Arch et al., 1989). 
When an agonist binds to a P subtype, adenylyl cyclase is activated and cyclic AMP 
(cAMP) is synthesized. Its increase activates protein kinase A (PKA), which then 
phosphorylates, and thus activates HSL. Insulin inhibits lipolysis stimulated by p 
agonists, whereas G H  significantly increases catecholamine-induced lipolysis. In humans, 
the P2 adrenoreceptor subtype is considered to be the most important in lipolysis and a 
possible role o f P3 has been suggested. As in lipogenesis, factors such as nutrition, exercise 
and aging, also play a role in lipolysis (Boschmann, 2001).
1.1.4 BAT function
In contrast to WAT, which stores energy, BAT is used for the release o f energy in the 
form o f heat. BAT, which is probably unique to mammals (Klaus, 2001), is the first form 
o f adipose tissue to appear during development and is characterised by the expression o f 
uncoupling protein 1 (UCP-1), which is uniquely expressed in this tissue (Dulloo &  
Samec, 2000). This protein is located in the inner mitochondrial membrane and acts by 
uncoupling mitochondrial respiration (Rousser et al., 2004). BAT has a specialised role in 
dissipating energy by thermogenesis. Thermogenesis in general can be categorised as 
either obligatory or regulatory (Pecqueur et al., 2001), the latter being subdivided into 
heat generated by shivering o f skeletal muscles in response to cold, non-shivering 
thermogenesis (NST), physical activity thermogenesis (exercise), non-exercise activity 
thermogenesis (NEAT) and diet- and drug- induced thermogenesis (DIT).
BAT is more highly vascularised than WAT, and is also more densely innervated by the 
SNS, with innervation o f individual adipocytes (Cinti, 2005). Increased sympathetic 
activity in BAT is characterised by both hypertrophic and hyperplastic expansion,
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increased blood flow and utilisation o f lipid and carbohydrate substrates for oxidative 
metabolism (Collins etal., 2001).
At birth, BAT is present in most mammals, including rodents. After birth, the 
surrounding temperature falls and fluids evaporate from the newborn’s skin. This cold 
exposure evokes N ST, which is crucial for the survival o f the newborn. In rodents, it is 
necessary at birth, but also needed at a slightly later stage when pups emerge from the 
nest (Cannon et al., 1988). BAT is also particularly important in animals with a special 
need to generate heat, such as cold-adapted rodents and hibernating mammals. It is also 
present in human newborns, where it has a clear role in generating heat. Although tiny 
amounts o f BAT still exist, the tissue has at best a minor thermoregulatory role in adults 
(Rosen &  Spiegelman, 2000). BAT thermogenesis can also be activated after excess 
dietary energy intake (Klaus, 2001).
The capacity o f BAT for N ST  is determined by the degree o f UCP-1 expression, the 
process being regulated mainly by the SNS basal tone that is modulated in response to 
cold, diet and photoperiod (Dulloo &  Samec, 2000). In rodents, the SNS acts on BAT 
via P3-adrenoreceptor to induce UCP-1 gene expression (Bays, 2004). It is worth 
mentioning at this stage that two UCP-1 homologues, UCP-2 and UCP-3 have been 
identified, the second being primarily expressed in BAT and skeletal muscle. However, 
their participation in metabolic regulation is not fully understood (Dulloo &  Samec, 
2000 ) .
1.1.5 Adipose tissue and adipocyte studies
There are two approaches for the study of adipose tissue, in vitro and in vivo studies. 
Three main in vitro systems are currently available for studying adipocytes. These are 
isolated mature adipocytes, primary culture and clonal cell lines. Mature adipocytes are 
harvested from freshly dissected adipose tissue following collagenase digestion. Although 
mature adipocytes are very fragile and have a very limited life span (usually a maximum 
o f 24 h), they are arguably the most closely related culture system to in vivo adipocytes,
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since they are a fully differentiated heterogeneous pool o f adipocytes directly from the 
source o f interest with the minimum o f experimental intervention.
In primary cultures and clonal cell lines, preadipocytes are converted to mature 
adipocytes once confluent. This is achieved by the addition o f three agents used to induce 
differentiation in vitro. These are insulin, dexamethasone and isobutylmethylxanthine 
(IBMX). While the addition o f insulin mimics the effects o f in vivo insulin and insulin- 
growth factor 1 (IGF-1), dexamethasone is representative o f natural glucocorticoids. 
Finally, IBM X acts to increase intracellular cAMP levels (Rosen &  Spiegelman, 2000).
Primary culture involves the isolation of fibroblastic pre-adipocytes from adipose tissue, 
usually following collagenase digestion, which are then induced to differentiate into 
adipocytes. Their life-span is longer than that o f mature adipocytes and they can be 
maintained in culture for 2-4 weeks. An adequate starting amount o f adipose tissue is 
required, as preadipocytes only make up a small proportion o f total adipose tissue, and 
care is required to ensure that preadipocytes are separated from fibroblasts and other 
stromal vascular cells. However, preadipocytes have a low proliferative capacity. 
Nevertheless, they are a good tool for adipose tissue study, as they are similar to isolated 
mature adipocytes, and are sourced directly from adipose tissue.
Probably the most widely used tool for the study o f adipose tissue is clonal cell lines, such 
as the Swiss mouse 3T3-L1 and 3T3-F442A cells, whose use is well established. In 
particular, the 3T3-L1 fibroblastic cell line provides a unique model for insulin-sensitive 
primary fat cells, as under defined conditions it can be converted to fully differentiated 
adipocytes, characterized by increased insulin receptor number and induction of 
adipogenic specific proteins (Grako et al., 1994). Clonal cell lines have some key 
advantages compared to primary cells. Firstly, they are homogeneous and at the same 
stage o f differentiation, thus allowing for a consistent response to a treatment. In 
addition, they are immortal as long as they are passaged and stored correctly. However, 
their main disadvantage is the fact that they are distant from their original source that has
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resulted in gene translocations and that could possibly affect the expression o f genes 
resulting in unexpected results.
Human multipotent adipose-derived stem cells (hMADs cells), which have recently been 
described (Rodriguez et al., 2004), are the first example o f a human preadipocyte clonal 
cell line. However, due to the lack o f a human cell line until recently, the SGBS human 
preadipocyte cell strain has been increasingly used as a tool for the study o f human 
adipocytes (Wabitsch et al., 2001). SGBS cells are derived from the subcutaneous white 
adipose tissue o f an infant with Simpson-Golabi-Behmel syndrome, a rare disorder 
characterized by tissue overgrowth. The cells are characterized by a high capacity for 
adipose differentiation over many generations, thus providing an almost unlimited source 
o f identical human preadipocytes.
In contrast to in vitro studies, in vivo studies enable the full integrated physiological 
response to a stimulus, such as fasting or cold exposure, to be ascertained. Studies on the 
effects o f certain compounds may also be studied in vivo, using a range of techniques for 
their administration to the animal. These include oral administration (in food/water or 
via gavage), internal administration (by cannulation), and injection (subcutaneously, 
intraperitoneally, intramuscularly, intracutaneously, and intravenously). A key advantage 
of an in vivo study compared to an in vitro one is that in the former the adipocytes can 
interact with neural and endocrine signals and with other cell types that might be present 
in adipose tissue through paracrine signals. In vitro studies on the other hand are better at 
identifying the specific cause leading to a certain effect, as any effect observed is likely to 
be the result o f a specific and direct response to an applied stimulus.
1.2 Energy balance
Basic metabolic processes, physical activity, food consumption and, as previously 
discussed, thermogenesis, all use energy. In order to maintain a constant body weight, 
energy intake must equal energy expenditure. Failure to do so will induce an imbalance, 
which will either result in excess body fat accumulation, if  there is a surplus o f energy, or 
in wasting and cachexia, if there is an energy deficit. Both conditions are accompanied by
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changes both in the morphology and regulation o f adipose tissue, and very importantly 
constitute health threatening conditions. In the following sections, obesity and cachexia, 
with the main focus on cancer-induced cachexia, and the metabolic changes occurring in 
these two conditions, are discussed in detail.
1.2.1 Obesity
When energy intake exceeds energy expenditure, a state o f positive energy is reached 
resulting in weight gain and subsequently obesity. Obesity is defined as a significant 
increase above ideal weight, and is a disease in which excess body fat has accumulated 
such that health may be adversely affected. Clinically, body fat is estimated by using a 
formula that combines weight and height. This is the body-mass index (BMI), which is 
the weight in kilograms divided by the square o f the height in meters. Because o f 
differences in body composition among individuals, BMI may not always correspond to 
the same degree o f fatness, but it is the commonest way of calculating it. A person with a 
BMI between 25.0 and 29.9 is classified as overweight, whereas a person with a BMI 
above 30.0 is classified as obese. In extreme cases where BMI is over 40, a person is 
classified as morbidly obese (Kopelman, 2000).
1.2.1.1 Epidemiology o f obesity
Obesity in modern societies has increased alarmingly, reaching pandemic proportions 
(WHO, 2000). Different surveys have shown a great increase in the prevalence o f obesity 
over time. At the moment, around 65% o f the United States adult population (Daniels, 
2006) and a slightly lower percentage o f the European population are either overweight 
or obese, with a higher percentage o f women. In the U K  the prevalence o f obesity has 
tripled from around 7% to 25% of the adult population since 1980s (Rennie &  Jebb, 
2005). If the current trend continues, by 2030 half o f the British population will be 
obese, these figures reflecting the fact that the prevalence o f obesity in children is 
increasing rapidly (Deckelbaum &  Williams, 2001).
This great recent increase in the percentage o f the population being obese has 
concentrated research on the causes leading to obesity. The leading causes o f obesity,
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however, are complex as they involve the interaction o f many factors. There are an 
estimated 300 genes which influence body weight and it is estimated that genetics 
account for about 30% to 40% of the differences in people’s weight, and predisposition 
to excess weight gain (Jequier &  Tappy, 1999; Barsh et al., 2000; Damcott et a i, 2003), 
but that the environment determines phenotypic expression (Barsh et al., 2000). 
Environmental conditions, such as food availability, cultural norms, and the level o f 
physical activity account for about 70% o f weight differences (Pi-Sunyer, 2002). It is 
suggested that evolution favours fat storage, as human bodies have not yet adapted to 
high-energy food abundance, but instead harbor fat as a safeguard against famine 
(Daniels, 2006).
1.2.1.2 Obesity as a medical problem
Obesity dramatically increases the risk o f developing several other disorders including 
type 2 diabetes, cardiovascular diseases, dyslipidaemia, arthritis, gallstone formation 
(Mokdad et al., 2001), and certain cancers, such as breast, colon, uterus, pancreas, and 
kidney cancer (Calle et al., 2003). In terms of diabetes, during obesity fasting plasma 
insulin is elevated and there is an increased insulin response to a glucose load. Fat depots 
and their distribution influence glucose metabolism, increase lipolysis and thus the release 
o f FFAs from abdominal adipocytes, which results in a greater uptake o f insulin by the 
liver and finally in increased gluconeogenesis and dyslipidaemia. These then result in 
hyperinsulinaemia and decreased skeletal insulin sensitivity. The inability o f ¡3-cells to 
cope long term with this situation and produce more and more insulin, leads to the 
development o f type 2 diabetes. It has been demonstrated that even a modest weight gain 
o f 5 to 7 kg increases the risk o f diabetes by 50%, while losing the same amount o f 
weight reduces the risk by the same amount (Kokkoris &  Pi-Sunyer, 2003).
Another major health problem is the effects o f obesity on cardiovascular function. This is 
because in obesity there is an increase in both lean and fat mass and in surface area. This 
results in an increase o f total body oxygen consumption and cardiac output. The total 
blood volume is also increased in proportion to body weight, which leads to an increase 
in stroke volume and cardiac output. So there is an increase in the blood volume
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returning to the heart, which sometimes results in failure o f the ventricles and atria to 
support and thus heart failure (Kopelman, 2000).
1.2.1.3 Obesity as an inflammatory state
Obesity is now considered as a state o f chronic low-grade inflammation (Das, 2001; Festa 
et al., 2001; Trayhurn &  Wood, 2004). This notion is basically supported by the 
observation that obesity is characterized by increased circulating levels o f several markers 
o f inflammation, such as pro-inflammatory cytokines and acute-phase proteins 
(Hotamisligil et al., 1993; Trayhurn &  Wood, 2004). As will be discussed in later 
sections, adipose tissue is a source o f some of these factors, contributing either directly to 
their elevated levels or indirectly via the stimulation o f cytokine production elsewhere 
(Wood &  Trayhurn, 2006). Furthermore, since obese subjects have been found to 
exhibit adipocyte infiltration in tissues such as skeletal muscle, it has recently been 
suggested that WAT may provide a source o f inflammatory markers within other organs 
(Caspar-Bauguil et al., 2005). It is proposed that this inflammatory state may lead to the 
development o f insulin resistance, hyperlipidaemia and the metabolic syndrome (Festa et 
al., 2001; Engstrom et al., 2003; Trayhurn &  Wood, 2004).
A possible explanation for this is that the inflammatory response is primarily local to 
adipose tissue as a response to hypoxia in areas o f the fat depots as the tissue mass 
increases during the development o f obesity. This is supported by evidence that a 
transcription factor induced by hypoxia, hypoxia-inducible factor-1 (HIF-1), regulates a 
number of genes, including angiogenic factors VEGF and PAI-1 (Trayhurn &  Wood, 
2004). Furthermore, a cross talk between macrophages and adipocytes may also 
contribute to this inflammatory status (Stout &  Suttles, 2004). An infiltration o f WAT 
by macrophages has been evidenced (Weisberg et al., 2003), which is possibly regulated 
by the increased release o f leptin, the chemokine monocyte chemoattractant protein 1 
(MCP-1) and macrophage migration inhibitory factor (MIF) from adipocytes during 
obesity (Trayhurn &  Wood, 2004; Skurk et al., 2005). A major role for WAT in the 
development o f inflammation-related complications o f obesity, particularly insulin 
resistance and atherosclerosis is considered plausible (Wood &  Trayhurn, 2006).
14
1.2.1.4 Study o f obesity: Genetic models
Much o f the current understanding of the mechanisms underlying energy regulation has 
come from studies on animal models o f obesity, including genetically obese (due to 
specific mutations) and diet-induced obese models. The most extensively studied obese 
model is the ob/ob (obese) mouse (Zhang et al., 1994). This model has an autosomal 
recessive mutation on chromosome 6  leading to a lack of biologically active leptin and 
subsequently preventing normal signaling of energy stores by the adipose tissue to the 
hypothalamus. This results in hyperphagia, decreased energy expenditure and subsequent 
accumulation o f excess fat (Zhang et al., 1994). ob/ob mice are also characterized by 
hyperinsulinaemia, insulin resistance and subsequent hyperglycaemia (Herberg &  
Coleman, 1977; Coleman, 1978). There are different variants o f ob/ob mice with specific 
mutations in the leptin gene, which either prevent gene transcription entirely or most 
commonly introduce a premature stop codon that results in a truncated and inactive 
form of leptin (Zhang et al., 1994).
The db/db (diabetic) mouse is another widely used model for obesity studies, db/db mice 
are insensitive to leptin due to a mutation in the long isoform o f the leptin receptor (OB- 
Rb) (Chen et al., 1996). As a result, leptin fails to exert its normal satiety and 
thermogenic effects. Thus db/db mice exhibit hyperphagia, obesity and 
hyperinsulinaemia, leading to insulin resistance followed by increasing hyperglycaemia, as 
insulin resistance advances, and finally to |3-cell hyperplasia (Berglund et al., 1978; 
Molina et al., 1984). In contrast to the ob/ob mouse where fat mass is increased by both 
hypertrophic and hyperplastic mechanisms, in db/db mouse the fat mass is said to be only 
hypertrophic (Johnson &  Hirsh, 1972). Furthermore, in these models brown adipocytes 
are unilocular and show moderate UCP-1 activity, supporting the fact that obesity due to 
a lack o f leptin or a functional leptin receptor is accompanied by reduced BAT adrenergic 
stimulation (Cinti et al., 1997; Cinti, 2005).
Other genetic models include the fa /fa  (Zucker) rat, fat/fat (fat) mouse, AH Ay (agouti) 
mouse and the tub/tub (tubby) mouse. The fa  gene lies on rat chromosome 5 and the fa  
phenotype is caused by a single mutation on the extracellular portion of the long form of
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the leptin receptor, which leads to a 90% reduction in binding affinity for leptin and 
impairment o f leptin’s central effects on energy balance (Phillips et al., 1996). Thus, 
similarly to ob/ob mice, fatty Zucker rats become obese through reduced stimulation o f 
BAT thermogenesis, hyperphagia and hyperinsulinaemia (Phillips et al., 1996). 
Furthermore, the agouti mutation results from gene rearrangements, which change the 
normally restricted expression o f agouti in the skin. In the hypothalamus, agouti acts as 
an endogenous antagonist o f the melanocortin-3 and -4 receptors (M C3-R and MC4-R), 
through which a-melanocyte-stimulating hormone (a-M SH), released by pro­
opiomelanocortin (POMC) neurons in the ARC, acts to inhibit feeding. Loss o f 
melanocortin-mediated inhibition of feeding is responsible for hyperphagia and 
development o f obesity in the A» mouse (Butler &  Cone, 2001). The tubby mouse has an 
autosomal recessive mutation which leads to mature onset obesity, hearing loss and 
retinal degradation as a result o f a splicing defect in the tub gene (Guan et al., 1998). 
Finally, the fa t  gene is a missense mutation o f the Cpe gene that encodes carboxypeptidase 
E, an enzyme involved in the processing of proinsulin to insulin in the P cell, and o f 
POM C and other neuroendocrine prohormones in the hypothalamus and pituitary 
(Leiter &  Herberg, 1997). The loss o f Cpe activity leads to defects in the processing o f 
pro-hormone forms o f neuropeptides associated with the control o f satiety, thus leading 
to hyperphagia and a diabetic and obese phenotype (Utsunomiya et al., 1998).
Further understanding o f the development o f obesity has been acquired from studies on 
transgenic knockout mice. For example, the M C4R knockout mouse which is obese, 
hyperleptinaemic and hyperisulinaemic confirmed that the obese phenotype in the agouti 
mouse is caused by inhibition o f the M C4R signaling by agouti (Butler &  Cone, 2003). 
Similarly, POM C knockout mice exhibit obesity and hyperphagia, while M C3R 
knockout mice exhibit obesity but not hyperphagia, as well as hyperleptinaemia and 
hyperinsulinaemia, although they do not develop diabetes (Butler &  Cone, 2003). 
Interestingly, selective knockout o f insulin receptors in white fat does not greatly disturb 
glucose metabolism, but decreases adipose tissue mass, reflecting the normally high 
sensitivity o f adipose tissue to the antilipolytic effects o f insulin (Abel et al., 2001). 
Furthermore, a transgenic mouse with ablated WAT throughout development
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emphasized the beneficial effects o f adipose tissue on growth, glucose metabolism and 
survival in fasting (Moitra et al., 1998). Finally, ablation o f BAT in mice led to decreased 
thermogenesis, early onset o f obesity without hyperphagia, and obesity with impaired 
glucose tolerance, confirming that increased metabolic efficiency and less wastage of 
energy through thermogenesis predispose to impaired glucose homeostasis (Hamann et 
al., 1996).
1.2.2 Cancer cachexia
Numerous chronic diseases are associated with cachexia, including cancer, AIDS, 
rheumatoid arthritis, tuberculosis, cystic fibrosis and congestive heart failure (Tisdale, 
2002). Cancer cachexia is a complex disorder characterized by progressive weight loss 
associated with anorexia, asthenia, anaemia, alterations in immune function, and 
disproportionate muscle wasting. This condition, most commonly seen in patients with 
gastrointestinal, lung and prostate cancer, occurs in up to 80% o f subjects with advanced 
forms o f cancers and accounts for about 2 0 % o f deaths, when subjects have lost around 
30% o f their pre-morbid weight (Warren, 1932; Fearon, 1992; Tisdale, 2002). The 
survival o f cancer patients is directly related to both the total weight loss and the rate o f 
weight loss. Furthermore, it has been estimated that cancer patients who have 
experienced weight loss respond almost 2.5 times less frequently to chemotherapy than 
patients who have not (Slaviero et al., 2003).
1.2.2.1 Pathogenesis o f cancer cachexia
In contrast to starvation, where weight is primarily lost from adipose tissue, in cachexia, 
weight loss is observed both in the fat and skeletal muscle compartments. In cachexia, 
loss o f skeletal muscle arises from a fall in protein synthesis and an increase in protein 
degradation, which then results in weakness, leading to immobility and death, usually 
because o f loss o f respiratory muscle function (Tisdale, 2002). Cachexia has often been 
attributed to anorexia, the loss o f appetite and early satiety, as it is present in up to one- 
half o f newly diagnosed cancer patients (Grosvenor et al., 1989). However, anorexia 
alone is unable to explain all the metabolic processes that occur during cachexia, as it has
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been clearly demonstrated by the differences in the metabolic changes taking place 
between subjects with cachexia and those suffering from starvation. In addition to the 
depletion o f skeletal muscle mass in patients with cachexia, which only occurs at the late 
stages o f starvation conditions, subjects with cachexia show an increase in liver mass due 
to metabolic recycling activity, while a decrease is observed in starved subjects (Wigmore 
et al., 1997). Furthermore, although in starvation the weight loss observed is easily 
reversed by feeding, in patients with cachexia the degree o f food intake does not 
correspond to the extent o f malnutrition and attempts to increase body weight fail to 
reverse the weight loss (Evans et al., 1985). Several appetite stimulants, such as 
corticosteroids, have been used without success. At present, progestogens are used for the 
treatment o f cachectic patients. These include megestrol acetate and 
medroxyprogesterone acetate, but although patients seem to gain some weight, there is 
no change in their body fat-free mass (Tisdale, 2 0 0 2 ).
Weight loss can in principle result from decreased energy intake and/or increased energy 
expenditure. Resting energy expenditure (REE) is the main determinant o f energy 
expenditure. Although REE accounts for 70% o f total energy expenditure in normal 
subjects, it varies considerably among different groups o f cancer patients. REE has, for 
example, been found to be elevated in patients with pancreatic and lung cancer but 
unaltered in patients with colorectal cancer (Fredrix et al., 1991). This observed increase 
could be related to the upregulation o f UCPs. Although, as previously mentioned, BAT is 
uncommon in adults where it is present in around 13% o f the population tested, it is 
present in around 80% o f patients with cachexia (Shellock et al., 1986). In addition to 
that, UCP-2 and -3, which are found in skeletal muscle, may also play a significant role 
in energy balance and lipid metabolism as they are upregulated in rodent models o f 
cachexia, although their exact role and degree o f involvement are still unclear, as different 
studies have presented contradictory results, one even suggesting that anorexia was 
driving their production (Sanchis et al., 1998; Bing et al., 2000; Busquets et al., 2005).
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1.2.2.2 Pathogenesis o f cancer cachexia in adipose tissue
In WAT, cachexia results in increased rates o f lipolysis, decreased lipogenesis, 
hyperlipidaemia, raised circulating levels o f free fatty acids and glycerol, and finally the 
loss o f up to 85% o f adipose tissue mass (Fearon &  Preston, 1990). It has been observed 
in some clinical studies (Costa et al., 1981) that increased fatty acid utilization precedes 
weight loss, thus suggesting the production o f lipid-mobilizing factors either by the 
tumour or by host tissues. This increased fatty acid mobilization from host adipose tissue 
may also be an important factor contributing to the tumour growth (Wicha et al., 1979; 
Hussey &  Tisdale, 1994) There are putative factors through which these changes may be 
mediated, such as pro-inflammatory cytokines and tumour-derived protein factors 
(Gordon et al., 2005).
1.2.2.3 Mediators o f cancer cachexia
The general metabolic abnormalities seen in cancer cachexia are driven by the production 
of a number o f factors, which include cytokines and other cachectic agents, by both the 
host and tumour. As seen in Figure 1.2, the presence o f a tumour results in a persistent 
host inflammatory response, characterized by the production o f T  helper 1 (Thl) 
cytokines, such as tumour necrosis factor a (TNFa), interleukin-1 [3 (IL-113), interleukin- 6  
(IL-6 ) and interferon-y (IFNy). On the other hand, tumours also produce specific 
cachectic factors such as proteolysis inducing factor (PIF) and lipid mobilizing factor 
(LMF), which promote protein and fat breakdown respectively.
Products o f the tumour and/or host cell have been associated with appetite suppression. 
IL-1 has been shown to be involved in the induction of anorexia, by blocking 
neuropeptide Y (NPY)-induced feeding, which is a feeding-stimulating peptide (Chance 
et al., 1994; Plata-Salaman, 2000). T N Fa has been associated with cachexia since it 
promotes lipolysis and inhibits lipogenesis, mainly through suppression o f LPL and the 
induction of proteolysis through the ubiquitin-proteasome proteolytic pathway (Tracey et 
al., 1990). It has been proposed that an elevation in plasma levels o f T N Fa is responsible 
for the metabolic alterations in adipose tissue seen with cancer cachexia (Argiles, 1997). 
Elevated circulating concentrations o f IL - 6  have also been shown to be associated with
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weight loss in some patients with lymphoma, lung cancer and colorectal cancer (Rubin, 
2003). Leukaemia-inhibitory factor (LIF), IL-1 and ciliary neurotrophic factor (CNTF) 
have also been suggested as mediators o f cachexia (Argiles, 2003).
LMF acts specifically on adipose tissue through the cyclic-AMP-mediated pathway and 
PIF, which is a sulphated glycoprotein that induces protein degradation in skeletal 
muscle, by upregulating the ubiquitin-proteasome proteolytic pathway. Although there is 
a strong correlation between these factors and cachexia, there is no effect on appetite 
(Tisdale, 2002). LM F, which appears to act through the [^-adrenoreceptor, is able to 
induce lipolysis in adipose tissue. It was first purified from the cachexia-inducing mouse 
colon adenocarcinoma, MAC16. It has also been found in the urine o f cancer patients, 
suggesting that it can induce lipid mobilization in these subjects. LM F is homologous to 
the plasma protein Zinc-a2-glycoprotein (ZAG) (Todorov et al., 1998), which is the main 
focus o f this study and is going to be discussed in the following sections.
PIF has been shown to be present in patients with weight losses greater than 10%, which 
were not attributed to cytokines. PIF has been found to be present at its maximum in the 
serum o f mice bearing the MAC16 tumour, with a weight loss between 11% and 20%. 
PIF has also been found in the urine of patients with different types o f carcinoma. These 
patients, in whose urine PIF was present, experienced great weight losses, especially o f 
lean body mass, and the action o f PIF is mainly mediated on skeletal muscle. 
Additionally, PIF may also be involved in cancer cachexia by contributing to a 
continuous cycle o f cytokine and acute phase protein production. Finally, the high degree 
of structural conservation between murine and human PIF suggests that cachexia in mice 
and humans is produced by the same tumour product (Tisdale, 2 0 0 2 ).
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Figure 1.2 Pathogenesis of cancer cachexia
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(Source: Gordon et a i, 2005)
Schematic representation of the mediators involved in the development o f the cancer 
cachexia syndrome.
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1.3 Endocrine function of adipose tissue
The traditional view of adipose tissue as an energy storage organ has dramatically changed 
during the last few years, with the identification of various factors, termed adipokines, 
which are secreted from the tissue and have been shown to be involved in a wide range o f 
physiological and metabolic processes. For a factor to be classified as an adipokine, its 
secretion from adipocytes has to be demonstrated. This is usually demonstrated in vitro, 
using either freshly isolated adipocytes, or adipocytes derived by differentiation from 
fibroblastic pre-adipocytes. When a factor is found to be expressed in adipose tissue, it is 
essential to determine whether it is expressed within mature adipocytes, or whether it is 
only found in the other cell types that constitute the tissue, such as fibroblasts, 
macrophages and endothelial cells. At present, more than fifty adipokines have been 
identified, which according to their known physiological functions can be categorized as 
presented in Figure 1.3 (Trayhurn &  Beattie, 2001; Trayhurn &  Wood, 2004). 
Lipoprotein lipase was in effect the first adipokine to be identified, however a major 
finding, which subsequently led to the focus on adipose tissue, was the discovery of leptin 
(Zhang et al., 1994). The wide range and diversity o f the factors secreted from WAT 
have made it evident that WAT is a major secretory and endocrine organ, which plays a 
key role in many metabolic and physiological processes in mammals. In the following 
sections, the major adipokines and their functions are discussed in more detail.
1.3.1 Free fatty acids and steroid secretions o f WAT
Before discussing the adipose tissue secreted protein factors, it is appropriate to mention 
that quantitatively fatty acids are the major secretory product o f WAT, reflecting the fuel 
storage role o f the tissue. Fatty acids are the product o f TAG lipolysis mediated by HSL. 
FFAs released from adipose tissue are a major source o f plasma FFAs, and both adipose 
tissue and plasma FFAs are elevated in obesity (Lewis et al., 2002). Furthermore, the 
largest percentage o f circulating FFAs is derived from subcutaneous adipose tissue; thus 
FFA lipolysis is unlikely to be the link between visceral adiposity and metabolic syndrome 
disorders (Nielsen et al., 2004). In addition, WAT stores cholesterol and is involved in 
the metabolism of steroid hormones. Although the tissue does not synthesize steroid
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A schematic presentation o f white adipose tissue and its products. Not all secreted 
proteins are listed. IL-6 , interleukin-6 ; T N Fa, tumour-necrosis factor a; MCP-1, 
monocyte chemattractant protein 1; PAI-1, plasminogen activator inhibitor-1; VEGF, 
vascular endothelial factor.
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hormones de novo, it expresses the enzymes involved in the conversion o f glucocorticoids 
and sex hormones, such as 170HSD which is responsible for the conversion o f oestrone 
to oestradiol and androstenedione to testosterone, these being additional secretory WAT 
products (Mohamed-Ali etal., 1998; Trayhurn &  Beattie, 2001).
1.3.2 Leptin
Leptin was originally identified in 1994 as a satiety factor secreted by adipose tissue and 
the obese (ob) gene which encodes the protein was first identified in genetically obese 
(ob/ob) mice using positional cloning (Zhang et al., 1994). The leptin gene (Lep (ob)) 
encodes an 18-kDa protein containing a signal sequence which is cleaved to produce the 
mature 16-kDa hormone (Zhang et al., 1994). Sequence analysis has shown that the rat 
ob gene has 96% homology with the mouse one, while the nucleotide and protein are 
84% and 82% homologous to the human ob gene, respectively (Clement et al., 1996).
Although it was initially suggested that leptin was only synthesized in WAT, it has since 
been detected in several additional sites, including BAT, the stomach, placenta, 
mammary gland, ovarian follicles, the heart and bone and possibly the brain (Trayhurn et 
al., 1999; Trayhurn et al., 2001). Nevertheless, WAT remains the major site o f leptin 
synthesis and the major contributor to leptin circulating levels (Considine et al., 1996).
1.3.2.1 Regulation o f leptin expression and production
The levels o f leptin mRNA in WAT and the circulating levels o f leptin are closely 
associated with the amount o f fat mass, both in rodents (Frederich et al., 1995) and in 
humans (Considine et al., 1996), its levels increasing with fatness. Furthermore, serum 
leptin levels are significantly higher in females compared to males (Havel et al., 1996) and 
exhibit a significant 24h pattern with a nocturnal maximum (Heptulla et al., 2001).
Leptin is expressed in all WAT depots; however there are substantial differences in the 
levels o f leptin mRNA between sites. Differences are also observed depending on the 
developmental stage and on species. It has been reported that although in mature rodents 
leptin mRNA levels are higher in the epididymal and perirenal depots compared to
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subcutaneous, where leptin mRNA levels are lowest (Trayhurn et al., 1995), in humans, 
the subcutaneous depots exhibits higher levels o f leptin mRNA compared to the omental 
site (Hube et al., 1996; Montague et al., 1997). Furthermore, and as will be discussed in 
greater detail in Chapter 6 , studies in rodents indicate that there are major developmental 
changes in the expression of leptin in WAT (Rayner et al., 1997).
Both in vitro and in vivo studies have demonstrated that a number of factors substantially 
influence leptin synthesis in WAT. Leptin expression is regulated by nutritional status. 
Fasting induces a rapid reduction both in ob gene expression in WAT and in the levels o f 
circulating leptin, which are however reversed upon refeeding (Trayhurn et al., 1995; 
Hardie et al., 1996). Similar to fasting, acute cold exposure leads to a rapid reduction in 
ob mRNA levels, which is subsequendy reversed by rewarming (Trayhurn et al., 1995; 
Flardie et al., 1996).
Furthermore, leptin expression in WAT is regulated by a number o f hormones. 
Catecholamines, both noradrenaline and adrenaline, have a major suppressive effect on 
leptin production (Trayhurn et al., 1995), which is primarily mediated through the p3- 
adrenoreceptor (Giacobino et al., 1996; Trayhurn et al., 1996), since selective ^-agonists 
strongly suppress ob gene expression and reduce leptin circulating levels (Mantzoros et al., 
1996; Trayhurn et al., 1996). It has also been demonstrated that thiazolidinediones 
(TZDs) repress both ob gene expression and circulating leptin levels through the 
activation o f peroxisome proliferator activator y (PPARy) (Mantzoros et al., 1996; 
Trayhurn et al., 1996). On the other hand insulin (Havel, 2001), glucocorticoids and 
oestrogens (Castracane et al., 1998) stimulate leptin production, with the opposite effect 
occurring with the administration of testosterone (Blum et al., 1997). Finally, leptin 
levels increase in response to inflammatory cytokines, such as T N F a, sepsis, and acute 
infection (Sarraf et al., 1997; Faggioni et al., 1998; Gualillo et al., 2000). It has been 
proposed that the sympathetic nervous system is the main physiological regulator o f 
leptin production and that it provides a negative feedback loop to adipose tissue in the 
production o f the hormone (Trayhurn et al., 1998).
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1.3.2.2 Functions o f leptin
Apart from its neuroendocrine effects on food intake and energy expenditure, a number 
of other functions have been attributed to leptin, including its action in the reproductive 
system, in angiogenesis and in the immune system. As will be discussed in the next 
section, leptin interacts with several central neuroendocrine systems leading to the 
inhibition o f food intake (Campfield et al., 1995; Halaas et al., 1995). Overall, leptin is 
involved in a wide and diverse spectrum o f physiological and metabolic processes 
(Trayhurn &  Beattie, 2001).
1.3.2.3 Leptin receptor
The leptin receptor (OB-R) is a member o f the class I cytokine family (Tartaglia et al., 
1995). As a result o f alternative splicing, in mice OB-R can exist as six isoforms: an OB-R 
long form (OB-Rb), four short forms (OB-Ra, -Rc, -Rd, and -Rf), and a soluble isoform 
(OB-Re) (Lee et al., 1996). Furthermore, there are four known isoforms o f the human 
leptin receptor (OB-R5, -15, -67, and -274) (Barr et al., 1999). All isoforms have 
identical extracellular ligand binding domains; they differ, however, at the intracellular 
carboxy terminus (Koerner et al., 2005).
Ob-Rb is the longer form and is essential for leptin’s weight reducing effects. Ob-Rb is 
highly expressed in hypothalamic neurons, as well as in T  cells and vascular endothelial 
cells. In the central nervous system, Ob-Rb is mainly expressed in the hypothalamic 
arcuate nucleus (ARC), dorsomedial nucleus (DM H), paraventricular nucleus (PVN), 
ventromedial nucleus (VMH) and the lateral hypothalamic area (LHA) (Ahima et al., 
2000; Elmquist, 2001). These nuclei express neuropeptides and neurotransmitters that 
regulate food intake and body weight. Key examples are the orexigenic neuropeptide Y 
(NPY), which responds through its receptors to absent or low levels o f leptin and the 
melanocyte-stimulating hormone (MSH), which acts through its melanocortin-4 receptor 
in response to an increased plasma leptin concentration. NPY mRNA levels are increased 
in ob/ob mice and decreased after leptin treatment (Friedman &C Halaas, 1998). The 
leptin receptor activates the janus-kinase/ signal transducer and activator o f transcription- 
3 (STAT-3) pathway. Leptin administration induces STAT-3 translocation,
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phosphorylation of phosphoinositide 3-kinase (PI (3) K) and the expression o f several 
lepdn-responsive genes (Niswender etal., 2001; Zigman &  Elmquist, 2003).
1.3.3 Insulin sensitivity and insulin resistance
1.3.3.1 Adiponectin
Adiponectin, which is also known as ACRP30, apM l, adipoQ and GPB28, is a 247 
amino acid hormone produced exclusively by adipocytes (Ouchi et al., 1999). It was 
initially identified from a cDNA, adipose most-abundant gene transcript 1, reflecting a 
gene that is specifically expressed in adipose tissue (Maeda et al., 1997). Adiponectin is a 
30-kDa polypeptide that belongs to the collagen superfamily sharing strong sequence 
homologies with type VIII and X  collagens, complement factor C lq  and T N F a (Scherer 
etal., 1995; Maeda etal., 1996; Chandran etal., 2003).
1.3.3.1.1 Expression, regulation and function o f adiponectin
As aforementioned, adiponectin is exclusively expressed in adipocytes, with increasing 
expression and secretion in adipocytes after the induction of differentiation (Ouchi et al., 
1999). In humans, adiponectin expression is higher in subcutaneous compared to visceral 
adipose tissue (Fain et al., 2004). In human blood, adiponectin occurs in high 
concentrations o f about 10 pg/ml, accounting for 0.01% of total serum protein (Bottner 
et al., 2004). Females have significantly higher levels o f plasma adiponectin than males, 
this sexual dimorphism developing during pubertal development in relation to serum 
androgens (Bottner et al., 2004). In contrast to most adipokines, its expression in WAT 
and circulating levels are decreased in obesity (Arita et al., 1999), in conditions o f insulin 
resistance and diabetes (Hotta et al., 2000) and in cardiovascular disease with increasing 
severity (Matsuzawa et al., 2004). In these conditions, the reduction o f adiponectin levels 
precedes the development o f the disorders (Yamamoto et al., 2004), and low adiponectin 
levels have been demonstrated to predict the development o f type 2 diabetes (Spranger et 
al., 2003). On the other hand, adiponectin levels increase when insulin sensitivity 
improves, such as after weight reduction, or treatment with insulin-sensitising drugs 
(Yang et al., 2001; Matsazawa et al., 2004). It has thus been suggested that adiponectin
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has a role in the development o f the metabolic syndrome (Diez et al., 2003; Matsazawa et 
al., 2004)
Furthermore, adiponectin exhibits anti-inflammatory and anti-atherogenic properties, 
including the inhibition of N FkB activation and the modulation o f endothelial adhesion 
molecules in response to inflammatory stimuli (Ouchi et al., 2000; Diez &  Iglesias, 2003; 
Matsazawa, 2005). It has also been proposed that the protein is involved in the link 
between atherosclerosis and obesity (Ouchi et al., 1999). Adiponectin may play a role in 
modulating insulin action and it is thought to mediate the insulin sensitizing effects o f 
TZD s (Stefan &  Stumvoll, 2 0 0 2 ).
Finally, overexpression of adiponectin in 3T3-L1 adipocytes was reported to result in 
more rapid cell proliferation and differentiation to adipocytes alongside increased 
expression o f adipogenic genes, increased lipid content, and improved insulin 
responsiveness for glucose transport (Fu et al., 2005).
1.3.3.1.2 Adiponectin receptors
The effects o f adiponectin are mediated through two recently identified receptors, 
AdipoRl and AdipoR2, which are predominantly expressed on muscle and liver cells 
respectively, although they are widely expressed in the body (Yamauchi et al., 2003). 
Adiponectin binds to both receptors and mediates the activation o f AMP kinase, PPARa 
activation, and consequently glucose uptake and fatty acid oxidation, which is most 
probably the main molecular mechanism accounting for the increase in insulin sensitivity 
mediated by adiponectin (Gil-Campos et al., 2004).
The expression levels o f adiponectin receptors are decreased in obesity (Kadowaki &  
Yamauchi, 2005), but are increased during fasting and decreased in re-fed mice 
(Tsuchida et al., 2004). In particular, AdipoRl expression seems to be associated with 
insulin sensitivity and insulin secretion in mice (Staiger et al., 2004) and humans 
(Civitarese et al., 2004), as diabetes and insulin treatment decrease AdipoRl expression, 
while AdipoR2 remains constant (Inukai etal., 2005).
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1.3.3.2 Resistin
Resistin (also referred to as FIZZ3 and ADSF) is a -12kDa protein that is secreted 
exclusively by mature adipocytes in the mouse, and is a marker for adipocyte 
differentiation (Kim et al., 2001). However it is expressed primarily in macrophages and 
monocytes in humans (Steppan &  Lazar, 2004). Resistin was initially reported to be 
elevated in obese rodents and to promote insulin resistance. In murine studies resistin 
administration was shown to induce insulin resistance, while it was demonstrated that 
anti-resistin strategies improved insulin sensitivity (Steppan et al., 2001). It was thus 
suggested that resistin functions as a link between obesity and insulin resistance. 
However, subsequent studies in rodents revealed contradictory results and thus a 
physiological role for the protein has failed to be established (Way et al., 2001). The role 
of resistin in humans is also not clear (Smith, 2 0 0 2 ), as human serum resistin levels are 
associated with adiposity and insulin resistance in many, but not all, studies (Janke et al., 
2002; Steppan &  Lazar, 2004), and it was even shown in a recent report that resistin 
levels are actually decreased in db/db mice compared to lean controls, the levels being 
increased by the administration o f metformin, an anti-diabetic agent with insulin 
sensitizing effects (Fujita et al., 2002). Due to the differences observed between resistin in 
human and rodents, it has been suggested that the adipokine may exert diverse effects 
and that further studies are required in order to understand its role (Steppan &  Lazar,
2004).
1.3.3.3 Visfatin
Visfatin (pre-B cell colony-enhancing factor) is a 52 kDa secreted protein and is one o f 
the most recently identified adipokines (Hug &  Lodish, 2005). In adipose tissue, visfatin 
is specifically expressed in the visceral depot o f both humans and mice, and visfatin serum 
levels are positively correlated with visceral adiposity. It was also demonstrated that 
visfatin has a high affinity for the insulin receptor, and thus a linkage between the 
functions o f the two proteins has been suggested (Fukuhara et al., 2005; Bae et al., 2006; 
Krzyzanowska et al., 2006). Unlike insulin however, visfatin levels appear to be 
unaffected by fasting or feeding (Fukuhara et al., 2005). In vitro, dexamethasone was
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shown to increase visfatin expression, while growth hormone, T N F a  and isoproterenol 
decreased its levels in 3T3-L1 adipocytes (Kralisch et al., 2005).
1.3.4 Cytokines
Adipose tissue is the source of several inflammatory cytokines, which are key regulators o f 
the inflammatory response (Trayhurn &  Beattie 2001).
1.3.4.1 Tumour necrosis factor a (TNFa)
T N F a was firstly identified in adipose tissue o f rodents in 1993, where it was shown to 
be markedly induced in obese animal models (Hotamisligil et al., 1993). T N F a is a 26- 
kDa protein that is subsequently cleaved into a 17-kDa biologically active protein that 
exerts its effects via type I and II T N F a receptors (Fain et al., 2004). T N Fa is expressed 
both in mature adipocytes and the stromovascular cells o f WAT, its levels being higher in 
human subcutaneous than visceral adipose tissue (Fain et al., 2004). Similarly, T N F a is 
expressed in preadipocytes; however, its levels increase with the degree of differentiation 
(Hube &  Hauner, 1999). Both types o f T N F a receptor are also expressed within 
adipocytes (Ruan &  Lodish, 2003).
Although T N F a  was originally thought to be involved in cachexia, it has now been 
implicated in the pathogenesis o f obesity and insulin resistance, its expression both in 
human and rodent adipose tissue being positively correlated with adiposity and insulin 
resistance (Hotamishigil et al., 1993; Ruan &  Lodish, 2003). In adipose tissue, T N F a 
suppresses genes involved in the uptake and storage of nonesterified fatty acids (NEFAs) 
and glucose, as well as genes for transcription factors involved in adipogenesis and 
lipogenesis. Furthermore, it affects the expression o f several adipocyte-secreted factors, 
including IL-6 , MCP-1 and nerve growth factor (NGF), whose levels are substantially 
increased with the administration o f T N F a  in vitro (Ruan et al., 2002; Wang &  
Trayhurn, 2006). Multiple effects have also been described in terms in relation to insulin 
action, such as the inhibition o f the insulin receptor signaling pathway (Coppack, 2001). 
T N F a is an important mediator o f inflammation and can induce several other 
inflammatory cytokines (Ruan &  Lodish, 2003; Wang &  Trayhurn, 2006).
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1.3.4.2 Interleukins
Both IL- 6  and its receptor, IL-6 R, are expressed by adipocytes and by the adipose tissue, 
IL- 6  expression and secretion being 2 to 3 times greater in visceral, mainly omental, 
relative to subcutaneous adipose tissue (Fain et a i, 2004). IL- 6  circulates at high levels in 
the bloodstream (Mohamed-Ali et a i, 1997), and it has been estimated that about one 
third of circulating IL- 6  originates from adipose tissue (Fernandez-Réal &  Ricart, 2003). 
IL- 6  circulates in multiple glycosylated forms ranging from 2 2  to 27-kDa in size, while 
its receptor, which is homologous to the leptin receptor, exists in two forms, an 80-kDa 
membrane-bound form and a 50-kDa soluble form (Fain et a i, 2004). Both plasma levels 
o f IL - 6  and IL - 6  expression in WAT are positively correlated with obesity, impaired 
glucose tolerance, and insulin resistance (Mohamed-Ali et al., 1997; Vozarova et al., 
2001), while circulating levels fall in response to weight loss (Bastard et al., 2000). 
Peripheral administration of IL- 6  induces hyperlipidaemia, hyperglycaemia and insulin 
resistance both in humans and rodents. Furthermore, IL - 6  inhibits adipogenesis and has 
been implicated in stimulating lipolysis (Path et a i, 2001) and in decreasing adiponecdn 
secretion (Fernandez-Real &  Ricart, 2003). Furthermore, IL- 6  is produced in the murine 
hypothalamus, suggesting a central role for this interleukin in the central regulation of 
appetite and energy expenditure, similarly to leptin (Jones, 1994). IL- 6  levels in the CN S 
are negatively correlated with fat mass in overweight humans, suggesting central IL- 6  
deficiency in obesity and central administration of IL- 6  increases energy expenditure and 
decreases body fat in rodents (de Benedetti et al., 1997; Wallenius et al., 2002). In vitro, 
IL- 6  expression in adipocytes is increased by insulin (Krogh-Madsen et al., 2004), and 
T N Fa (Wang et al., 2005), as well as by prostaglandin D 2 and its metabolites PGJ2 and 
A12PGJ2 (Peeraully et a i, 2006).
Other interleukins expressed in white adipose tissue include IL-ip, IL-8 , IL-10, IL-17D 
and IL-18. IL-ip  has been shown to stimulate leptin release from human adipocytes 
(Flower et al., 2003), and to mediate leptin induction in mice administered with 
inflammatory stimuli (Faggioni et al., 1998). The IL-8 gene is expressed in human 
adipocytes, the protein being secreted by the cells (Bruun et al., 2000). IL- 8  release is 
stimulated by IL-ip  and T N Fa, while being inhibited by dexamethasone (Bruun et al.,
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2001) . Furthermore, IL- 8  plasma levels are increased in obesity (Straczkowski et al.,
2002)  .
The anti-inflammatory cytokine IL-10 is also secreted from human adipocytes, as well as 
from the stromal vascular fraction of human fat depots (Fain et a i, 2004£), its levels 
being elevated in obesity both in humans and rodents (Esposito et al., 2003; Juge-Aubry 
et al.,2005). Finally, IL - 8  expression is induced by LPS and T N F a  (Juge-Aubry et al.,
2005). Similarly, IL-18 circulating levels are increased in obesity and fall with weight 
reduction (Esposito et a i, 2 0 0 2 ). IL-18 is a pro-inflammatory cytokine and it has recently 
been demonstrated that IL-18 is expressed in human adipose tissues and cultured human 
adipocytes, where its levels are increased by the administration o f T N F a (Skurk et al., 
2005; Wood et al., 2005). However, its release from adipocytes has not been 
documented, so it is only considered as a putative adipokine (Wood et al., 2005). 
Similarly to IL-18, IL-17D expression in adipocytes has been reported and it has 
demonstrated to stimulate the production o f IL- 6  and IL- 8  (Starnes et a i, 2002); 
however, there has been no report o f its release from these adipocytes.
1.3.5 Chemokines
It has been demonstrated during the last few years that obesity is associated with 
increased adipose tissue infiltration by macrophages (Weisberg et a i, 2003; Wellen &  
Hotamisligil, 2003). Monocyte chemoattactant protein-1 (MCP-1), a chemokine that 
recruits monocytes to sites o f inflammation, is expressed and secreted by adipose tissue, 
both by adipocytes and the stromal vascular fraction (Wellen &  Hotamisligil, 2003), its 
levels being higher in visceral compared to subcutaneous human adipose tissue (Bruun et 
a i, 2005). The observation that M CP - 1  expression levels in adipose tissue and circulating 
levels are elevated in obesity, has suggested that MCP-1-mediated macrophage 
infiltration o f adipose tissue may contribute to the metabolic abnormalities related with 
obesity and insulin resistance (Sartipy &  Loskutoff, 2003; Dahlman et a i, 2005). 
Furthermore, increased circulating MCP-1 levels in obesity are associated with increased 
circulating monocytes (Takahashi et al., 2003). On the other hand, weight loss leads to a
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reduction in MCP-1 levels (Christiansen et al., 2005). When MCP-1 is applied to 
cultured adipocytes, both insulin-stimulated glucose uptake and insulin-induced insulin 
receptor tyrosine phosphorylation are decreased, suggesting that MCP-1 directly 
contributes to adipose tissue insulin resistance (Gerhardt et al., 2001; Sartipy &  
Loskutoff, 2003). In addition, MCP-1 inhibits adipocyte growth and differentiation by 
decreasing the expression o f a number o f adipogenic genes (Sartipy &  Loskutoff, 2003). 
In vitro, MCP-1 expression and secretion by adipocytes is stimulated by T N F a (Wang et 
al., 2005) and prostaglandin D 2 and j 2-series prostaglandins (Peeraully et al., 2006). 
However, adipose tissue is not a major contributor to circulating MCP-1 levels 
(Dahlman et al., 2005).
Macrophage migratory inhibitory factor (MIF) is another factor possibly involved in the 
macrophage infiltration process in WAT. MIF is secreted by human adipocytes, its levels 
positively relating to BMI. It has thus been suggested that it may be an obesity-dependent 
regulator o f macrophage infiltration into adipose tissue (Skurk et al., 2005; Trayhurn, 
2005).
1.3.6 Growth factors
Several growth factors are synthesized in WAT. Transforming growth factor-P (TGFP) is 
a multifunctional cytokine produced by a variety o f cells that regulates the growth and 
differentiation of various cell types. It is involved in cell adhesion and migration, 
extracellular matrix production, tissue remodeling and wound repair (Sporn et al., 1987). 
TGFP is expressed in adipose tissue, its levels being elevated in murine models o f obesity 
(Samad et al., 1997). Since TGFP has been shown to increase preadipocyte cell 
proliferation, it has been suggested that its increased levels in obese adipose tissue may 
contribute to the elevated cellularity o f fat depots related to the obese phenotype 
(Frllhbeck et al., 2001). In vitro, T N F a stimulates TGFP production, which in turn leads 
to an increase in the production of PAI-1 (Samad et al., 1997).
Insulin-like growth factor- 1 (IGF-1 ) is another growth factor secreted from WAT acting 
to stimulate preadipocyte proliferation and differentiation (Hausman et al., 2001).
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Vascular endothelial factor (VEGF) is a potent angiogenic factor and a WAT product. Its 
levels are increased in the plasma o f db/db mice compared to their lean counterparts and 
it is mainly synthesized by visceral WAT (Miyazawa-Hoshimoto et al., 2005). In vitro, 
VEGF is upregulated by insulin, while dexamethasone has the opposite effect (Fain &  
Madan, 2005).
As discussed in a previous section, WAT is innervated by the SNS, the sympathetic 
system being a major physiological regulator o f lipolysis in WAT (Hales et al., 1978; 
Bartness &  Bamshad, 1998), cell number (Bartness 6 C Bamshad, 1998) and adipokine 
synthesis, particularly leptin (Trayhurn et al., 1995; Rayner &  Trayhurn, 2001). In 
various tissues, the development and survival o f sympathetic neurons depend on the 
presence o f neurotrophins, N G F being the best characterized one (Vega et al., 2003). 
NGF is a newly identified adipokine, the N G F  gene being expressed in human and 
mouse WAT, and the protein being secreted from murine adipocytes in culture 
(Peeraully et al., 2004). Various factors have been identified which affect N G F expression 
and release by these adipocytes. T N F a strongly upregulates N G F expression, while both 
dexamethasone and rosiglitazone suppress its expression, suggesting a role for the 
neurotrophin in the inflammatory response of WAT (Peeraully et al., 2004). 
Furthermore, it has been demonstrated that N G F synthesis is regulated by 
prostaglandins, the levels being upregulated by PGD 2 , PGJ2 and A12PGJ2 , while 
downregulated by 15d-PGj2, PGE2, PGF2a, and PGI2 (Bullo et al., 2005). N G F is also 
synthesized and released by BAT, with expression in brown adipocytes being inhibited by 
prolonged cold exposure and norepinephrine (Nechad et al., 1994; Nisoli et al., 1996).
1.3.7 Haemostatic factors
Plasminogen-activator inhibitor 1 (PAI-1) is a serine protease inhibitor, whose elevated 
plasma levels are a risk factor for thrombosis (Fay, 2004). PAI-1 is produced both by 
adipocytes and the stromal vascular fraction o f WAT, its secretion and expression being 
greater in visceral relative to subcutaneous white tissue (Fain et al., 2004). Adipose tissue 
is thought to be a major source o f PAI-1 in obesity, its circulating levels positively
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correlating with visceral adiposity, as well as insulin resistance (Kershaw &  Flier, 2004). 
On the other hand, weight loss and treatment with TZD s significantly reduce PAI-1 
circulating levels (Mertens &  Van Gaal, 2002). T N F a is a major regulator o f elevated 
PAI-1 levels in obesity (Mertens &  Van Gaal, 2002; Juhan-Vague et al., 2003). 
Furthermore, a possible role for PAI-1 in the development o f adipose tissue has been 
proposed, as PAI-1 deficient mice show less weight gain, smaller adipocyte size and lower 
tissue triglyceride levels compared with wild-type mice in response to a high-fat diet 
(Schafer et al., 2001; Ma et al., 2004).
The renin-angiotensin system (RAS) is an important regulator o f systemic blood pressure 
and renal electrolyte homeostasis (Engeli et al., 2000). Numerous RAS proteins are 
synthesized and secreted by WAT, including renin, angiotensinogen (AGT), angiotensin 
I and II, angiotensin receptors type I (ATI) and II (AT2), and angiotensin-converting 
enzyme (ACE), with the expression o f AGT, ACE and ATI receptors being higher in 
visceral compared to subcutaneous tissue (Engeli et al., 2003). RAS expression is 
positively correlated with adiposity in humans, while AG T expression is decreased by 
fasting and increased by refeeding, the changes being accompanied by changes in blood 
pressure. It has been demonstrated in rodents that inhibition of RAS decreases weight 
and increases insulin sensitivity (Engeli et al., 2003; Goossens et al., 2003). Furthermore, 
RAS proteins influence adipose tissue development in multiple ways. For example, both 
RAS and angiotensin II are induced during adipogenesis; the latter promotes adipocyte 
growth and differentiation as it inhibits lipolysis, promotes lipogenesis and decreases 
insulin-dependent glucose uptake. Furthermore, RAS proteins affect the expression of 
other adipose tissue-secreted factors, such as prostacyclin, PAI-1 and leptin (Engeli et al., 
2003). Further evidence for the role o f RAS in obesity and hypertension has been 
provided by different murine models, as it has been demonstrated that AGT-knockout 
mice have decreased blood pressure and adipose tissue mass (Massiera et al., 2001a), 
while transgenic mice overexpressing AG T in adipose tissue exhibit the opposite traits 
(Massiera et al., 2001b).
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1.3.8 Acute-phase proteins
Several acute-phase proteins are now recognized as adipokines, with adipose tissue being a 
potential contributor to the raised circulating levels o f these factors in obesity (Trayhurn 
& Wood, 2004).
Haptoglobin is a tetrameric glycoprotein which binds haemoglobin, preventing both iron 
loss and kidney damage during haemolysis. It has an antioxidant function and has been 
reported to be angiogenic, stimulating endothelial cell differentiation, and vascularisation 
(Cid et al., 1993). Haptoglobin is expressed and secreted by mouse and human adipose 
tissue solely by mature adipocytes and, similarly to resistin (Haugen et al., 2001), it is a 
late marker o f adipocyte differentiation (do Nascimento et al., 2004). Its circulating levels 
are increased in obesity and type 2 diabetes (Engstrom et al., 2003), the same having been 
observed in ob/ob mice (do Nascimento et al., 2004). In vitro, haptoglobin levels are 
enhanced by glucocorticoids, catecholamines, and T N F a while being suppressed by 
TZD s (do Nascimento et al., 2004). Thus, haptoglobin in adipose tissue might be 
involved in the inflammatory response, or play a role as an antioxidant and in 
angiogenesis (do Nascimento et al., 2004), functions which have also been proposed for 
metallothionein (MT), another acute phase response protein (Trayhurn &c Beattie, 
2001).
M T is mainly synthesized in the liver and kidney and it has been suggested to have an 
antioxidant role in BAT (Beattie et al., 2000). Both MT-1 and M T-2 are expressed in all 
major WAT depots, with no substantial site differences and their expression is adipocyte 
specific, with no expression in the stromal vascular fraction (Trayhurn et al., 2000). In 
vitro, M T levels are stimulated by dexamethasone and forskolin and it has been suggested 
that it might function in WAT as an antioxidant protecting fatty acids from oxidative 
stress (Trayhurn et al., 2 0 0 0 ).
Serum amyloid A (SAA) is the precursor o f amyloid A protein found in secondary 
amyloid plaques, recognized as a risk factor for coronary artery disease. WAT has only 
recently been identified as a source o f SAA. Serum SAA positively correlate with weight
36
gain, adiposity and SAA mRNA levels in adipose tissue (Sjoholm et al., 2005). Both SAA 
adipose tissue expression levels and circulating levels decrease in response to weight loss, 
thus indicating that SAA could be a possible link between obesity and cardiovascular 
disease (Poitou et al., 2005; Sjoholm et al., 2005).
1.3.9 Prostaglandins
1.3.9.1 Prostaglandin synthesis
White adipose tissue is known to synthesise various prostaglandins, adipocytes themselves 
producing prostaglandins and expressing several o f the receptors through which PGs 
exert their effects (Bell-Parikh et al, 2003). Prostaglandins are lipid-derived autacoids 
generated by sequential metabolism o f arachidonic acid by the cyclooxygenase (COX) 
and prostaglandin synthase enzymes. There are two C O X  isoforms, C O X - 1  and COX-2, 
with prostaglandins produced via the former being ascribed a role in physiological 
homeostasis, while those produced via the latter usually being responsible for 
inflammatory effects. COX-2 is thus a major target for non-steroidal anti-inflammatory 
drugs such as aspirin and indomethacin. In general, phospholipase h i catalyzes the release 
o f arachidonic acid from membrane phospholipids. Upon its release, arachidonic acid 
undergoes oxidation by CO X to PGG 2 followed by reduction to the unstable 
endoperoxide PGH 2 , the central prostanoid precursor. PGH 2 serves as a substrate for the 
prostaglandin synthase enzymes, namely PG D 2 , PGE2 , PGF2a> prostacyclin and 
thromboxane synthase, which are responsible for the production o f the five principal 
bioactive prostaglandins generated in vivo, PGD 2 , PGE2 , PGF2a, TXA 2 (thromboxane) 
and PGI2 (prostacyclin) (Fig 1.4) (Straus &  Glass, 2001; Hata &  Breyer, 2004).
Prostaglandins are ubiquitously produced and act locally in an autocrine or paracrine 
manner to elicit a diverse set o f pharmacological effects modulating many physiological 
systems, including the endocrine, respiratory and immune systems. However, they are 
only locally active, due to their rapid breakdown. PG D 2 is sequentially degraded to PGJ2 , 
which then isomerizes to yield 9-deoxy-A9,A12,13,l4-dihydro-PGj2 (AI2-PGJ2). Furthermore, 
PGJ2 may be converted directly to 15-deoxy-A12,14-PGj2 (15d-PGj2) in the presence of
37
albumin. In contrast to conventional prostaglandins, PGJ2 and its derivatives possess a 
highly reactive cyclopentenone ring that permits them to ligate nuclear receptors and to 
modify intracellular signaling molecules (Bell-Parikh et al., 2003). Similarly, PGE2 may 
be converted to PGA2 , PGC 2 and PGB2 , while 6 -keto-PGFia is the natural metabolite o f 
PGI2 (Fig. 1.4) (Straus &  Glass, 2 0 0 1 ).
Prostaglandins exhibit both pro-inflammatory and anti-inflammatory effects in many 
pathophysiological conditions, this usually depending on cell population, and the context 
of activation, but mainly on the receptor subtype that they bind to (Plata &  Breyer, 
2004).
1.3.9.2 Prostaglandin receptors
The physiological effects o f prostaglandins are partly mediated by a family o f rhodopsin- 
like seven transmembrane spanning G-protein-coupled prostanoid receptors (GPCRs). 
The prostaglandin receptor subfamily comprises eight members (DP, EP1-4, FP, IP and 
TP), which are classified according to the prostaglandin ligand that each binds with the 
highest affinity. More specifically, DP binds PGD 2, PGJ2 and A12-PGj2,while PGE2 exerts 
its effects by binding and activating four receptors, EP 1 to EP4. Furthermore, PGI2 binds 
IP, PGF2„ to FP and TXA 2 to TP (Hata &C Breyer, 2004). A ninth prostaglandin receptor 
has recently been identified, the chemoattractant receptor homologous molecule 
expressed on Th 2  cells (CRTH 2 ), which binds PGD 2 and its metabolite 15d-PGj2 (Hirai 
et al., 2001; Sawyer et al., 2002). However, the CR TH 2  receptor is more closely related 
to chemoattractant receptors rather than the other prostaglandin receptors. The exact 
roles o f prostaglandin receptors in physiologic and pathologic conditions are determined 
by ligand-receptor interactions which depend on multiple factors such as ligand affinity, 
receptor expression profile, differential coupling to signal transduction pathways and the 
cellular context in which the receptor is expressed, and prostaglandins may activate more 
than one subtype o f prostaglandin receptors (Hata &  Breyer, 2004).
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Figure 1.4 Prostaglandin synthetic pathway
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Schematic representation o f the general pathway for prostaglandin synthesis. 
Phospholipids are converted into arachidonic acid, which is metabolized by CO X - 1  and - 
2 to PGH2, the common precursor for the five principal prostaglandins, generated by 
individual prostaglandin synthase enzymes, (adapted from Hata &  Breyer, 2004)
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In addition to the G-protein coupled receptors, prostaglandins act through intracellular 
targets, the PPAR family of nuclear receptors. Both 15d-PGj2 and A12-PGj2 bind to 
PPARy, the former representing the highest affinity ligand for PPARy identified (Forman 
et al., 1995; Kliewer et al., 1995), its anti-inflammatory effects most probably being 
mediated through stimulation o f this receptor (Ricote et al., 1998; Bell-Parikh et al., 
2003). 15d-PGj2also activates PPARa and PPAR8 , although less potently than PPARy 
(Forman et al., 1997). Similarly, PGI2 has been proposed as a ligand for PPARa and 
PPAR8 , through which it possibly mediates angiogenic effects (Kubis &  Levy, 2004; Pola 
et al., 2004).
1.3.93 Prostaglandins in W AT
As aforementioned, it has been known for some time that adipocytes can synthesize 
prostanoids (Shillabeer et al., 1998), with PGE2, 6 -keto-PGFia, PGF2a and 15d-PGj2 
being secreted by 3T3-L1 adipocytes (Borglum et al., 1999). Similarly, the capacity o f 
3 T 3 -L 1 adipocytes and human adipose tissue to synthesize PGD 2 and its derivatives has 
been demonstrated (Jowsey et al., 2003) and both PGI2 and PGE2 are secreted by isolated 
human adipocytes, although their expression is higher in the stromal vascular fraction 
(Fain et al., 2002) and in rat adipocytes (Shillabeer et al., 1998). Various roles have been 
attributed to prostaglandins in WAT.
Prostaglandins play various roles in adipogenesis. PGF2a has been shown to inhibit 
adipocyte development (Curtis-Prior, 1975). Diverse actions have been attributed to 
PGE2 most possibly explained by it binding to four EP subtypes, which differ in their 
signal transduction pathways (Negishi et al., 1995). Although PGE2and PGI2 are the two 
prostaglandins predominantly synthesized by adipocytes, they appear to have opposing 
effect on early adipogenesis, the former inhibiting adipocyte differentiation (Vassaux et 
al., 1992) through the EP4 receptor (Tsuboi et al., 2004), while the latter promotes it 
(Vassaux et al., 1992). Furthermore, PGE2 has been reported to stimulate leptin release 
by adipose tissue (Fain et al., 2000), to have an antilipolytic effect on mammalian 
adipocytes (Castan et al., 1994) and to stimulate metabolism o f BAT via the EP1 
receptor (Tsuboi et al., 2004). Additionally, studies with 3T3-F442A adipocytes have
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demonstrated that the stimulation o f lipolysis induced by some cytokines such as IL-ip  is 
mediated through a cytokine-induced stimulation o f prostaglandin synthesis, as the 
lipolytic effect o f these agents on the adipocytes is blocked by indomethacin, a non- 
selective C O X  inhibitor (Feingold et al., 1992).
1.3.10 Proteins o f lipid and lipoprotein metabolism
Several proteins involved in lipid and lipoprotein metabolism are released from white 
adipocytes. The enzyme lipoprotein lipase (LPL), the first identified secreted protein 
factor o f adipocytes, is responsible for the breakdown of circulating TAGs to release fatty 
acids for uptake by adipocytes and its expression is stimulated by insulin and 
glucocorticoids (Enerback &  Gimble, 1993; Trayhurn et al., 2001). WAT also secretes 
cholesteryl ester transfer protein, which plays an important role in the accumulation o f 
cholesteryl ester by adipose tissue, and apolipoprotein E (Trayhurn &  Beattie, 2001). 
Furthermore, WAT is a major site o f retinol-binding protein (RBP) synthesis (Makover 
et al., 1989), although liver and kidney are the main contributors to the circulating levels 
o f this protein. RBP which is required for the transport o f retinol (vitamin A) from the 
liver and adipose tissue to target tissues (Trayhurn &  Beattie, 2001), has recently been 
reported to be involved in the development o f insulin resistance in obesity and type 2  
diabetes (Yang et al., 2005)
Adipsin, also known as complement factor D, is an adipose tissue derived factor required 
for the enzymatic production of acylation-stimulating protein (ASP), also known as 
C3ades-Arg, a complement factor protein that affects both lipid and glucose metabolism 
(Cianflone et al., 2003). Although adipsin was initially shown to be reduced in rodent 
obesity (Flier et al., 1987), later studies in humans have positively correlated both adipsin 
and ASP levels with adiposity, insulin resistance and dyslipidemia (Cianflone et al., 
2003). Furthermore, ASP enhances fatty acid uptake by increasing LPL activity and 
triglyceride synthesis, as well as glucose transport in adipocytes, while on the other hand 
it decreases lipolysis and release o f FFAs from adipocytes (Cianflone et al., 2003). Finally, 
adipocytes express C5L2, a G protein-coupled receptor for ASP (Kalant et al., 2003).
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Fasting-induced adipose factor (FIAF) is an angiopoietin-like protein and a target for 
PPARa (Kersten et al., 2000). FIAF, whose circulating levels generally increase with 
fasting (Kersten et al., 2000), has been shown to inhibit LPL activity affecting the 
accumulation o f TAGs by adipocytes (Backhed et al., 2004). Finally, zinc-alpha2- 
glycoprotein is a recently identified adipokine (Bao et al., 2005) with a possible role in 
adipose tissue lipid metabolism.
1.4 Zinc-a2-glycoprotein (ZAG)
ZAG is a soluble protein first identified in human plasma in 1961. Its name is attributed 
to the fact that it can be precipitated by adding zinc ions and it displays electrophoretic 
mobility in the 0C2 region o f the plasma globulins (Biirgi &  Schmid, 1961). The human 
ZAG gene is composed of four exons and has been mapped to human chromosome band 
7q22.1 (Ueyama et al., 1994). Human ZAG consists o f a single polypeptide chain o f 276 
amino acid residues and has a molecular weight o f 38,487 daltons as calculated from its 
polypeptide and carbohydrate structure (Araki et al., 1988), very close to the original 
estimate o f M r 41,000 based on physiological studies (Biirgi &  Schmid, 1961). The rat 
and mouse proteins are slightly longer, consisting o f 279 and 290 residues in the mature 
form, respectively. Comparison among them has shown that there is a 59.4% overall 
amino acid sequence identity between human and rat and a 58.6% identity between 
human and mouse ZAG (Ueyama et al., 1994). However, murine and human ZAG can 
share up to 1 0 0 % identity in regions that are thought to be involved in lipid metabolism 
(Hale et al., 2001). On the other hand, identity between rat and mouse ZAG reaches 
88.5% (Ueyama et al., 1994).
ZAG has been associated with antigens o f the major histocompatibility complex, due to 
similarities in their amino acid sequence and in domain structure (Sanchez et al., 1997; 
Sanchez - et al., 1999). Furthermore, it has been shown to be a member o f the 
immunoglobulin gene superfamiy (Araki et al., 1988). These findings have been further 
confirmed by the crystal structure o f human ZAG, which reveals an MHC-like fold 
without a P2M  light chain, and a groove that closely resembles the peptide-binding sites
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of classical class I M H C molecules. But instead o f a peptide, the ZAG groove contains a 
nonpeptidic compound that might be implicated in lipid metabolism under pathological 
conditions (Sanchez et al., 1999).
1.4.1 ZAG expression
ZAG protein has been found within the cytoplasm o f many normal secretory epithelial 
cells, such as those in breast, prostate and liver. Consistent with that, ZAG is expressed in 
most body fluids, including serum, sweat, saliva, seminal plasma, cerebrospinal fluid, 
breast milk, colostrum, amniotic fluid, urine and synovial fluid (Biirgi &  Schmid, 1961; 
Tada et al., 1991). The expression of ZAG in various differentiated cell types is o f great 
interest, and the observation that its expression increases with the degree o f 
differentiation (Lei et al., 1997; Brysk et al., 1999; Hale et al., 2001) explains its use as a 
clinical marker. ZAG is present in breast cysts and is produced by 40% of breast 
carcinomas. It has also been shown that it is inducible in breast cancer cell lines by 
glucocorticoids and androgens and that its expression correlates with tumour 
differentiation and does not independently affect prognosis (Tada et al., 1991; Diez-Itsa 
etal., 1993).
1.4.2 Biological functions o f ZAG
ZAG is a putative mediator o f cancer cachexia, although the mechanisms o f its action are 
yet to be determined. As discussed earlier, the function o f ZAG was recently indicated 
when it was found to be identical, in terms o f molecular weight, amino-acid sequence, 
electrophoretic mobility, and immunoreactivity, to the lipid-mobilising factor (LMF) 
isolated from a cachexia-inducing murine adenocarcinoma (MAC 16) and from the urine 
of patients with unresectable pancreatic carcinoma and established weight loss. It was 
thus suggested that tumour-produced ZAG may contribute to the development o f cancer 
cachexia (Todorov et al., 1998). Both ZAG and LMF were shown to stimulate adenylate 
cyclase in murine adipocyte plasma membranes and release glycerol from isolated 
adipocytes (Hirai et al., 1998). ZAG is produced by normal prostate epithelium. In 
addition to that, the protein is produced by around 73% of prostate cancers and as with
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breast cancer, the greater the degree o f differentiation, the greater the production o f ZAG 
(Hale et al., 2001).
1.4.3 ZAG is involved in body weight regulation and is expressed in 
adipose tissue
The involvement o f ZAG in the induction o f lipolysis has been demonstrated both in 
vivo and in vitro. The in vivo administration o f ZAG to mice induces a rapid and 
selective reduction on body fat and increases serum-free fatty acid levels, by activating 
hormone-sensitive lipase through increased intracellular cAMP levels. Furthermore, in 
vitro, ZAG stimulates lipolysis in a dose-dependent manner when applied to adipocytes 
isolated from murine adipose tissue (Hirai et al., 1998). It has recently been 
demonstrated that the lipolytic effect o f ZAG is attenuated by the specific P3- 
adrenoreceptor antagonist SR59230. This finding indicates that ZAG activity in rodents 
is mediated via the P3 adrenoreceptor with up-regulation o f the cAMP pathway (Russell et 
al., 2002). Furthermore, it has been shown in a recent study using KK/Ta mice, a 
spontaneous model o f type 2  diabetes (Ikeda, 1994), that ZAG might be a possible 
candidate gene for the regulation o f body weight and age-dependent changes in the 
genetic control o f obesity, its overexpression in 3T3-L1 adipocytes leading to an increase 
in adiponectin mRNA levels (Gohda et al., 2003).
The secretory function o f adipocytes, together with the lipolytic effect o f ZAG led to a 
recent study examining whether ZAG is produced locally in WAT. Indeed, it was shown 
that ZAG is expressed both in human and mouse WAT, and 3T3-L1 murine adipocytes, 
while its levels are elevated in WAT of mice bearing the M AC 16 tumor (Bing et al., 
2004). ZAG stimulates adipose tissue breakdown through the cAMP-dependent 
pathway, as mentioned above, and upregulates uncoupling proteins found in adipose 
tissue, potentially contributing to changes in REE (Sanders &  Tisdale, 2004). It was 
further demonstrated that the protein is a new adipokine secreted by human SGBS 
adipocytes, its expression being regulated particularly through the PPARy receptor and by 
T N F a  (Bao et al., 2005).
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1.5 Aims of this thesis
As indicated in the preceding sections, WAT is now recognized as a major endocrine and 
secretory organ in addition to its traditional role in the storage o f energy and thermal 
insulation. WAT is a heterogeneous organ, consisting o f multiple specific depots with 
distinct anatomical locations and different molecular characteristics, as shown by the 
differential expression of most adipokines in these sites.
ZAG is a potent mediator o f cancer cachexia, which induces lipolysis and lipid 
utilization. ZAG is expressed in murine WAT and in BAT and human WAT (Bing et al., 
2004) and it was subsequently shown that ZAG protein is secreted from human 
adipocytes, thus being a novel adipokine with a possible role in lipid metabolism and 
inflammation in WAT (Bao et al., 2005).
In this context, it is important to study in more detail the expression and regulation o f 
ZAG in adipose tissue and thus further explore the function of this adipokine. In this 
work, two approaches were employed. The first was in vivo studies using rodents, and the 
second was in vitro studies using the 3T3-L1 murine fibroblastic clonal cell line. These 
studies would allow the investigation of the following:
1 . A comparison of ZAG gene and protein expression among different WAT depots 
and BAT to determine whether there are key depot differences.
2. ZAG gene and protein expression in mature adipocytes and the stromal vascular 
fraction o f WAT depots in order to determine the fraction relative importance of 
the different cell in WAT.
3. A comparison of ZAG gene and protein expression in WAT depots o f lean and 
obese mice.
4. Examination o f whether alterations in the nutritional status affect ZAG 
expression in vivo.
5. Examination o f the early postnatal development o f ZAG in rat adipose tissue to 
assess how early is ZAG expressed in development.
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6 . Expression o f the ZAG gene in vitro at different stages o f adipocyte 
differentiation.
7. The role o f sympathetic agonists, hormones and inflammatory mediators in the 
regulation o f ZAG expression in 3T3-L1 adipocytes.
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Chapter 2 
Materials &  Methods
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Rainbow molecular weight marker Amersham
RNase AWAY Molecular BioProd
Rosiglitazone GlaxoSmithKline
Sigmaclean® water bath treatment Sigma




Sodium dodecyl sulphate BDH
Sodium dihydrogen orthophosphate BDH






Tris -  Borate - ED TA  lOx buffer pH8.3 (TBE) Fisher Scientific
TEM ED Sigma
T N Fa Sigma
Trichloroacetic acid (TCA) Sigma
TRIzol reagent Sigma
Tris -  Base Sigma
T ris hydrochloride Qbiogene
T  rypsin Calbiochem
Tween 20 (polyoxyethylene sorbitan monolaurate) Sigma
Ultra pure water DakoCytomation
ZAG monoclonal antibody Santa-Cruz
2.1.2 Commercial kits
K its Su pplier
ECL Western Blotting detection reagents and analysis system Amersham
qPCR™ Core Kit Eurogentec
ReddyMix Master PCR Master Mix Kit ABgene
Reverse-iT™  1st strand synthesis ABgene
TURBO  DNA-Jiw™ Ambion
2.1.3 Equipment
Equipm ent Su pplier
ABI Prism 7700 real-time PCR machine Applied Biosystems
Beckman Preparative Ultracentrifuge Beckman





Corning filter system (0.22 pm membrane) 
Compact Electro-blotting unit 
GallenKamp shaking water bath 
Glass homogenisers (borosilicate)
HB-1000 hybridisation oven 
Hetovac V R-1 vacuum centrifuge 
Hybond ECL Nitrocellulose Membrane 
Hyperfilm ECL
Kodak Digital Science D C  120 digital camera 
Mx3005P Q PCR system 
Nescofilm® membrane 
PCR express thermal cycler 
PolytronUltra-Turrax T25 electric homogenizer 
Real-time PCR plates 
Real-time PCR cover slips 
SARAN wrap




Beacon Designer, PREM IER 
Excel, 2003
HP Precision Scan Pro 2.5
Kodak Digital Science ID 1 image analysis software 
M CID  Basic 7.0 Software 




























Imaging Research Inc 
Bio-rad
MxPro QPCR Software 
Primer Express® Software 




2.1.5 Suppliers’ addresses and URLs
ABgene, ABgene House, Blenheim Road, Epsom KT19 9AP, UK.
http://www. abvene. com
Alexis Biochemical, 6181 Cornerstone Court East Suites 102-104, 92121-4727 San 
Diego, USA. http:IIwww. alexis-corp. com
Antec Europe BV, Sydneystraat 33, 3047 BP Rotterdam, the Netherlands.
http://www.antec. com
Ambion Ltd, Spitfire Close, Ermine Business Park, Huntingdon, Cambridgeshire, PE29 
6XY, UK. http://www. ambion. com
Amersham Biosciences U K  Ltd, Amersham Place, Little Chalfont, Buckinghamshire,
HP7 9NA, UK. http:!!  www. amersham. co. uk
Applied Biosystems, Kelvin Close, Birchwood Science Park North, Warrington, 
Cheshire, WA3 7PB, UK. http:IIwww. appliedbiosystems. com
Beckman Instruments Inc, Palo Alto, Fullerton, CA 92634, USA.
http:!!  www. beckman. com
BD H  laboratory supplies, Poole Dorset, BH15 1TD, UK. http:!/www. bdh. com 
Bio-Rad Laboratories Ltd, Bio-Rad House, Maxted Road, Hemel Hempstead, 
Hertfordshire, HP2 7DX, UK. http://www. bio-rad.com
Dako, Denmark House Angel Drove Ely, Cambridgeshire, CB7 4ET, UK.
http://www. dako. co. uk
Eppendorf U K  Ltd, Endurance House, Chivers Way Histon, Cambridge, CB4 9ZR,
UK. http://www. eppendorf.com/uk/
EM D Biosciences Inc, Calbiochem Brand, 10394 Pacific Center Court, San Diego, 
California, 92121, USA. http://www. merckbiosciences. co. uk/html/CBC/
Eurogentec Ltd, P.C House, 2 South Street, Hythe, Southampton, Hampshire S 0 4 5  
6EB, UK. http://www. europentec. com
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Fisher Scientific, Bishop Meadow Road, Loughborough, Leicestershire, LE11 5RG, UK.
http://www.fisher. co. uk
GlaxoSmithKline Ltd, Stockley Park West, Stockley Park, Uxbridge, UB11 1BT, 
Middlesex, UK. http://www. vlaxowellcome. co. uk
Helena Laboratories (UK) Ltd, Colima Avenue, Sunderland Enterprise Park, Sunderland 
SR5 3XB, UK. http:llwww. helena. co. uk
Hybaid (UK) Ltd, Action Court, Ashford Road, Ashford, Middlesex, TW 15 1XB, UK.
http://www. hybaid. com
Imaging Research Inc, Brock University, 500 Glenridge Avenue, St. Catherines, 
Ontario, Canada L2S 3A1. http://www. imapiwresearch. com
Invitrogen Ltd, 3 FountainDrive, Inchinnan Business Park, Paisley, PA4 9RF, UK.
http://www. invitropen. com
Janke &  Kunkel, Janke-&-Kunkel- Str 10, 79219 Staufen, Germany, http://www. ika. net 
Kodak Ltd, P.O. Box 66, Station Road, Hemel Hempstead, Hertfordshire, HP1 1JU,
UK. http://www. kodak, co. uk
Roche Diagnostics Ltd, Bell Lane, Lewes, East Sussex, BN7 1LG, UK.
http://'www. biochem. roche, com
Microsoft Ltd, Microsoft Campus, Reading, RG6 1WG, UK.
http://www. microsoft. com/uk/
Norlab Lab Care, Unit 6, Aberdeen, AB21 7HG, UK.
PREMIER Biosoft International, 3786 Corina Way, Palo Alto, CA 94303-4504, Cilicon 
Valley, USA. http://www.premierbiosoft. com
QBiogene, Wellington House, East Road, Cambridge, CB1 1BH, UK.
http://www. abiopene. com
SANYO UK, SANYO House, 18 Colonial Way, Watford, Hertfordshire, W D24 4PT,
UK. http://www. sanyo. co. uk
Santa-Cruz Biotechnology Inc, 2145 Delaware Avenue, Santa Cruz, California 95060, 
USA. http://www. scbt. com
Scie-Plas, Unit 3 Gainsborough, Trading Estate, Old Road, Southam, Warwickshire, 
CV47 1HP, UK. http://www.scie-plas.com
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Sigma-Aldrich Company Ltd, Fancy Road, Poole, Dorset, BH12 4QH , UK.
»
http:IIwww. sipma-aldrich. com
Stratagene, Hogehilweg 15, 1101 CB Amsterdam Zuidoost, Netherlands.
httpd/www. stratapene. com
Tocris Cookson Ltd, Northpoint, Fourth Way, Avon Mouth, Bristol, BS11 8TA, UK.
http'.Hwww. tocris. com
Ultra-Violet Products Ltd, Unit 1, Trinity Hall Farm Estate, Nuffield Road, Cambridge, 
CB4 1TG, UK. http:Hwww. uvp. com
Whatman PLC, Whatman House, St Leonards Rd, 20/20 Maidstone, Kent, M E16 OLS,
UK. http://www. whatman. co. uk
2.2 Animals
All animal studies were conducted according to the U.K. Home Office Guidelines for the 
care and use o f laboratory animals.
2.2.1 Mice
Ten-week old male mice (CD1) from an inbred colony at the University o f Liverpool 
were housed at an ambient temperature o f 22 ± 1°C under a 12:12 h light -  dark cycle 
(lights were on at 07:00 h) and fed a standard pelleted diet (CRM diet, LAbsure, 
Witham, U.K.) containing 19.2% protein and 4.3% lipid (wt/ wt). Both food and water 
were available ad libitum. The mice were killed by cervical dislocation and the following 
tissues were rapidly dissected and frozen in liquid nitrogen: WAT (subcutaneous, 
epididymal, perirenal, mesenteric, and omental depots), interscapular brown adipose 
tissue (BAT), liver, spleen, heart, kidneys, lungs, skeletal muscle (gastrocnemius), whole 
brain and the hypothalamus. All tissues were stored at -80°C until RNA extraction.
For a fasting experiment, sixteen ten-week mice (CD1) were used. The mice were kept 
under the aforementioned conditions and two days prior to the experiment were divided 
into the fed and the fasted groups and were housed in grid bottomed cages. On 
commencing the experiment, mice o f the control group were still kept on the same diet.
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In contrast, all food was removed from the fasted group’s cage, while they still had ad 
libitum access to water. Sixteen hours later, animals were sacrificed by cervical dislocation 
and the following tissues were rapidly dissected and frozen in liquid nitrogen: WAT 
(subcutaneous, epididymal, perirenal, mesenteric, and omental), BAT and liver.
For the study of the effects o f diet composition on ZAG expression, WAT 
(subcutaneous, epididymal, and perirenal) from lean and diet-induced obese female 
C57BL/6J mice from Lund University (Lund, Sweden) was provided by Dr Wang 
(University o f Liverpool, U.K.). The mice were purchased from Taconic (Skensved, 
Denmark) and maintained at 22°C on a 12:12 h light - dark cycle. One week after 
arrival, the mice were divided into two groups. The first group was on a low-fat diet 
(11% fat by energy) while the second one was on a high-fat diet (58% fat by energy, 
Research Diets, New Brunswick, USA). Both groups were kept on these diets for 12 
weeks before being sacrificed.
For the study o f the effects o f obesity on ZAG expression, WAT (subcutaneous, 
epididymal, perirenal, and omental) from eight-week old lean (+/+ or +/ob) and 
genetically obese (ob/ob) C57BL/6J male mice (Charles River Laboratories, Wilmington, 
MA, USA) was also utilised. After being received, the mice were housed for one week 
under controlled environmental conditions (22 ± 1°C; 12:12 h light-dark cycle and lights 
on at 07:00) to allow recovery from stress induced by the transportation. They were then 
killed by cervical dislocation and dissected tissues were snap frozen in liquid nitrogen.
2.2.2 Rats
Ten-week old male Wistar rats from an inbred colony at the University o f Liverpool were 
housed at an ambient temperature o f 22 ± 1°C under a 12:12 h light -  dark cycle (lights 
on at 07:00) and fed a standard pelleted diet (CRM diet, Labsure, Witham, U.K.) 
containing 19.2% protein and 4.3% lipid (wt/wt). Both food and water were available ad  
libitum. The rats were killed by C O 2 inhalation and the following tissues were rapidly 
dissected and frozen in liquid nitrogen: WAT (subcutaneous, epididymal, perirenal, 
mesenteric, and omental depots), interscapular brown adipose tissue (BAT), liver, spleen,
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heart, kidneys, lungs, esophagus, stomach, skeletal muscle (gastrocnemius), whole brain 
and the hypothalamus. All tissues were stored at -80°C until RNA extraction.
For the study o f ZAG expression during early postnatal development, WAT (as soon as it 
was large enough to sample), BAT and liver were dissected from 1, 3, 5, 7, 10, 15, 21, 
and 32-days-old female Wistar rats (University o f Liverpool, U.K). The animals were 
housed at an ambient temperature o f 22 ± 1°C under a 12:12 h light -  dark cycle (lights 
were on at 07:00 h). The animals were weaned at day 21 and had ad libitum access to lab 
chow from day 18. Animals were killed by C O 2 inhalation.
For the study o f the effects o f obesity on ZAG expression, WAT (epididymal and 
retroperitoneal) from three - month old lean (+/+ or +lfa) and genetically obese (fa/fa) 
male Zucker rats, bred at Rowett Research Institute (Aberdeen, Scotland) were a gift 
from Dr Rayner.
2.3 Mature adipocytes and stromal vascular cell fractionation
2.3.1 Reagents
(i) 10 x Mixed salts:
1.35 M sodium chloride 
47 mM Potassium chloride 
25 mM Calcium chloride
12.5 mM Magnesium sulphate 
Sterile water
The mix was filtered through a 0.2 pm filter disc and stored at -20°C.
(ii) 10 x HEPES:
100 mM HEPES
12.5 mM Sodium dihydrogen orthophosphate
12.5 mM ¿//-sodium hydrogen phosphate 
Sterile water
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The pH o f the mix was adjusted to 7.6 at room temperature; it was then fdtered through 
a 0.2 pm filter disc and stored at -20°C.
(iii) 10 % BSA
After the 10% solution was made up in water, it was left at 4°C  overnight to dissolve. Its 
pH was then adjusted to 7.4 and the mix was then filtered through a 0.2 pm filter disc 
and stored at -20°C.
(iv) Collagenase buffer:
1 mg/ ml Collagenase 
0.1 mg/ ml Glucose
3.5 % BSA 
1 x Mixed salts 
1 x HEPES 
Sterile water
The collagenase and glucose were mixed in a sterile universal, while the rest o f the 
components were mixed into another container and were then added to the first mix. 
The buffer was then put through a 0.2 pm filter, and into a fresh universal.
2.3.2 Fractionation with collagenase digestion method
The six mice were sacrificed and the subcutaneous, epididymal and perirenal fat depots 
were dissected, using different scissors among depots. Each sample was placed in a 7 ml 
1% albumin buffer aliquot. The albumin aliquots containing the fat were then 
transferred to a sterile cell culture hood. An aliquot o f 5 ml o f albumin buffer was added 
into each half o f a sterile Petri dish, and the fat from one aliquot was transferred onto one 
side o f the Petri dish and cleaned o f any visible blood vessels and any other non-adipose 
tissue fragments. The cleaned fat was then transferred to the other side o f the Petri dish, 
where it was finely chopped using two disposable scalpels, before transfer it into a 7 ml 
aliquot o f collagenase buffer. The universals were then sealed using parafilm wrap and 
placed in a shaking water bath at 37°C for 1 h (or until the fat had been digested). 
During this time the universals were removed every 15 min and shaken vigorously. After
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the collagenase digestion was complete, the samples were passed through a 250 pm mesh 
into fresh universals. The samples were then centrifuged for 10 min at 1,000 rpm at 
room temperature. At this stage, the mature adipocytes had floated to the top and were 
removed to a clean tube and left to settle for a short time, after which, any unwanted 
buffer was carefully removed with a needle. The remaining buffer was then removed from 
the original universals and the stromal vascular pellet was left at the bottom and 
transferred into a fresh tube. Both fractions were then stored at -80°C until further 
analysis.
2.4 3T3-L1 adipocyte cell culture
For 3T3-L1 adipocyte culture, all precautions needed were taken to prevent any infection 
passing onto the cells. All glassware was autoclaved and plastic ware was sterile. All bottles 
and universals were opened within a sterile cell culture hood, firstly wiped with 1% 
vircon solution followed by 70% ethanol. All media components were mixed together 
and then filter sterilised through a 0.22 pm filter membrane. Prepared media were kept at 
4°C  for one week maximum and were always pre-warmed at 37% in a water bath, which 
was kept sterile with the addition o f Sigmaclean, before adding to the cells to avoid cell 
shock. However, induction medium was always freshly prepared prior to actual use and 
any excess was discarded afterwards.
2.4.1 Reagents
(i) Culture medium:
1 x DM EM  
10% Fetal Calf serum
(ii) Induction medium:
1 x DM EM
10% Fetal Calf serum
5 pg/ ml Insulin
0.25 mM Dexamethasone
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0.5 mM IBM X
Both dexamethasone and IBM X stock solutions were made fresh each time in 95% 
ethanol.
(iii) Feeding medium post-differentiation:
1 x DM EM
10% Fetal Calf Serum
5 pg/ ml Insulin
(iv) Trypsin/ EDTA:
l
For 10 ml stock: 8 ml sterile water
Stock trypsin/ ED TA (0.05% / 0.02%)
10 x PBS
2.4.2 Cell storage
3T3-L1 cells were obtained from the American Type Culture Collection (Manassas, 
Virginia, USA) and aliquots were stored in liquid nitrogen. Cells were cultured at 37°C 
in an incubator with a humidified atmosphere of 5% C O 2/ 95% air.
2.4.2.1 Cell generation and maintenance
To start a cell culture experiment, a frozen aliquot o f cells was removed from liquid 
nitrogen storage and defrosted in a water bath at 37°C. One ml o f pre-warmed culture 
medium was then added to the aliquot to help defrosting and the sample was gently 
pipetted up and down a few times to aid thawing. The thawed aliquot was then added to 
a 25 cm2 flask containing 3 ml o f culture medium and placed in an incubator. The 
culture medium was replaced with fresh medium every 48h to ensure the survival o f the 
cells.
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2.4.2.2 Cell passaging and plating
Once the cells were around 80% confluent, the medium was aspirated off, 1 ml o f 
Trypsin/EDTA was added and the flask was placed in the incubator for 1-2 min until the 
cells detached. The detachment o f the cells was verified by light microscopy. After the 
cells had been detached, 9 ml o f pre-warmed culture medium was added to neutralise the 
trypsin and prevent cell lysis and the suspension was then gently pipetted up and down to 
break up any clumps. The cells were then either plated out to six well plates or into 25 
cm2 flasks to increase the numbers. In the first case, 300 pi o f the cell suspension was 
added to each well, where 1.5 ml o f culture medium had already been placed, whereas in 
the latter, 1 ml o f the cell suspension was added to 3 ml o f media already placed in the 
flasks, to be plated out to six well plates as soon as they were confluent using the same 
procedure.
2.4 .23  Cell differentiation
Once plated out, the cells were allowed to grow confluent, and then left for another 24 h. 
The cells were induced to differentiate by replacing the culture medium with 1.5 ml o f 
differentiation medium. The feeding medium also remained in the wells for 48 h, and as 
with culture medium it was replaced with fresh medium every subsequent 48 hours. This 
continued up until 24 h before the cells were ready for treatment. Differentiation o f cells 
into adipocytes was confirmed by the accumulation of lipid droplets, which usually 
started around day 3 after the induction o f differentiation.
2.4.2A  Cell treatment
In the first instance, the time-course o f ZAG gene expression in 3T3-L1 cells was 
studied. For this experiment, 6 wells o f cells were collected from 2 days before 
differentiation up to 15 days post-differentiation. As soon as that was established, the 
effect o f different agents on ZAG mRNA levels o f expression was investigated.
At day 7 after induction o f differentiation, the feeding medium was aspirated off the cells 
and was replaced with fresh feeding medium, insulin-free feeding medium, or FCS-free 
medium as appropriate. After 24 h, the different treatment agents were mixed in feeding
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media, or insulin-free media or FCS-free media and 1 ml was added to the cells as 
appropriate. Cells used as controls also had their feeding media replaced. Cells were 
incubated with the treatment agents for 24 h before being collected. When a dose- 
response experiment was performed, cells were treated with increasing concentrations o f 
the agent for 24 h.
2.4.2.5 Cell and media collection
The medium was first collected in 2 ml sterile RNase free tubes, and then 700 pi o f 
Trizol reagent was added in each well to remove cells from the bottom of the well. The 
Trizol/cell mixture was gently pipetted up and down to ensure collection o f the 
maximum number of cells and was then placed into sterile RNase free tubes and stored at 
-80°C to prevent RNA degradation until further analysis. Collected medium was first 
centrifuged at 1,000 g for 10 min, the supernatant was transferred to a fresh tube and was 
then stored at -80°C as well.
2.4.3 Light microscopy
Cells were visualised using phase contrast light microscopy. The image was captured and 
photographed using a C C D  video camera (WILD MPS 515, SPOT, Switzerland).








(Vi) UV-irradiated distilled water
(vii) Ultra-pure water
6 1
2.5.2 Trizol - Reagent RNA extraction method
Before starting, scissors, tweezers and the homogeniser blade attachments to be used were 
sprayed with RNase AWAY, left for 30 min and then rinsed with UV-irradiated distilled 
water to remove any RNases present. The homogeniser blade was rinsed four times 
between samples in four different universal flasks containing UV-irradiated water, with 
the flasks being changed between samples from different groups.
A sample o f 100 mg o f WAT and BAT, or 50 mg in the case o f other tissues, either fresh 
or frozen was placed in a sterile 5 ml tube containing 1 ml o f Trizol reagent, the volumes 
being adjusted accordingly. The samples were disrupted using an electronic homogeniser. 
In the case o f RNA extraction from cells, cells were already kept frozen in 700 pi o f 
Trizol reagent per well o f cells and were then passed through a 23 gauge needle ten times, 
ensuring that the needle was changed between different groups o f cells.
I f  WAT was used, then an intermediate step was required in order to remove the lipid. 
After homogenisation the sample was centrifuged at 14,000 rpm for 10 min at 4°C. This 
usually resulted in a fatty layer on top o f the supernatant which was avoided while the 
supernatant was transferred to a fresh tube, taking care not to disrupt the cell debris pellet 
formed at this stage.
The sample was then incubated for 5 min at room temperature, before adding 200 pi o f 
chloroform. It was then shaken vigorously for 15 sec, let stand at room temperature for 
10 minutes and centrifuged at 14,000 rpm for 15 min at 4°C  creating three layers, a 
colourless upper aqueous phase containing RNA, a white interphase containing DNA 
and a bottom red phenol phase containing protein. The top layer was transferred to a 
fresh tube, the interphase was discarded, while the lower layer was transferred to a new 
tube and kept at -80°C for protein extraction. Fifty pi o f isopropanol were then added to 
the sample, which was vortexed and kept for 10 min at room temperature. The sample 
was centrifuged at 14,000 rpm for 10 min at 4°C  and the supernatant was transferred to 
a new tube. Another 450 pi o f isopropanol was then added to the sample, which was 
vortexed, let stand for 10 min at room temperature and then centrifuged at 14,000 rpm
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for 10 min at 4°C. Following that, the supernatant was discarded taking care o f the 
pellet, which was vortexed in 500 pi o f 75% ethanol. The sample was then centrifuged at 
14,000 rpm for 10 min at 4°C. The supernatant was removed and the pellet was allowed 
to air dry for 5-10 min. The pellet was dissolved in 10-30 pi o f ultra-pure water and 
stored at -80°C until further use.
2.5.3 TURBO DNase treatment o f RNA
Although all possible care was taken not to contaminate RNA samples, a certain degree of 
contamination could not be avoided. DNA contamination o f RNA samples however 
would later result in inaccurate quantification. To minimise this problem, whenever 
RNA samples were used for real-time RT-PCR analysis, a TU R BO  DNA-free Kit was 
used to remove any remaining traces o f DNA from RNA preparations and thus improve 
the efficiency o f the quantification analysis.
2.5.3.1 Reagents
(i) 1 Ox TU RBO  DNase buffer
(ii) TU R BO  DNase (2 units/ pi)
(iii) DNase Inactivation Reagent
2.5.3.2 Method
According to manufacturer’s instructions, 0.1 volume of lOx TU R BO  DNase Buffer and 
1 pi TU R BO  DNase, which is suitable for removing up to 1 pg o f DNA from RNA in 
an up to 100 pi reaction volume, were added to the RNA sample and mixed gently. The 
sample was then incubated at 37°C in a hybridisation oven for 30 min with gentle 
shaking. Two pi or 0.1 volume DNase Inactivation Reagent, whichever was greater, was 
then added and the sample was incubated for 2 min at room temperature, mixing 
occasionally to redisperse the Inactivation Reagent, which removes the DNase and any 
divalent cations from the sample. The sample was then centrifuged at 10,000 g for 1.5 




RNA samples were quantified using a spectrophotometer (Biophotometer). One pi o f the 
RNA was diluted, the diluted sample was placed in a disposable plastic cuvette and the 
absorbance was measured at 260 nm and 280 nm with distilled water used as a blank. 
The concentration o f RNA (pg/ pi) was automatically calculated.
Since the maximum absorbance o f nucleic acids is at 260 nm and RNA has an extinction 
coefficient o f approximately 44 at that wavelength, the concentration o f RNA can be 
calculated by the spectrophotometer using the Beer-Lambert law:
[RNA] pg/ pi = A260 x 44 x Dilution Factor/ 1000
The ratio between A260 and A280 was used as a measure o f the purity o f the RNA. A value 
o f 2 indicated a pure sample, whereas a value o f 1.6 or less indicated contamination 
(essentially from protein).
2.6 Reverse-transcription polymerase chain reaction (RT- 
PCR)
2.6.1 First-strand cDNA synthesis
This procedure is used to generate single-stranded D N A (ssDNA) strands (cDNA) 
complementary to the mRNA sequences in the total RNA samples. For this, anchored 
oligo-dT primers were used instead of standard dT primers or random decamers. 
Standard dT primers anneal at random points within the poly-(A) tail and cDNAs 
generated this way contain long 3 ’ poly (dA/dT) sequences that are largely responsible for 
the low efficiency o f identification of the genes expressed at lower levels. Oligo-dT 
primers also generate truncated cDNA through internal poly (A) priming which in turn 
interrupts the generation o f full-length cDNA (Wang et al., 2000). Furthermore, random 
decamers anneal at a random point along the mRNA sequence. It has been demonstrated 
(Nam et al., 2002) that this problem o f internal poly-(A) can be minimized with 
replacement o f these primers with anchored oligo-dT primers, since they are designed to
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anneal at the mRNA/ poly-(A) junction instead, thus starting transcription at the start o f 
the 3 ’ end o f the coding mRNA sequence. This minimizes the generation o f truncated 
cDNA, thus providing high-quality cDNAs, and further improving the efficacy o f PCR 
and real-time PCR for the study o f genes that are not highly expressed.
2.6.1.1 Reagents
First strand D N A was reverse transcribed from total RNA by using a Reverse-iT™ first 
strand synthesis kit (ABgene, UK), which contained:
(i) Anchored oligo-dT (500 ng/ pi)
(ii) dNTP mix (5 mM each)
(iii) 5x 1st strand synthesis buffer
(iv) D T T  (1 M)
(v) Reverese iT™ RTase Blend (50 units/ pi)
(vi) Ultra-pure water
2.6.1.2 Method
The procedure was carried out using sterile RNase/ DNase -  free tubes and filter tips. 
For a 20 pi reaction, 1 pg of RNA, 1 pi oligo dT primer and up to 12 pi sterile water 
were added to a 0.5 ml tube, vortexed, and then heated to 70°C for 5 min in order to 
remove any secondary structure. The sample was then immediately placed on ice, before 
adding the following: 4 pi o f 5x buffer, 2 pi o f dNTP mix, I pi o f 1M D TT, and 1 pi o f 
reverse transcriptase. The sample was then vortexed and incubated at 47°C for 30 min. 
To inactivate the Reverse-iT RTase, the sample was finally incubated at 75°C for 19 min. 
The sample was then either stored at -20°C or immediately used for polymerase chain 
reaction (PCR).
2.6.2 Polymerase Chain Reaction (PCR)
For PCR, first the cDNA sequence is used to design a pair o f primers, one 
complementary to each strand o f the DNA double helix and lying on opposite sites o f the 
region to be amplified. How this pair o f primers is designed is discussed in the following
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section. Previously made cDNA is used as a template for PCR reaction and DNA 
polymerase is used to amplify the quantity o f the cDNA o f interest. The process starts 
with a denaturation phase at 94°C, which is followed by 20 to 40 amplification cycles. 
Each cycle doubles the amount o f DNA synthesized in the previous cycle and consists o f 
three steps; denaturation, annealing and extension. Denaturation results in the 
dissociation o f double-stranded DNA (dsDNA) into single-stranded DNA (ssDNA) and 
the unwinding o f its helical structure. Annealing enables the primers to hybridise to their 
complementary bases on the ssDNA. Annealing temperature, as further discussed in the 
following section, is primer specific and depends on the primer length and G C  content. 
Finally, during extension, the DNA polymerase synthesises a complementary DNA 
strand starting from the primer. The duration o f the extension phase depends on the size 
o f the product being amplified and as general rule it is 60 sec/ kb of the target gene.
There are a number o f potential housekeeping genes. These should be expressed at a 
constant level in different tissues, and at a constant level within the same tissue in all 
conditions, and they include P-actin, glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), hypoxanthine guanine phosphoribosyl transferase (HPRT), 18S ribosomal 
RNA and RNA PolyA II. Housekeeping genes are used to assess the relative degrees o f 
expression o f the genes o f interest and also indicate the quality o f the template material. 
In this study, p-actin was used for both PCR and real-time PCR assays (see section 
2.7.5). In PCR assays, a p-actin PCR was performed as soon as the cDNA samples had 
been synthesised to check the samples’ quality, thus verifying the integrity o f the original 
RNA. If bands had been faint or undetectable, suggesting degradation o f the original 
isolated RNA, then the RNA integrity could have been checked directly by denaturing 
gel electrophoresis, which would allow RNA visualisation. However, no problems of this 
nature were encountered throughout this study.
2.6.2.1 PCR prim er design
Primers were designed using Primer Premier 5 software (Biosoft International, Palo Alto, 
CA, USA) and synthesised commercially (MWG Biotech. Ebersberg, Germany or 
Eurogen tec, Romsey, UK).
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There a few rules that apply to PCR primer design, which were followed in the studies 
described in this thesis for optimal results. Primers were designed to span at least one 
intron, in order to avoid the generation o f PCR products from any genomic DNA 
contaminants present in the cDNA template solution. Intron locations were identified 
using the N C BI ‘s Map Viewer utility. Primers need only be 18-30 nucleotides long. The 
longer the primer the more specific it is during amplification but longer primers are more 
likely to form secondary structures. Both primers had similar G +C  content, between 40% 
and 60% (so that they had similar annealing temperatures), with a minimal degree o f 
self-complementarity (to avoid formation o f secondary structures) and no 
complementarity to each other (so that primer duplexes were not formed).
Annealing temperatures (Ta) are based around melting temperature (Tm), the temperature 
at which 50% o f the primers are annealed to their target sequence. For primers o f <20 
bases, T m  can be calculated in °C  from the equation: Tm  = 4(G+C) + 2(A+T), where G, 
C, A and T  are the number of bases in the primer. Using this as a starting point, the 
optimum annealing temperature can be determined by trial and error. The individual 
primer T ms were between 60° and 65°C, and within 2°C of each other, so that the T a of 
the pair would not be below 55°C, as low T a promotes non-specific binding. The primers 
were ideally designed to amplify a 180-600 bp product, as larger products would require 
longer annealing times to be amplified. The sequence of both primers and that o f the 
expected product were finally BLAST searched to ensure specificity.
Table 2.1 includes all primers used for PCR analysis in the studies to follow.
2.6.2.2 PCR prim er optimization
Primers were tested on receipt by performing PCR on some cDNA samples in which a 
signal for that particular gene was expected. During that first step o f the optimization, a 
high number o f cycles (35-38) was used and a gradient analysis was performed to 
determine the optimal annealing temperature. To do that, samples containing the same 
cDNA underwent PCR amplification over a range of annealing temperatures. The 
highest temperature at which a strong signal was obtained with no non-specific products
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Table 2.1 Sequences of the primers and the PCR conditions








m Z A G  s 
m Z A G  as
G C CT TC TT CC A CT A C A A CA G
T T C A G G A C A C T C C T C C T C T A
54 30 396 N M _ 0 13478
m(3-actin s 
m(3-actin as
T G C T G T C C C T G T A T G C C T C T
A G G TC TT TA C G G A T G T C A A C G
60 23 463 N M _007393
mresistin s 
mresistin as
GAAGAACCTTT C A T T T  C C C C T C C  
C T T  CACGAAT G T  C C C A C G A G C C
60 25 266 N M _022984
rZA G  s 
rZA G  as
AAATAACAGAAGCAGTGGAGCAG
TTTG T G G G TA G A A G TC A TA G G C
54 30 322 N M _ 0 12826
rLeptin a 
rLeptin as
G T  CCA G G AT G ACACCAAAACCC 
T C T C G C A G G T T C T C C A G G T C A T
60 30 239 N M _ 0 13076
rAdip. a 
rAdip. as
G T  C C C T  CCACCCAAGGAAACT 
G C C C TA C G C T G A A T G C T G A G T
56 28 271 N M _144744
rP-actin s 
rP-actin as
G C C C A T C T A T G A G G G T T A C G C
GAGCCACCAATCCACACAGAG
62 23 543 N M _031144
T a °C, annealing temperatures; Cycle no, cycle numbers; bp, base pair indicating size of 
the expected products, m, mouse; r, rat; s, sense primer; a, antisense primer. Adip, 
adiponectin.
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was selected. In general, primer optimization was performed using cDNA from a source 
with a relatively weak signal o f the specific gene of interest, so as to ensure that it could 
then be detected in samples expressing it at a low level.
2.6 .23  Reagents
(i) Ultra-pure water
(ii) 100 pM stock solution o f each sense and antisense primers
(iii) l . l x  ReddyMix (ReddyMix PCR MasterMix kit)
2.6.2.4 M ethod
The procedure was carried out using sterile RNase/ DNase — free tubes and filter tips. 
One pi o f each RT reaction, 2 pi in the case o f ZAG, was amplified in a 25 pi PCR 
reaction containing 0.02 mM of each primer and l . l x  Reddy Mix™ PCR Master Mix 
that consists o f 1.5 mM M gCl2, 1.25 units Taq polymerase, 75 mM Tris HC1 (pH 8.8 at 
25°C), 20 mM (NHihSO.*, 0.01% Tween 20 (v/v) and 0.2 mM each o f the dNTPs. 
Sterile water was used to make up to 25 pi reaction when needed.
PCR was performed on a thermal cycler (Hybaid, U.K). The sample was incubated with 
an initial denaturation at 94°C for 2 min, followed by 23-35 cycles, depending on the 
gene amplified (see Table 2.1), consisting o f denaturation at 94°C for 20 sec, annealing, 
whose temperature varied among different genes (see Table 2.1), and extension at 72°C 
for 40 sec, or 60 sec in the case o f ZAG. After the last cycle, the sample underwent 
elongation at 72°C for 5 min in all cases. Negative control RT-minus reactions were 
carried out to establish that the target RNA was not contaminated with DNA.
2.6.3 Agarose gel electrophoresis
PCR products were visualised on 1% agarose gels stained with ethidium bromide. 
Ethidium bromide is fluorescent and contains a planar group that intercalates between 
the stacked bases o f DNA and is the most convenient method for visualising DNA under 




(ii) 5 mg/ml Ethidium bromide
(iii) lx  T BE buffer
(iv) 100 bp DNA ladder
2.6.3.2 M ethod
Gel casting trays were used for running gels, assembled with tape at each end. The 
amplification o f targeted genes was checked on a 1% agarose gel. The volumes o f gel 
made up varied, according to the size o f the tank and tray used. Agarose was weighed out 
into a 250 ml conical flask and then 1 x T BE was added to the required volume. The 
mixture was then heated in a microwave oven, mixing occasionally, until the agarose 
melted. Once melted the mixture was allowed to cool slightly, before adding 5 ng/pl 
ethidium bromide. The gel was then poured into the gel - casting tray, and allowed to set 
for at least 30 min. Once the gel had set, the tape was removed and it was placed into the 
electrophoresis tank. 1 x TBE was added until the gel had completely submerged, and the 
comb was then removed. Ten -  20 pi o f PCR product was loaded into each well, taking 
care that wells did not overflow, and run alongside 2 pi o f 100 bp ladder, at a constant 
100 -  120 V  and maximum current for 30 -  60 min.
When the samples had been electrophoresed, the gel was placed on a U V transiluminator 
(2011 Macrovue) to allow visualisation o f the products. The images were recorded using 
a digital camera (KDS D C  120) and analyzed using KDS ID 1 image analysis software.
2.7 Real-time Polymerase chain reaction (qPCR) -  Taqman 
system
Real-time PCR has become the most popular method and the ‘gold standard’ for 
quantitating steady-state mRNA levels. It measures formation during the exponential 
phase, by taking advantage of the fact that DNA amplifications do occur efficiently early
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in the reaction process. This measurement correlates to the amount o f specific starting 
DNA, thereby allowing quantification.
2.7.1 Taqman system description
The real-time work performed in this study used the Taqman system. This system 
continuously measures PCR product accumulation using a set o f primers and a dual- 
labeled fluorogenic oligonucleotide probe called the Taqman probe. This probe is 
composed o f a short oligodeoxynucleotide (20-30 bases) that is labelled with two 
different fluorescent dyes. As schematically presented in Figure 2.1, on the 5’ terminus is 
a reporter dye and on the 3 ’ terminus is a quenching dye (usually TAMRA). This probe 
sequence is homologous to an internal target sequence present in the PCR amplicon. 
When the probe is intact, energy transfer occurs between the two fluorophores and 
emission from the reporter is quenched by the quencher (FRET -  fluorescence resonance 
energy transfer). During the extension phase o f PCR, the probe is cleaved by 5’ nuclease 
activity o f Taq polymerase thereby releasing the reporter from the oligonucleotide 
quencher, thus ending FRET and producing an increase in reporter emission intensity (at 
518 nm for FAM), which increases in each cycle proportional to the rate o f probe 
cleavage. In the real-time machine, the laser light source excites each well and a CCD  
camera measures the fluorescence spectrum and intensity from each well to generate real­
time data during PCR amplification. The software examines the fluorescence intensity o f 
reporter and quencher dyes and calculates the increase in normalized reporter emission 
intensity over the course o f amplification (AR). The results are then plotted [usually as 
ARn, after normalisation o f the reporter dye signal to a reference dye (usually ROX) to 
correct for differences in reaction mix volumes between wells] versus time, represented by 
cycle number, to produce a continuous measure o f PCR amplification. To provide 
precise quantification o f initial target in each PCR reaction, the amplification plot is 
examined at a point during the early log phase o f product accumulation. This is 
accomplished by assigning a fluorescence threshold above background and determining 
the time point at which each sample’s amplification plot reaches the threshold (Ct) 
(Busdn, 2002; Giulietti et al., 2001; Valasek &  Repa, 2005).
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Figure 2.1 The principle of Taqman assay
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(Source: Bustin &  Mueller, 2005)
This diagram shows the steps at each Taqman cycle. After dénaturation, primers and 
probes anneal to their targets. The probe contains a reporter dye at the 5 ’ end and a 
quencher (Q) at the 3 ’ end. During the polymerisation step, the 5’ nuclease activity of 
the Taq polymerase displaces and cleaves the probe. This physically separates the reporter 
dye and quencher dyes, resulting in reporter fluorescence. The increase in signal is 
directly proportional to the number of molecules released during that cycle. 
Accumulation of PCR products is detected directly by monitoring the increase in 
fluorescence o f the reporter dye.
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2.7.2 Primers and Taqman probes design and optimisation
Murine and rat primers (apart from ZAG rat primers) and Taqman probe sequences were 
designed (with the kind assistance of Dr J  Jenkins) with Primer Express software (Applied 
Biosystems). ZAG rat primers and probe were designed using Beacon Designer software 
(PREMIER, Biosoft International). All sets o f primers and probes were synthesised 
commercially (Sigma-Genosys, Haverhill, U K  and Eurogentec, Romsey, UK). They were 
all designed to be 20-30 bases in length, while the PCR product size was designed to be 
no more than 150 bases, as PCR is more efficient with smaller amplicons. Primers’ T ms 
were 58-60°C, while their individual T ms did not differ more than 1-2°C. In addition the 
forward primer contained no more that 2 G + Cs in the last 5 bases o f the 3’ and T m of 
the probes was significantly greater (approximately 10°C) than that o f the primers, to 
ensure that they hybridise before the primers. The probes did not overlap with, or have 
sequence complementarity with either o f the primers and they did not contain a G at 
their 5’ ends, as a G adjacent to the reporter dye quenches reporter fluorescence even 
after the probe has been cleaved. Finally, they were designed so that there were no more 
than 4 Gs in a row and the number of Gs was smaller than that o f Cs. Finally, as for RT- 
PCR, primers were designed to span an intron.
All the sequences for primers and probes used in Taqman assays in this study are 
presented in Tables 2.2 and 2.3, together with the optimised final reaction 
concentrations. For each new set o f primers and probe an optimisation o f the 
concentrations was first conducted. An assay was performed with final primer 
concentrations ranging from 50 nM to 900 nM (in all possible combinations o f 50 nM, 
300 nM and 900 nM), while the probe concentration was fixed at 200 nM. The 
combination that gave the lowest C t and the highest R n was then selected and was used 
to determine the probe optimal final concentration, which ranged from 25 nM to 225 
nM. As with the primers, amplification plots were used to select the optimal 
concentration.
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Table 2.2 Sequences of primers and Taqman probes of mouse target genes and
working conditions for real-time PCR
Gene Sequence (5’-3’) Cone. nM Size, bp
mZAG
S GAGCCTGTGGGACCTTGGA 900




A ATCCA G G CTCTCTGG CTTCTG 900
P AGCT G CT CCCTG CCT CAGACCAGT G 225
mAdipo 97
S G G CTC TG TG CTCC TC CA TCT 900
A AG AGTCGTT G ACGTTAT CT G CATAG 900
P CCCATACACCTGG AGCCAGACTT G GT 225
mp-actin
S ACGGCCAGGTCATCACTATTG 900 97
A CAAGAAGGAAGGCTGGAAAAG 900
P ACGAGCGGTTCCGATGCCCTG 225
Cone, the working concentrations for each primer and probe; bp, base pair indicating the 
product sizes (S, sense primer; A, antisense primer; P, probe; m, mouse. Adipo, 
adiponectin.
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Table 2.3 Sequences of primer and Taqman probe sequences of rat target
genes and working conditions for real-time PCR





S CCTTCAGGAGACTGGGTCTTATTC 900 99
A GTTGAGAAATGCGGTGGCTTG 900
P CCTCTACACCGGGTTGTCCAGGCC 225
rL e p tin
S AACCCT CAT CAAGACCATT GTCA 900 100
A CCCGGGAATGAAGTCCAAA 900
P T G AC ATTT CAC ACACG CAGT CG GTAT CC 225
rA d ip o .
S CCCCTGGCAGGAAAGGA 900 64
A CCTACGCT GAAT G CT GAGT GAT 900
P AGCCCGGAGAAGCCGCTTACATG 225
rM C P - 1
S CT GT CT CAG CCAGATGCAGTTAA 300 69
A TGGGATCATCTTGCCAGTGA 300
P CCCCACTCACCTGCTGCTACTCA 225
r N G F








S GACAGGAT GCAGAAGGAGATTACT G 300 101
A GAGCCACCAATCCACACAGA 300
P CACC AT G AAG AT CAAG AT C ATT GCTCCTCCT 225
Cone, the working concentrations for each primer and probe; bp, base pair indicating the 
product sizes (S, sense primer; A, antisense primer; P, probe; r, rat; adipo, adiponectin).
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2.7.3.1 Reagents
(i) qPCR  Core Kit:
lOx Reaction Buffer 
50 mM Magnesium chloride 
5 mM dNTP mix 
5 U/pl Hot Goldstar enzyme




Working solutions o f the primers and probes were prepared at lOx concentrations by 
diluting the stock solution with ultra-pure water. Each 25 pi reaction contained the 
following:
2.7.3 Preparation of 96 well plates for real-time PCR
1 Ox Reaction buffer 
50 mM M gCli 




5 U/pl H ot Goldstar enzyme 
Ultra-pure water
2.5 pi (lx  final concentration)
2.5 pi (5mM)
1 pi (200mM)
2.5 pi (see Table 2.2 and 2.3)
2.5 pi (see Table 2.2 and 2.3)
2.5 pi (see Table 2.2 and 2.3) 
0.125 pi (0.025 U / pi)
11.375 pi
A master mix was made up, with 5-10% excess to allow for pipetting errors, which 
contained all the above components for the PCR, minus the cD NA template. Twenty- 
four pi, or 23 pi in the case of ZAG, o f the master mix were then aliquoted to each well. 
One or 2 pi cDNA was then added to each well for a total reaction volume o f 25 pi. All
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samples were added on the plate in duplicate or triplicate if  that was possible. ‘No 
primer’, ‘no probe’ and ‘no template’ control samples were also added on the plate for 
each set o f  primers and probe and the plate was sealed with an optical cover. The plate 
was then spun at 1000 rpm for 1 min to ensure the reaction mix was not sticking to the 
sides o f the well. Since the Stratagene machine (see section 2.7.4) was more sensitive, in 
most cases 12.5 pi reactions were prepared instead of 25 pi. In that case 11.5-12 pi o f 
master mix were placed in each well before adding the cDNA. If two or more plates 
needed to be compared, a number o f standards were used in all the plates.
2.7.4 Taqm an system real-time PCR machine setup
Some studies described in this thesis were performed using an ABI Prism 7700 
instrument (Applied Biosystems), while the rest were performed using the Mx3005P 
QPCR system (Stratagene). The same sets o f primers and probes were used in both 
systems. The ABI Prism 7700 system requires an Apple Macintosh which runs the 
Sequence Detector v l.7a software (Applied Biosystems). The Mx3005 system was 
connected to a PC (Dell Optiplex GX280) and data was collected and analysed with 
Mx3005P v2.02 software (Stratagene). In both programs, wells were labelled according to 
content on the plate setup screen. In the latter, FAM was specified as the reporter dye 
and ROX as the reference dye. The plate was inserted into the heat block and an optical 
pad placed on top so that the holes aligned with the well positions. The cover was locked 
into position and the run started.
Amplifications were performed starting with a 2 min activation stage at 50°C, then a 10 
min denaturation step at 95°C followed by 40 cycles consisting o f a denaturation step o f 
15 sec at 95°C  and a combined primer annealing and extension step o f 60 sec at 60°C. 
Data was collected automatically by the software, and analysed once the run was 
complete.
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The amplification plots were displayed in log scale using the Sequence Detector software 
and the threshold was then manually adjusted. The representations were then switched 
back to linear and the software automatically recalculated the C t  value for each well 
(Figure 2 . 2 ) .  As mentioned above, the C t  is defined as the cycle number at which the 
fluorescence emitted from the well crossed the threshold. The results were then exported 
as a Microsoft Excel file and mRNA levels o f expression were analysed by relative 
quantitation with the 2'AACr method (Livak &  Schmittgen, 2001). All samples were 
normalised to values o f P-actin, which was used as the internal standard in all 
experiments. Results were expressed as fold changes o f C t  values relative to controls.
2.7.5 Analysis of real-time PCR data
2.8 Protein detection using western blotting method
Western blotting (Towbin et al., 1979) is a method used to detect protein in a given 
sample o f tissue homogenate or extract. It uses gel electrophoresis to separate denatured 
proteins by mass. The proteins are then transferred out o f the gel and onto a 
nitrocellulose membrane where they are probed using antibodies specific to the protein of 
interest. The technique relies on the primary antibody to detect the protein of interest 
from the total o f proteins found on the membrane. The secondary antibody then 
recognizes the primary antibody and binds to it. Horse radish peroxidase (HRP) 
conjugated to the secondary antibody converts a luminol substrate to a light releasing 
substance and this light is detected as a spot on a film (Figure 2.3). Western blotting is 
broadly used to examine the amount o f protein in a sample, or compare protein 
expression in different groups.
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Figure 2.2 Default baseline plot-log and linear view
The figure shows an image o f an amplification plot with default settings, as seen on the 
Mx3005P v2.02 software (Stratagene). (A) Log view: while here the plot could be 
adjusted, ideally set above the background fluorescence, within the exponential phase of 
the PCR. (B) shows the linear view of the same assay.
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Figure 2.3 Schematic diagram of protein detection
2  Secondary Antibody
(Source: http:Hwww. molecularstation. comlimaeeslwestem-blot.gif)
This schematic diagram represents the detection procedure during immunoblotting. The 
membrane is shown in dark green. Milk proteins block non-specific antibody binding. 
The protein of interest is shown in light green. Primary and secondary antibodies are 
shown as upside-down Ys. HRP is shown in yellow. When the membrane is soaked into 
the EC L detection reagents, a peroxidase catalyzed oxidation of luminol is elicited and 
subsequently enhanced chemiluminescence, where the HRP labeled protein is bound to 
the antigen on the membrane. The resulting light is detected on the Hyperfilm.
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2.8.1 Protein Isolation
Different methods were used for protein isolation from frozen and frozen tissues, through 
Trizol reagent after RNA had been extracted first, and from 3T3-L1 cells.
2.8.1.1  Protein isolation from frozen tissues
2.8.1.1.1 Reagents
(i) SH E buffer:
250 mM Sucrose 
1 mM HEPES 
0.2 mM EDTA 
Distilled water
Protease Inhibitors (1 tablet per 10 ml buffer)
The pH o f the solution was adjusted to 7.2 and stored at 4°C for up to three months.
2.8.1.1.2 Method
One hundred mg o f tissue sample were homogenised in a glass homogeniser in 500 pi 
SH E buffer. The sample was then centrifuged at 12,000 g for 15 min at 4°C. The 
supernatant containing the protein was retrieved, while the pellet, which contained cell 
debris, nuclei and mitochondria, was discarded. The protein concentration was then 
determined using the BCA assay (Section 2.8.2) and the sample was either used or stored 
at -80°C.
2.8.1.2  Protein Isolation from TRizol reagent
2.8.1.2.1 Reagents
(i) Wash Solution [0.3 M Guanidine Hydrochloride in 95% ethanol (0.3M 
GHC1)
(ii) 100% ethanol




As previously described in the RNA extraction method (Section 2.5.2), the phenol 
(bottom) layer after the chloroform precipitation was stored to perform protein 
extraction. Three-hundred pi o f 100% ethanol was then added to the sample per 1 ml o f 
TRizol reagent used for the initial homogenization. Volumes were adjusted accordingly 
when 700 pi had originally been used, as in 3T3-L1 cells. The sample was then mixed by 
inversion and allowed to stand at room temperature for 2-3 min before being centrifuged 
at 2,000 x g for 5 min at 4°C to pellet any remaining traces o f DNA. The supernatant 
containing the protein was then carefully transferred into a fresh tube and 1.5 ml of 
isopropanol was added per 1 ml o f TRizol initially used, to precipitate the protein. The 
sample was then incubated for 10 min at room temperature and centrifuged at 12,000 x 
g for 10 min at 4°C. The supernatant was discarded and the pellet containing the protein 
was washed in 2 ml o f wash solution per 1 ml o f TRizol used initially. The sample was 
allowed to stand for 20 min at room temperature and was centrifuged at 7,500 x g for 5 
min at 4°C . The wash solution was then discarded, replaced by fresh one and the whole 
washing procedure was repeated twice more. After discarding the wash solution the third 
time, the protein pellet was vortexed in 2 ml o f 100% ethanol and incubated for 20 min 
at room temperature. The sample was then centrifuged at 7,500 x g for 5 min at 4°C. 
The ethanol was discarded and the protein pellet was vacuum dried for 5 min. The 
sample was then sonicated, in 20-30 pi o f 1% SDS containing protease inhibitors, three 
times each lasting 10 sec with a ten sec interval between them in order for the pellets to 
dissolve. The sample was finally centrifuged at 10,000 x g for 10 min at 4°C  to sediment 
any insoluble material and the protein supernatant was transferred into a fresh tube. The 
sample was stored at -80°C or immediately used to proceed with the rest o f the western 
blotting procedure.
2.8.1.3 Protein isolation from 3T3-L1 adipocyte media using TCA 
precipitation
2.8.1.3.1 Reagents
(i) 50% TCA  solution in water (used cold)
(ii) 1% SDS with protease inhibitors (1 tablet per 10 ml)
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(iii) lx  PBS
2.8.1.3.2 Method
Five hundred pi o f TCA  solution was added in 1.5 ml o f medium, collected as previously 
described in Section 2.3.2.5, giving a final TCA  concentration o f 12.5%. The sample was 
then incubated for 3 h on ice before being centrifuged at 14,000 rpm for 30 min at 4°C. 
The supernatant was then discarded and the pellet containing the protein was first 
washed in 200 pi o f lx  PBS and then dissolved in 1% SDS. If the medium did not 
contain serum, it was dissolved in 10 pi, whereas otherwise in 300 pi o f 1% SDS. The 
sample was then stored at -80°C.
2.8.2 Protein quantification by the BCA method
2.8.2.1 Reagents and equipment
(i) Bicinchoninic acid (BCA) solution
(ii) Copper (II) sulphate solution




A standard curve was created using Bovine serum albumin (BSA) as a protein standard 
with final concentrations o f 0, 4, 8, 12, 16, 24 and 40 pg/ well. To do that, 0, 2, 4, 6, 8, 
12 and 20 pi o f BSA were added to the wells in duplicate and made up to 20 pi with 1 % 
SDS. In terms o f the samples, 1 pi o f each sample o f unknown concentration was added 
to the wells and then made up to 20 pi with 1% SDS. A 1:50 dilution of copper sulphate 
in BCA solution, which contains BCA, sodium carbonate, sodium tartrate and sodium 
bicarbonate in 0.1 M N aO H  (pH 11.25), was prepared and 200 pi o f this solution was 
added into each well. The plate was then incubated for 30 min at 37°C in a hybridization 
oven and after that time the samples containing the protein could be seen changing from 
green to purple. The extinction was then measured at 570 nm in a Benchmark Type 
plate reader. Data was collected with Microplate Manager 5.2 software and a standard
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curve was made relative to which the protein concentration o f the samples was 
determined (see Figure 2.4). The correlation coefficient (r) o f the standard curve should 
ideally be 1. In cases where r was lower than 0.996 the process was repeated. 
Furthermore, in cases when protein samples were either too concentrated or too diluted 
for the reader to determine a concentration, the reactions were repeated by adjusting the 
volume o f the samples accordingly.




125 mM Tris-HCL pFI 6.8 
2.5% SDS
2.5% P -  Mercaptoethanol 
6.25% Glycerol
2.5 mg/ml Bromophenol blue
Once the ingredients had been added together, loading buffer was aliquoted and stored at 
-20°C up to a few months.
(ii) Separating gel (10 ml) (10%):
4.825 ml distilled water 
2.475 ml 40% Acrylamide/ bis
2.5 ml 1.5 M Tris pH 8.8 
100 pi 10% SDS
100 pi 10% Ammonium Persulfate (AP) 
lO p lT E M E D  
AP was made fresh each time
(iii) Stacking gel (5ml) (4%):
3.732 ml Distilled water 
498 pi 40% Acrylamide/ bis
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Figure 2.4 Standard curve for protein concentration estimation
Standard Curve. A bs = 0 .0749 *  Cone + 0.108 
Correlation Coefficient 0.999
This figure represents a standard curve for protein concentration estimation using the 
BCA assay as obtained by MicroplateManager 5.2 software. BSA was used as a protein 
standard at final concentrations o f 0, 2, 4, 6, 8, 12, and 20 pg. The optimum correlation 
coefficient (r) is as close to 1 as possible. Concentration is in ml.
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630 jil 1.0 M Tris-HCl pH 6.8 
50 pi 10% SDS 
50 pi 10% AP 
5 pi TEM ED
(iv) Running buffer:
25 mM Tris-base 
192 mM Glycine 
0.1% SDS 
Distilled water
The running buffer was stored at room temperature and was used only once.
2.8.3.2 Equipment
(i) Main vertical electrophoresis unit with safety lid
(ii) 2.0 mm notched glass plates
(iii) 2.0 mm plain glass plates
(iv) 1.0 mm spacers
(v) 1.0 mm comb, 12 or 16 wells
(vi) Casting base with silicone seals
2.8.3.3 Method
At first all the gel components were cleaned with ethanol, dried and then assembled 
following the manufacturer’s instructions (Scie-Plas, Instruction manual for vertical 
electrophoresis units). Once assembled and locked onto the casting base, distilled water 
was poured between the glass plates to check for leaks. The water was then removed using 
filter paper. The separating gel was prepared and injected between the glass plates, 
without delay, using a 5 ml syringe and 21-gauge needle, leaving about 1/3 o f the space 
for the stacking gel. Minimum pressure was applied to the syringe while injecting to 
avoid the formation o f bubbles and using a fresh syringe and needle, 0.01% SDS was 
added to the top o f the gel to a depth of 5 mm to stop it drying out and to keep the gel
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level. Once the separating gel had set (10-20 min), the SD S was removed using filter 
paper, the stacking gel was prepared, injected between the glass plates the same way and 
the comb was inserted. It was then allowed to set for 20-30 min.
The protein concentration had already been estimated using the BCA method (see 
section 2.8.2). From the protein stock, 5 to 20 pg were run on the gel. The samples were 
made up to equal volume by adding 0.1% SD S and were then diluted 1:1 with loading 
buffer. They were then heated at a 95°C waterbath for 5 min, to denature the proteins 
allowing them to unfold completely. The SDS in the sample then surrounded the protein 
with a negative charge and the P-mercaptoethanol prevented the reformation of disulfide 
bonds.
The gel was then removed from the casting base and placed into the gel tank, which was 
filled with running buffer until both ends o f the gel apparatus were completely 
submerged. The comb was then removed, the wells were repaired with a gauge needle if 
needed and the samples were loaded slowly so as not to overflow and run alongside 5 pi 
of rainbow protein marker at 40 mAmps constant and maximum voltage until the 
bromophenol blue dye was seen running off the gel (usually 1.5-2 h). During the run the 
tank was connected to cold water so that the system was kept cool. The electrophoresis 
unit was then disassembled and the gel transferred for electroblotting.
2.8.4 Electroblotting
2 .8.4 .1  Reagents a n d  equipm ent
(i) Transfer buffer:
25 mM Tris-base 
192 mM Glycine 
20% Methanol 
Distilled water
The buffer was made fresh and only used once
(ii) Fibre pads
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(iv) Extra thick blotting paper
(v) Hybond ECL Nitrocellulose Membrane
(vi) Compression Cassettes (black (-) and white (+))
(vii) Running tank and lid
(viii) Internal Electroblotting module for two gels
All the components for the transfer were soaked into transfer buffer for about 15 min 
before assembling the blotting unit in the following order while still in buffer to prevent 
the formation o f bubbles which interfere with the transfer procedure:
1.+ cassette, 2. foam pad, 3. blotting paper, 4. transfer membrane, 5. gel, 6. blotting 
paper, 7. foam pad, 8. — cassette
Before finalising and while still in buffer, it was made sure that there were no bubbles in 
between the components. The tank was filled with running buffer until the whole system 
was fully submerged and transfer was performed at 100 V  constant for an hour, while 
cold water was constantly circulating at the bottom o f the tank to keep it cool.
2.8.5 Immunological detection o f proteins
2.8.5.1 Reagents and Equipment
(i) 0 . 1 %  PonceauS
(ii) Tris Buffered Saline (TBS) pH 7.5:
20 mM Tris - Base
500 mM Sodium Chloride 
Distilled water




10% skimmed milk powder in TTBS
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(v) Antibody diluent:
3% skimmed milk powder in TTBS
(vi) Primary and secondary antibodies
(vii) EC L Western blotting detection reagents
(viii) Photographic Developer (stored in the dark)
(ix) Photographic Fixer (stored in the dark)
(x) Intensifying screen cassette
(xi) Hyperfilm ECL
2.8.5.2 Ponceau S  staining
Before proceeding with the detection, Ponceau S staining was performed on the 
membrane to ensure the success o f the transfer and the equal loading of protein in all the 
lanes. As soon as the transfer was finished, the blotting unit was disassembled and the 
membrane was carefully placed in a small container face up and was submerged into 
Ponceau S. It was then placed onto a shaking platform for 15 min. The Ponceau was 
then tipped off and the membrane was washed in TBS buffer. After a period the protein 
bands could be visualised. TBS was then replaced until all red colour disappeared. The 
detection steps then followed.
2.8.5.3 Detection method
The membrane was placed in a box containing 100 ml o f blocking solution and was 
incubated at room temperature for 1 h on a shaking platform or overnight at 4°C. The 
primary antibody solution was prepared by making up 2 ml o f antibody diluent 
containing 1:1000 antibody. The ZAG primary antibody was a mouse monoclonal 
(Santa-Cruz, USA). Monoclonal antibodies are better than polyclonal ones for western 
blotting since they create lower background on the blot and are more specific, thus 
producing cleaner results as less non-specific bands are detected. The membrane was 
placed into a pouch together with the primary antibody solution and incubated at 4°C 
overnight on a shaking platform. The following day the membrane was placed into a 
clean box and washed with 50 ml o f TTBS at room temperature for 10 min on a shaking 
platform. The T T B S was then replaced and the procedure was repeated twice more. The
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membrane was then once again placed into a pouch and incubated with 2 ml o f 
secondary antibody (HRP conjugated goat anti-mouse) solution (1:1000) at room 
temperature for 1 h on a shaking platform. After 1 h the membrane was once again 
placed in a box and washed three times in TTB S buffer, for 10 min each time. These 
were followed by 3 washes in TBS for ten min each. All 6 washes took place at room 
temperature on a shaking platform. The TBS was then replaced and the membrane was 
left standing for about 15 min while preparing for the development procedure.
For detection, 1.5 ml o f each of the two ECL (Enhanced Chemiluminescence) reagents 
were mixed together, gently poured over the membrane, and incubated for 1 min at 
room temperature. After that any excess ECL detection reagent was discarded and the 
membrane was heat-sealed in Saran wrap membrane, gently smoothing out any air 
bubbles with tissue, and immediately preceded with the development procedure as the 
chemiluminescent signal only lasts for 1 h.
The development procedure took place in a dark room. The sealed membrane was placed 
face up into the intensifying screen with a piece o f High performance chemiluminescence 
on top. The cassette was then shut and the membrane was exposed (usually for 30 sec -  1 
min for tissue samples and 30 min for cell extracts). The film was then placed into the 
developer solution, shaking it gently, and as soon as the bands appeared, it was 
transferred to the fixer solution, again shaking gently, for 1-2 min. The film was finally 
rinsed in water for 15 min, to clean it from the fixer solution, before it was allowed to air 
dry.
The membrane was handled very carefully and with forceps at all stages. It was then 
stored at 4°C  and if desired could be re-probed with another antibody.
2.8.5.4 Determination o f optimal prim ary antibody dilution
To obtain clean results with low background, it was important to determine the optimal 
primary antibody dilution for detection, as the secondary antibody dilution was known. 
For this purpose, a series o f dot blots were carried out. A dilution range of protein sample 
was applied directly onto the nitrocellulose membrane, one blot being prepared for each
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antibody dilution to be tested, and the membrane was allowed to air dry. The 
membranes were then blocked and washed exactly as described above. Several dilutions o f 
primary antibody were then prepared (usually 1:100, 1:500, 1:1000 and 1:2000) and 
incubated with the membranes overnight at 4°C. All subsequent steps were then the same 
as the ones mentioned above.
2.8.6 Protein quantification from western blotting
Once dried, the film was scanned using HP Precision Scan Pro 2.5 software and the 
optical density o f the bands was then measured with M CID  Basic 7.0 software. Density 
was measured as D x A-ROD and values were exported to Excel for further statistical 
analysis.
2.9 Statistical analysis
Statistical analysis was performed using Microsoft Excel 2003 or SPSS for Window v l2  
software. Comparisons between samples from two groups were assessed by Student’s t- 
test (either paired or unpaired), while for 3 or more groups o f samples one-way ANOVA 
with post-hoc multiple comparisons using a Bonferroni correction was employed. 
Differences were considered to be significant when P<0.05. All results are presented as 




ZAG expression in rodent adipose tissue and genetic models
of obesity
3.1 Introduction
As previously discussed in Chapter 1, it has been demonstrated that ZAG is involved in 
lipid metabolism. Briefly, both in vivo and in vitro studies have shown that ZAG induces 
a rapid reduction in body fat and that it stimulates lipolysis (Hirai et al., 1998), its 
lipolytic effect probably being mediated through the P3-adrenoreceptor with upregulation 
of the cAMP pathway (Russell et al., 2002). The possibility that ZAG is a candidate gene 
in the regulation o f body weight has been raised (Gohda et al., 2003). It was thus 
intriguing when ZAG (mRNA and protein) was recently shown to be expressed both in 
white and brown adipose tissue o f mice, as well as in white fat o f human (Bing et al., 
2004) and might thus contribute to the local modulation of lipid metabolism within the 
tissue.
Rodents are a good animal model for studying ZAG, due to the degree o f homology in 
the protein between them and humans. Although both rat and murine ZAG display 59% 
amino acid sequence homology with the human counterpart (Ueyama et al., 1994), they 
share up to 100% identity in specific regions thought to be important in lipid 
metabolism (Sanchez et al., 1999). Furthermore, there is an 88.5% identity between rat 
and mouse ZAG amino acid sequence (Ueyama et al., 1994).
The adipose organ is a multidepot organ consisting o f several subcutaneous and visceral 
depots, with distinct anatomical locations, which are different both in terms o f fat cell 
size and function (Pond &  Mattacks, 1991). Rodents have two main subcutaneous fat 
depots, anterior and posterior, and several visceral depots including retroperitoneal, 
perirenal, omental, and mesenteric depots. In terms o f functional differences, it is 
important to mention that the omental adipose tissue contains more blood vessels and 
sympathetic nerve fibres than the subcutaneous depot, implying a greater degree o f 
metabolic activity in the former (Kelley, 2004). Furthermore, there are more 
monocytes/macrophages present in omental compared to subcutaneous adipose tissue 
(Bornstein et al., 2000). In addition to that, a higher degree o f lipolytic activity has been 
demonstrated in the omental site (Flarmelen et al., 2002). It has been suggested that
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omental and subcutaneous adipocytes might originate from different precursor cells that 
are genetically different or that are programmed differentially by the surrounding tissue 
before their differentiation (van Harmelen et al., 2002). These differences further justify 
the fact that different adipose tissue depots show differential capacity with respect to 
adipokine secretion (Trayhurn &  Beattie, 2001). It is thus o f great interest, after having 
established the expression of a factor in adipose tissue to explore, using quantitative 
methods, its differential presence in different depots.
Another important issue is that adipocytes do not account for the whole o f the organ. 
Mature adipocytes constitute around 50% o f the total cell content o f WAT (Hausman, 
1985). The remaining stromal vascular fraction consists o f a number o f different cell 
types including fibroblasts, macrophages and endothelial cells. Thus, when a factor is 
expressed in adipose tissue, it is important to establish whether it is indeed expressed in 
mature adipocytes.
In the present chapter, in terms o f the ZAG expression in murine adipose tissue, the first 
consideration was to investigate whether there are differences in ZAG gene and protein 
expression among depots, and thus gain a greater insight into ZAG’s potential 
physiological functions in adipose tissue. Furthermore, since it has been previously shown 
by RT-PCR that ZAG is expressed in both mature adipocytes and the stromal vascular 
fraction o f mouse epididymal WAT (Bing et al., 2004), the second aim o f this study was 
to explore, again quantitavely, in which fraction ZAG (mRNA and protein) is mostly 
expressed.
Further studies were also designed to focus on examining ZAG expression in 
pathophysiological conditions in which energy balance and substrate flux are changed to 
determine whether ZAG is a component o f local fat mobilisation in adipocytes. Obesity 
is a low-grade inflammatory state (Festa et al., 2001) resulting from chronically positive 
energy balance by excess energy intake and/or energy expenditure. As a result, the levels 
of many adipokines change in the obese state (Trayhurn &  Wood, 2004). Obese rodent 
models are commonly used to study possible factors in the pathogenesis o f obesity and to
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investigate the biochemical, physiological and morphological changes that are present in 
obesity. Therefore, the third aim o f this study was to compare ZAG mRNA levels in 
WAT between lean and obese animals in two rodent models o f obesity: the genetically 
obese (ob/obj mouse, which was first identified in 1950 (Ingalls et al., 1950), and the 
genetically obese ifa/fa) Zucker rat (Zucker &  Zucker, 1961). A specific mutation o f the 
leptin gene is responsible for the obese phenotype of the ob/ob mouse (Zhang et al., 1994), 
which is characterised by the lack o f biologically active leptin and this effectively prevents 
normal signalling o f energy stores by the adipose tissue to the hypothalamus. Thus, one 
o f its first symptoms is hyperphagia, while othes include hyperinsulinaemia, insulin 
resistance and hyperglycaemia (Friedman &  Halaas, 1998; Fruhbeck &  Salvador, 2000). 
The fa/fa rat on the other hand has a point mutation in the gene encoding the leptin 
receptor (OB-R) that has been identified as the underlying cause o f its phenotype, and it 
is characterised by hyperinsulinaemia (Chua et al., 1996).
All experiments described in this chapter were conducted in reference to leptin. Leptin is 
the most studied adipokine in terms o f differential expression both in humans and 
rodents. In addition to that, its upregulation in obesity is well documented.
3.2 Methods
3.2.1 Animals and tissues
Ten-week-old male CD -I mice and Wistar rats were from an inbred colony maintained 
at the University o f Liverpool. Animals were housed at an ambient temperature o f 22 ± 
1°C under a 12:12 h light-dark cycle (lights on at 07:00 h) and fed a standard pelleted 
diet (CRM diet, Labsure, Witham, U.K.). Both food and water were available ad libitum. 
Animals were killed by cervical dislocation and the following tissues were rapidly 
dissected and frozen in liquid nitrogen: WAT (subcutaneous, epididymal, perirenal, 
mesenteric, and omental depots), interscapular brown adipose tissue (BAT), liver, spleen, 
heart, kidneys, stomach, skeletal muscle (gastrocnemius), hypothalamus, lung and 
esophagus. All tissues were stored at -80°C until further analysis. For part o f this study,
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collagenase digestion was employed to separate mature adipocytes from the stromal 
vascular fraction, and the two fractions o f subcutaneous, epididymal and perirenal WAT 
depots were kept separately at -80°C until further analysis.
WAT from 8-week-old male lean (+/+ and +/ob) and genetically obese (ob/ob) C57BL/6J 
mice (Harlam Olac) was also used. Upon arrival, the mice were housed for one week 
under controlled environmental conditions (22 ±  1°C under a 12:12 h light-dark cycle, 
lights on at 07:00 h) to allow recovery from any transportation-induced stress. They were 
killed by cervical dislocation and WAT depots (subcutaneous, epididymal, perirenal and 
omental) were quickly dissected, snap-frozen in liquid nitrogen and stored at -80°C until 
further analysis.
Retroperitoneal and epididymal WAT samples from 3-month-old male Zucker rats (both 
lean (+/+ or +lfa) and genetically obese ifa/fa), bred at the Rowett Research Institute 
(Aberdeen, Scotland), were a gift from Dr D V Rayner.
All animal studies were conducted according to the U.K. Home Office Guidelines for the 
care and use o f laboratory animals.
3.2.2 RT-PCR and real-time PCR
Total RNA was extracted from tissues using Tri-Reagent as previously described in 
section 2.5. RNA was then treated using a DNA-free kit (section 2.5.3) and quantified 
using a BioPhotometer (section 2.5.4). First-strand DNA was reverse-transcribed from 1 
pg of total RNA using the Reverse-iT First Strand Synthesis kit (section 2.6) and the 
patterns o f gene expression were analysed by RT-PCR (section 2.6.2). For the studies o f 
ZAG gene expression on adipose tissue 2 pi o f cDNA (equivalent to 100 ng o f RNA) 
were used, while 1 pi o f cDNA was used as a template for expression analysis o f ZAG and 
other target genes in all other tissues. Relative mRNA levels were quantitated by real-time 
PCR using a qPCR Core Kit on a ABI Prism 7700 instrument (section 2.7).
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3.2.3 Western blotting
Protein was extracted from tissues using Tri-Reagent after the RNA had been removed 
for total RNA extraction (section 2.8.1.2) or from frozen tissues (section 2.8.1.1). The 
concentration o f samples was determined using the BCA method (section 2.8.2) and 10 
pg of protein were mixed with equal volumes o f loading buffer and separated by 
electrophoresis on 10% SDS-polyacrylamide gels (section 2.8.3). Immunoblotting was 
then performed as described in section 2.8.4 by using an anti-mouse ZAG monoclonal 
primary antibody (Santa Cruz Biotechnology, USA) at a 1:1000 dilution, followed by 
incubation with a goat anti-mouse secondary antibody conjugated to horseradish 
peroxidase at a 1:1000 dilution. Densitometric analysis was carried out (section 2.8.6) 
and gels were stained with Ponceau S to confirm equal loading (section 2.8.5.2).
3.2.4 Statistical analysis
Data are expressed as mean values ±  SE. Comparisons between two groups were assessed 
by Student’s r-test, while for differences among more than two groups one-way ANOVA 
coupled with Bonferroni’s r-tests was employed, as previously described in section 2.9. 
Differences were considered as statistically significant when P  < 0.05.
3.3 Results
3.3.1 ZAG expression in adult rodent adipose tissue
3.3.1.1 ZAG expression in mouse adipose tissue
As part o f the present study, the expression o f the ZAG gene in WAT depots was verified 
by RT-PCR. Although RT-PCR indicated that the ZAG gene is expressed in all WAT 
sites tested, the signal intensity appeared to vary among depots, which suggests that there 
are inter-depot differences in ZAG expression levels. Real-time PCR was therefore used 
to quantify ZAG mRNA levels in different depots (Figure 3.1). The results clearly 
demonstrate that ZAG mRNA levels varied considerably between depots. The mRNA 
levels were significantly higher in perirenal and omental WAT when compared to
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Figure 3.1 ZAG gene expression in adipose tissue depots of mice
Six adipose tissue depots were dissected from mice and total RNA was extracted. Real­
time PCR was used for the relative quantification of ZAG mRNA levels. Results are 
presented relative to the ZAG mRNA levels in epididymal WAT and are presented as 
means ±  SE (bars) for 5-6 mice. Epi, epididymal; subc, subcutaneous; mes, mesenteric; 
peri, perirenal; om, omental; BAT, interscapular brown adipose tissue. aP  < 0.01 vs peri, 
P  < 0.01 vs om; hP  < 0.01 vs peri, P  < 0.01 vs om; CP < 0.05 vs peri, P  < 0.05 vs om; dP < 
0.05 vs om; eP < 0.01 vs BAT (One-way ANOVA, post-hoc multiple comparisons with 
Bonferroni correction).
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epididymal, subcutaneous, and mesenteric depots, while the lowest levels were detected in 
epididymal WAT. ZAG was expressed in BAT, its levels in the tissue being significantly 
lower than the levels in omental WAT. As a comparison, leptin mRNA levels were also 
determined in the same WAT depots and leptin levels were at their highest in epididymal 
and at the lowest in omental adipose tissue (Figure 3.2).
Following mRNA analysis, ZAG protein levels in the same depots were measured. 
Similar to mRNA, ZAG protein levels were significantly higher in perirenal and omental 
WAT when compared to mesenteric, subcutaneous and epididymal WAT and BAT. 
However, in contrast to mRNA, the lowest ZAG protein levels were detected in BAT 
(Figure 3.3).
3.3.1.2 ZAG expression in mature adipocytes and the strom al vascular (SV) 
fraction o f WAT depots
In order to explore whether ZAG is mainly produced in the mature adipocytes or the 
stromal vascular fraction of mouse white adipose tissue, subcutaneous, epididymal and 
perirenal WAT depots were dissected from six mice, and following collagenase digestion 
the two fractions were separated. Real-time PCR was employed to analyse the mRNA 
levels o f expression. The results showed that there were no significant differences in ZAG 
mRNA levels between the two fractions in all the depots examined (Figure 3.4A). ZAG 
protein was also detected in both fractions, and as with the mRNA results there was no 
significant difference between them (Figure 3.5).
Leptin gene expression was also determined in subcutaneous adipose tissue as a reference, 
by real-time PCR (Figure3.4B), and leptin was found to be expressed exclusively in 
mature adipocytes no signal being detected in the SV fraction.
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Figure 3.2 Leptin gene expression adipose tissue depots of mice
Six adipose tissue depots were dissected from mice and total RNA was extracted. Real­
time PCR was used for the relative quantification o f leptin mRNA levels. Results are 
presented relative to the leptin mRNA levels in omental WAT and are presented as 
means ±  SE (bars) for 5-6 mice. Om, omental; subc, subcutaneous; peri, perirenal; mes, 
mesenteric; epi, epididymal; BAT, interscapular brown adipose tissue. *P < 0.05 vs BAT; 
bP < 0.01 vs peri, P < 0.01 vs epi; CP < 0.01 vs epi; dP  < 0.01 vs mes; eP  < 0.05 vs subc, P  
< 0.01 vs peri, P < 0.01 vs mes, P < 0.001 vs epi, P < 0.01 vs BAT (One-way ANOVA, 
post-hoc multiple comparisons with Bonferroni correction)
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Six adipose tissue depots were dissected from mice and protein was extracted. Western 
blotting (A) was used for detection of ZAG and quantification o f ZAG protein expression 
levels (B). Results are presented relative to ZAG protein levels in BAT and are presented 
as means ±  SE (bars) for 4 mice. BAT, interscapular brown adipose tissue; mes, 
mesenteric; subc, subcutaneous; epi, epididymal; peri, perirenal; om, omental. bP < 0.05 
vs peri; P  < 0.05 vs om; CP < 0.05 vs epi; P  < 0.01 vs peri; P  < 0.05 vs om; ¡P < 0.05 vs 
epi, P  < 0.01 vs peri, P  < 0.01 vs om (One-way ANOVA, post-hoc multiple 
comparisons).
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Figure 3.4 ZAG mRNA levels in mature adipocytes and stromal vascular
fraction of white adipose tissue depots
(A)
(B) Subcutaneous WAT
Three WAT depots were dissected from normal mice and following collagenase digestion 
mature adipocytes were separated from the SV fraction. Real-time PCR was used for 
relative quantification of ZAG (A) and leptin (B) mRNA levels. Results are expressed 
relative to SV for each depot and are presented as means ±  SE (bars) for 5-6 mice. Subc, 
subcutaneous; epi, epididymal; peri, perirenal; SV, stromal vascular. ***P  < 0.001 (paired 
Student’s t test) compared to SV group and normalized to P-actin.
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Figure 3.5 ZAG protein expression in mature adipocytes and stromal vascular
fraction of subcutaneous white adipose tissue in mice
(A)
Protein samples were extracted from the mature adipocytes and SV fraction of 
subcutaneous WAT. Western blotting (A) was used for detection o f ZAG protein and 
quantification o f protein levels (B). Results are expressed as means ±  SEM (bars) for 4 
mice. Adip, mature adipocytes; sv, stromal vascular fraction. P > 0.05 (paired Student’s t- 
test).
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To this point, studies have demonstrated the detailed expression pattern o f ZAG in 
mouse adipose tissue, which has led to subsequent studies on ZAG expression in rat 
adipose tissue. Since it has not been reported previously, it was important to first 
establish the expression pattern of ZAG in the tissues, including rat WAT and BAT. 
Since the ZAG gene contains 4 exons, primers were designed to span two exon-exon 
boundaries to ensure that no product could be derived from genomic DNA 
contamination. The presence o f ZAG mRNA would be expected to result in a 322-bp 
product being generated. For this purpose, tissues were collected from a 10-week old 
Wistar rat and ZAG mRNA distribution was studied by RT-PCR, while the protein 
expression was analysed by western blotting.
As shown in Figure 3.6A, in addition to the liver, which is known as the main source of 
ZAG production, a strong signal for ZAG mRNA was also detected in the stomach, 
kidney, spleen, oesophagus, muscle and lung. However, ZAG mRNA was barely 
detectable in the heart and hypothalamus. Most importantly ZAG gene expression was 
detected in all the WAT depots tested, subcutaneous, gonadal, perirenal, mesenteric and 
omental, as well as in BAT. ZAG mRNA was also detected in pericardial fat.
Following mRNA analysis, ZAG protein expression pattern in all the tissues was analysed 
using western blotting (Figure 3.6B). The results revealed a very similar pattern to that o f 
the mRNA expression. In particular, ZAG protein was detected in all the WAT depots 
examined, subcutaneous, omental, epididymal, perirenal, mesenteric and pericardial and 
in BAT.
3 .3 .1 .3  ZAG expression in rat adipose tissue
104
Figure 3.6 Tissue distribution of ZAG gene and protein in the rat
(A)
(B)
ZAG  g e n e  a n d  p r o te in  e x p r e s s io n  in  t is s u e s  d is s e c te d  fr o m  a  3 -m o n th  o ld  f e m a le  
w is t a r  rat. ( A )  Z A G  m R N A  b y  R T - P C R ,  ( B )  W e s te r n  b lo t  o f  Z A G .
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Having studied the levels o f ZAG expression in adipose tissue depots under normal 
conditions, it was investigated whether expression o f ZAG gene was changed in obesity. 
For this purpose two models were used: the genetically obese mouse (ob/ob) and the 
genetically obese (fa/fa) Zucker rat.
3 3 .2 .1  ZAG gene expression in WAT o f lean and ob/ob mice
ZAG mRNA levels were examined in subcutaneous, epididymal, perirenal and omental 
WAT depots o f lean and ob/ob mice using real-time PCR. As a comparison, leptin gene 
expression was also studied in the same samples.
In subcutaneous and epididymal WAT, ZAG gene expression was significantly lower (P < 
0.05) in the obese compared to the lean mice, the difference being 3- fold and 10-fold for 
the two tissues respectively (Figure 3.7A). It can be seen from the results that a similar 
trend was observed in the perirenal and omental depots, although the differences were 
not statistically significant (P > 0.05).
Leptin gene expression, on the other hand, was significantly higher in the obese than in 
the lean mice in all depots tested, with differences varying from 9-fold in subcutaneous (P 
< 0.001) to 4-fold (P < 0.05) in epididymal WAT (Figure 3.7B).
3.3.2 ZAG expression levels in rodent models o f obesity
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Four WAT depots were dissected from lean and ob/ob mice and total RNA was extracted. 
Real-time PCR was used for relative quantification of ZAG (A) and leptin (B) mRNA 
levels. Results are expressed relative to the expression levels in the lean group for each 
depot and are presented as means ±  SE (bars) for 4-6 mice. Subc, subcutaneous; epi, 
epididymal; peri, perirenal; om, omental. *P  < 0.05, ***/> <  0.001 compared to leans and 
normalized to P-actin (unpaired Student’s t- test).
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ZAG mRNA levels were examined in epididymal and retroperitoneal WAT o f 3-month
old fa/fa Zucker rats and their lean counterparts.
ZAG mRNA levels were significantly downregulated in the fa/fa group both in 
epididymal and retroperitoneal WAT by -5-fold (P < 0.05) (Figure 3.8A). ZAG protein 
expression was also analysed in retroperitoneal WAT samples. Although, there was an 
indication that ZAG is downregulated in the obese group, statistical analysis revealed no 
significant difference between the two groups (Figure 3.9).
Leptin mRNA levels were also analysed in retroperitoneal WAT. As shown in Figure 
3.8B, leptin was upregulated in the fa/fa group compared to their lean counterparts by 
-2.5-fold (P <  0.05).
3.4 Discussion
Consistent with previous studies (Bing et al., 2004), it has been shown in this study that 
ZAG (mRNA and protein) is expressed in adipose tissue. A signal for ZAG was detected 
in all major adipose tissue sites, both in mice and rats. As part o f this study, the tissue 
distribution o f ZAG in the rat was explored using RT-PCR and western blotting. 
Consistent with previous screening using northern blotting analysis (Ueyama et al., 
1994), a strong signal for ZAG mRNA was detected in the liver, which is a major 
production site o f ZAG in the body, and in lung, kidney and stomach. Furthermore, the 
current study is the first indication o f ZAG expression in rat spleen, oesophagus and 
skeletal muscle. Importantly, it is the first study reporting the expression o f ZAG in all 
the major rat WAT depots and in rat BAT. ZAG protein was also detected in all the 
aforementioned tissues. It is interesting to note that although liver gave a strong signal in 
mRNA analysis, a weak signal was seen in the protein analysis. A possible explanation for 
this observation, which has previously been reported in humans (Tada et al., 1991), is
3 3 .2 .2  ZAG expression in WAT o f lean an d fa/fa Zucker rats
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Figure 3.8 ZAG gene expression in white adipose tissue of lean and obese
(fa/fa) Zucker rats
(B) Retroperitoneal WAT
3 .5 , *
fa/fa
Epididymal and retroperitoneal depots were dissected from 3-month old lean and fa/fa 
Zucker rats and total RNA was extracted. Real-time PCR was used for relative 
quantification of ZAG (A) and leptin (B) mRNA levels in retroperitoneal. Results are 
expressed relative to the expression levels in the lean group for each depot and are 
presented as means ±  SE (bars) for 6-8 rats. Epi, epididymal; rp. Retroperitoneal. *P  < 
0.05 compared to leans and normalized to P-actin (unpaired Student i-test).
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Figure 3.9 ZAG protein expression in retroperitoneal white adipose tissue of









Protein was extracted from the retroperitoneal samples from lean and fa/fa Zucker rats 
aged 3 and 9 months. Western blotting (A) and densitometric analysis (B) were used for 
relative uantitation of ZAG protein levels. Results are expressed relative to the expression 
level in retroperitoneal WAT of 3-month old lean animals and are presented as means ±  
SE (bars) for 4-5 rats.
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that the liver may secrete ZAG into the blood immediately after its synthesis, or ZAG 
protein in the liver may be in a masked state that does not allow the antibodies to bind 
(Ueyama et al., 1994). Although, WAT is not the major site o f ZAG production, the fact 
that ZAG is an adipokine produced locally by adipose tissue and the possible functions 
that have been attributed to it has led to further study, particularly the characterisation of 
its expression patterns, in adipose tissue.
Differences were clearly evident between the levels o f ZAG mRNA and protein in the 
different adipose tissue depots o f mice, as measured by real-time PCR and western 
blotting, ZAG levels being significantly elevated in perirenal and omental depots. 
Differences in the degree of lipolysis/ lipogenesis may account for this variability in ZAG 
expression levels among depots. As mentioned above, visceral adipose tissue has higher 
lipolytic activity compared to subcutaneous adipose tissue. This can be attributed to 
regional variation in the action o f the major lipolysis-regulating hormones, 
catecholamines and insulin, the lipolytic effect o f the former being more pronounced and 
the antilipolytic effect o f the latter being weaker in visceral than in subcutaneous adipose 
tissue (Bolinder et al., 1983; Arner, 1998). IL-6, which decreases adipose tissue LPL 
activity (Fried et al., 1998) and similar to ZAG (Bing et al., 2004) has been implicated in 
stimulating lipolysis (Path et al., 2001; Vantall et al., 2003) is also mostly expressed in the 
omental compared to the subcutaneous depot (Fried et al., 1998).
Furthermore, this site variation has been attributed to the amount o f adrenoreceptors 
present in visceral fat (Wajchenberg, 2000). In rodents, the P3-adrenoreceptor is viewed 
as the principle receptor-subtype through which the stimulation o f lipolysis occurs 
(Giacobino, 1996). Visceral tissue is characterised by the increased expression and 
function o f P3-adrenoreceptors and a decreased insulin receptor affinity and signal 
transduction in visceral adipocytes (Arner et al., 1990). Furthermore, studies on isolated 
adipocytes from different adipose sites in humans showed that the P3-adrenoreceptor is 
functionally expressed mainly in omental adipose tissue (Lonnqvist et al., 1993). It has 
been reported that in vitro the potent lipolytic effect o f ZAG is attenuated by the specific
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p3-adrenoreceptor antagonist SR59230, suggesting that ZAG activity in rodents is 
mediated via the p3-adrenoreceptor (Russell et al., 2002).
Consistent with previous reports (Masuzaki et al., 1995; Hardie et al., 1996; Hube et al., 
1996; Montague et al., 1997; van Harmelen et al., 1997; Zhang et al., 1999), leptin 
production was higher in the subcutaneous than in the omental depot in this study, the 
highest levels being observed in epididymal WAT.
A number o f cell types have been shown to secrete TAG, including epithelial cells o f 
breast, prostate and liver (Tada et al., 1991). The SV fraction o f adipose tissue contains a 
variety o f other cell types, such as fibroblasts and macrophages, as well as preadipocytes. 
It has previously been shown, both in mice (Bing et al., 2004) and in human (Bao et al., 
2005) that ZAG is expressed in both fractions. In the present study, it has been 
demonstrated that there are no statistically significant differences in the levels o f ZAG 
expression in the two fractions, both at the mRNA and protein levels, in all three mouse 
depots tested. However, studies in human subcutaneous and omental WAT indicated 
that the ZAG gene was expressed primarily in mature adipocytes (Bao et al., 2005), 
although a non-quantitative approach was used. It could be that this is a difference in 
ZAG expression between human and rodents. The fact that leptin is solely expressed in 
mature adipocytes was also verified as part o f this study, consistent with previous 
observations (Einstein et al., 2005).
When ZAG mRNA levels were analysed in WAT depots from lean and genetically obese 
(iob/ob) mice, a significant difference between the two genotypes was shown as ZAG 
expression was reduced in subcutaneous and epididymal WAT. Although the results were 
not statistically significant, the same trend o f reduced expression was observed in 
perirenal and omental WAT o f ob/ob mice. As a reference point it was also shown that 
leptin mRNA level was higher in the depots o f ob/ob mice as previously reported 
(Frederich et al., 1995). In genetically obese rats ifa/fa), ZAG mRNA was significantly 
downregulated in the epididymal and retroperitoneal WAT o f 3-month-old obese 
animals. Consistent with previous studies which have shown that leptin mRNA levels are
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markedly elevated in rats with the fa/fa  mutation (Masuzaki et al., 1996), mRNA levels o f 
leptin were increased in the retroperitoneal WAT o f obese compared to lean animals. It 
thus seems that there is a link between obesity and decreased ZAG expression and the 
fact that some o f the results were not statistically significant may be a consequence o f 
small sample groups and variation among animals.
Obesity is now considered to represent a state o f chronic low-grade inflammation (Das, 
2 0 0 1 ), an assumption based on the increased circulating levels o f several markers o f 
inflammation in obesity, including IL-6 , T N Fa, haptoglobin and MCP-1 (Das 2001; 
Bullo et al., 2003; Sartipy &  Loskutoff, 2003). Contrary to other adipokines, adiponectin 
levels decrease in the obese state (Arita et al., 1999), and it is considered to have anti­
inflammatory (Ouchi et al., 1999), as well as insulin sensitising properties (Spranger et 
al., 2003). Similarly to adiponectin, ZAG has been shown in the present study to be 
reduced in genetically obese rodent models. Similar results were demonstrated in a recent 
study on obese women (Dahlman et al., 2005). Assuming that relative mRNA levels o f 
ZAG in adipose tissue reflect relative rates o f ZAG production within the tissue, and 
based on the similar patterns observed for the two adipokines, an anti-inflammatory role 
for ZAG in the obese state might be suggested. The potential involvement o f ZAG in 
anti-inflammatory processes in WAT has also been suggested in a recent in vitro study 
which demonstrated that rosiglitazone increases, while T N F a reduces ZAG mRNA levels 
in human adipocytes (Bao et al., 2005) and is also suggested by in vitro studies on the 
regulation o f ZAG expression in murine adipocytes as part o f the present thesis (see 
Chapter 5).
Furthermore, the suppression o f ZAG in obesity could also be related to a role o f ZAG in 
the regulation of energy metabolism. It has previously been shown that ZAG induces 
lipolysis in vitro and that in vivo administration o f ZAG reduces body fat (Hirai et al., 
1998). However, as a result o f increased insulin resistance, obesity is characterised by 
increased basal lipolysis, reduced antilipolytic action o f insulin and reduced LPL 
expression and activity (Hauner &  Skurk, 2001). In addition, the degree of obesity is 
correlated with the extent o f loss o f P3- and Pi-adrenoreceptors in WAT in both genetic
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and dietary obesity in mice (Boschman, 2001). It might be suggested that ZAG is not 
only affected by lipolysis but is also inversely regulated by the degree o f adipogenesis, 
which increases in the obese state.
It should be noted that most observations o f ZAG expression in obesity presented in this 
chapter are only based on ZAG mRNA levels, which do not always represent protein 
expression levels in the tissue or circulatory levels o f the protein. Further studies would 
thus provide stronger indications o f the role o f ZAG in adipose tissue in obesity.
In conclusion, ZAG (both gene and protein) is expressed in all the major white adipose 
tissue depots and BAT in mouse and rats, its levels being higher in perirenal and omental 
fat. Crucially, ZAG has been shown to be present in both mature adipocytes and stromal 
vascular fraction o f all major depots. Finally, there is evidence that obesity has an 
association with decreased levels o f ZAG in white adipose tissue, and this suggests that 
ZAG could conceivably have an anti-inflammatory role and act locally in the modulation 
o f lipolysis in rodent adipose tissue.
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Chapter 4
Regulation of ZAG expression in mouse adipose tissue: effects
of fasting and high-fat diet
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4.1 Introduction
In Chapter 3, the differential expression o f ZAG in adipose tissue was explored revealing 
that ZAG is mostly produced in visceral depots, and equally by mature adipocytes and 
the stromal vascular fraction o f the tissues. It was also demonstrated using two rodent 
genetic models o f obesity that in contrast to most adipokines, ZAG is down-regulated in 
obesity. It is known that nutritional status can alter the gene expression and /or plasma 
levels o f adipose-secreted factors as demonstrated by various studies (Trayhurn et al., 
1995; Zhang et al., 2001; Berdle &  Raclot, 2004; Rajala et al., 2004; Einstein et al., 
2005; Korhonen 6C Saarela, 2005), such as the downregulation o f leptin in response to 
fasting (Trayhurn et al., 1995; Zhang et al., 2001), presumably to contribute to adapting 
overall metabolism to the new nutritional environment (Giordano et al., 2005). In the 
current chapter the effects o f changes in the diet on ZAG expression are explored.
To examine nutritional effects on ZAG expression two studies were carried out. In the 
first one, mice were fasted for 16 h, after which time, ZAG mRNA and protein 
expression were analysed and compared to those in the normally fed group. In the second 
study, mice were kept on a high-fat diet (58% lipid by energy) for twelve weeks and ZAG 
levels were then compared to those in mice fed a low-fat diet (11% lipid by energy).
Fasting is a state when food intake has been arrested for a significant amount o f time. 
Long-term food deprivation is characterized by changes in fuel availability and in adipose 
tissue lipid content (Goodman et al., 1980). The absence o f energy entering the body 
evokes a complex physiological response aimed at maintaining whole body homeostasis. 
An important event in the fasting response is the exhaustion o f carbohydrate reserves. As 
a result, the lipids stored in white adipocytes as triacylglycerols are catabolised by lipolysis 
and secreted as fatty acids. The metabolic adaptations accompanying fasting are governed 
by numerous endocrine and cellular factors (Kersten et al., 2000). Fasting results in 
marked changes in the plasma concentrations o f important metabolic hormones such as 
reduced insulin, leptin, glucocorticoids, (Trayhurn et al., 1995), resistin (Rajala et al., 
2004) and glucagon (Kersten et al., 2000). In addition, fasting causes altered expression
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levels o f important transcription factors such as sterol response element-binding protein, 
c-Myc and PPARa, directing specific changes in the expression o f metabolic enzymes 
(Kersten et al., 2000). Some differences have also been evidenced in terms of the 
differential response to fasting depending on the anatomical location o f adipose tissue, 
the mobilization o f visceral fat pads being greater than that o f subcutaneous WAT 
(Sugden et al., 1994). Furtheromore, when refeeding, a preferential restoration o f internal 
adipose tissue is observed (Bertile et al., 2003).
There has been evidence that this fasting-dependent lipid mobilization in WAT is 
primarily due to sympathetic noradrenergic innervation (Bartness &  Bamshad, 1998; 
Giordano et al., 2005). BAT, which functions as a heat-producing organ, both for 
thermoregulation through the action o f UCP-1 in rodents and in relation to the 
regulation of whole-body energy balance (Rothwell &  Stock, 1979; Himms-Hagen, 
1990), exhibits a suppressed capacity for nonshivering thermogenesis both in mice and 
rats as a result o f food deprivation (Jourdan et al., 1983). It has recently been 
demonstrated that during fasting BAT is -7 times more innervated than epididymal 
WAT (Giordano et al., 2005).
In Chapter 3, the regulation of ZAG gene expression in two rodent genetic models o f 
obesity was studied. However, obesity arises as a consequence of a prolonged imbalance 
between energy intake and expenditure (Bray, 2004). Recent studies in rats have 
demonstrated that high-fat diets, in which the animal consumes a substantial energy 
surplus for a certain period leading to obesity, influence gene expression in WAT (Lopez 
et al., 2003).
Most o f the experiments described in this chapter were conducted in reference to leptin 
and in some cases adiponectin, as the effects o f diet alterations on both adipokines have 
been previously documented (Trayhurn et al., 1995; Zhang et al., 2001; Bertile &C Raclot, 




Sixteen ten-week old male mice (CD1) from an inbred colony at the University o f 
Liverpool were housed at an ambient temperature o f 22 ± 1°C under a 12:12 h light — 
dark cycle (lights were on at 07:00 h) and fed a standard pelleted diet (CRM diet, 
LAbsure, Witham, U.K.) containing 19.2% protein and 4.3% lipid (wt/ wt). Two days 
prior to the initiation of the fasting experiment mice were divided into two groups (the 
fed and fasted groups) and housed in grid bottomed cages. On commencing the 
experiment all food was removed from the fasted group’s cage, while they still had ad  
libitum access to water. This lasted for 16 h, at which point the animals were sacrificed by 
cervical dislocation and the following tissues were rapidly dissected: WAT (subcutaneous, 
epididymal, perirenal, mesenteric, and omental), BAT, and liver. Animals were sacrificed 
according to the regulations for animal treatment o f the University o f Liverpool. As soon 
as the tissues were dissected, samples were weighed, snap frozen in liquid nitrogen and 
stored at -80°C until further analysis.
Subcutaneous, gonadal and perirenal WAT depots from lean and diet-induced obese 
female C57BL/6J mice from Lund University (Lund, Sweden) were provided by Dr B 
Wang (University o f Liverpool). The mice, weighing 18g, were purchased from Taconic 
(Skensved, Denmark) and kept in a temperature-controlled room (22°C) on a 12h:12h 
light:dark cycle. The study was approved by the Local Animal Ethics Committee. One 
week after arrival the mice were divided into two groups and subsequently fed either a 
low-fat (11% fat by energy) or a high-fat diet (58% fat by energy; Research Diets, New 
Brunswick, N J, USA) for 12 weeks (Winzell etal., 2004).
4.2.2 RT-PCR and real-time PCR
Total RNA was extracted from tissues using Tri-Reagent as previously described in 
section 2.5. RNA was then treated using a DNA-free kit (section 2.5.3) and quantified 
using a BioPhotometer (section 2.5.4). First-strand DNA was reverse-transcribed from 1
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fig o f total RNA using the Reverse-iT First Strand Synthesis kit (section 2.6) and relative 
mRNA levels o f expression were assessed by real-time PCR using the qPCR Core Kit on 
the Stratagene Mx3005P instrument (section 2.7).
4.2.3 Western blotting
In the study o f the effects o f the high-fat diet, protein was extracted from tissues using 
Tri-Reagent after the RNA had been removed for total RNA extraction (section 2.8.1.2), 
while for the fasting study, protein was extracted from frozen tissues (section 2.8.1.1). 
The concentration of samples was determined using the BCA method (section 2.8.2) and 
10 pg o f protein were mixed with equal volumes o f loading buffer and separated by 
electrophoresis on 10% SDS-polyacrylamide gels (section 2.8.3). Immunoblotting was 
then performed as described in section 2.8.4 by using an anti-mouse ZAG monoclonal 
primary antibody at a 1:1000 dilution, followed by incubation with a goat anti-mouse 
secondary antibody conjugated to horseradish peroxidase at a 1:1000 dilution. 
Densitometric analysis was carried out (section 2.8.6) and gels were stained with Ponceau 
S to confirm equal loading (section 2.8.5.2).
4.2.4 Statistical analysis
Data are expressed as mean values ±  SE. Comparisons between two groups were assessed 
by unpaired Student’s r-test, as previously described in section 2.9. Differences were 
considered as statistically significant when P < 0.05.
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4.3 Results
4.3.1 Effects o f I6h-fasting on ZAG expression in mouse adipose tissue 
depots
As shown in Figure 4.1 A, the body weight o f fasted animals was considerably reduced 
compared to that o f normally fed mice. The same was observed for net weight o f 
individual depots (Figure 4 .IB), and when the data was presented as a proportion of 
individual depot weights to whole body weights (Figure 4.1C).
As shown in Figure 4.2, in epididymal WAT, ZAG mRNA levels were significantly lower 
in the fasted compared to the fed group (P < 0.01). Although not statistically significant, 
the same trend was observed in subcutaneous, epididymal, and perirenal depots. In 
contrast to what was observed in WAT, in BAT, fasting induced an 8-fold increase in 
ZAG mRNA levels (P < 0.01). After examining the ZAG response to fasting at the 
mRNA levels, it was important to explore its possible effect at the protein level. In the 
epididymal WAT, fasting had no effect in ZAG protein expression levels (Figure 4.3). In 
perirenal WAT (Figure 4.4), there was an indication that the protein expression levels o f 
ZAG were reduced in the fasted group, but the results were not statistically significant (P 
> 0.05).
ZAG mRNA levels were also examined in liver samples o f the two groups. As shown in 
Figure 4.5, a 2.8-fold increase was induced in ZAG mRNA levels (P  < 0.001) in the liver 
as a result o f  16 h fasting.
Fasting induced an acute and marked reduction o f leptin mRNA levels in all WAT 
depots tested and in BAT, the highest effect being observed in the epididymal and 
perirenal depots (both -15-fold, P < 0.001) (Figure 4.6). A depot-specific response to 
fasting was on the other hand observed for adiponectin gene expression (Figure 4.7). 
Fasting induced a decrease in adiponectin mRNA levels in subcutaneous WAT (P < 
0.01), while no response was observed in the epididymal depot. However, a 2-fold (P  < 
0.01) and a 4-fold (P  < 0.001) increase was induced in perirenal WAT and BAT 
respectively, in response to fasting.
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For total body weight (g), mice were weighed as soon as sacrificed, while individual WAT 
depots were weighed immediately after dissection. Results are presented as mean ±  SEM 
(bars) for 8 mice for each group. *P <  0.05, ***P  < 0.001 compared to fed group.
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Figure 4.2 ZAG mRNA levels in adipose tissue depots of mice fasted for 16 h
□  fed 
■  fasted
Four WAT depots and interscapular BAT were dissected from fed and 16h-fasted mice 
and total RNA was extracted. Real-time PCR was used for relative quantification of ZAG 
mRNA levels. Results are expressed relative to the expression levels in the fed group for 
each depot and are presented as means ±  SE (bars) for 6-8 mice. Subc, subcutaneous; epi, 
epididymal; peri, perirenal; mes, mesenteric; BAT, interscapular brown adipose tissue. 
**P  < 0.01 compared to the fed group for each depot and normalized to P-actin 
(unpaired Student’s t- test).
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Figure 4.3 ZAG protein expression in epididymal WAT of mice fasted for 16 h
Protein samples were extracted from epididymal WAT o f fed and I6h-fasted mice. 
Western blotting (A) followed by densitométrie analysis (B) was used for quantification 
o f ZAG protein levels. Results are expressed as means ±  SEM (bars) for 5 mice. P  > 0.05 
compared to fed group (unpaired Student’s i-test).
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Figure 4.4 ZAG protein expression in perirenal WAT of mice fasted for 16 h













Protein samples were extracted from perirenal WAT o f fed and I6h fasted mice. Western 
blotting (A) followed by densitométrie analysis (B) was used for quantification of ZAG 
protein levels. Results are expressed as means ±  SEM (bars) for 5 mice. P  > 0.05 
compared to fed group (unpaired Student’s r-test).
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Liver samples were dissected from control (fed) and I6h-fasted mice. Real-time PCR was 
used for relative quantification o f ZAG mRNA levels. Results are expressed relative to the 
expression levels in the fed group and are presented as means ±  SE (bars) for 8 mice. " ’P 
< 0.001 compared to the fed group and normalized to p-actin (unpaired Student’s r-test).
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Figure 4.6 Leptin mRNA levels in adipose tissue depots of mice fasted for I6h
Four W AT depots and interscapular BAT were dissected from fed and 16h-fasted mice 
and total RNA was extracted. Real-time PCR was used for relative quantification o f 
leptin m RNA levels. Results are expressed relative to the expression levels in the fed 
group for each depot and are presented as means ±  SE (bars) for 6-8 mice. Subc, 
subcutaneous; epi, epididymal; peri, perirenal; mes, mesenteric; BAT, interscapular 
brown adipose tissue. **P  < 0.01, ***P  < 0.001 compared to the fed group for each depot 
and normalized to P-actin (unpaired Student’s t- test).
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Figure 4.7 Adiponectin mRNA levels in adipose tissue depots of mice fasted
for 16 h
</)
Three W AT depots and interscapular BAT were dissected from fed and 16h-fasted mice 
and total RNA was extracted. Real-time PCR was used for relative quantification o f 
adiponectin mRNA levels. Results are expressed relative to the expression levels in the fed 
group for each depot and are presented as means ±  SE (bars) for 6-8 mice. Subc, 
subcutaneous; epi, epididymal; peri, perirenal; BAT, interscapular brown adipose tissue. 
**P  < 0.01, ***P  < 0.001 compared to the fed group for each depot and normalized to P- 
actin (unpaired Student’s t- test).
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4.3.2 Effects o f high-fat diet on ZAG expression in mouse adipose tissue 
depots
Feeding the mice with a high-fat diet (58% fat by energy) for 12 weeks led to a 
substantial increase in body weight to the extent that they were considered obese. Net 
weight o f adipose tissue depots was also substantially increased (weight data not shown).
As shown in Figure 4.8, ZAG gene expression displayed a site-specific pattern in response 
to the high-fat diet. The high-fat diet for 12 weeks induced a 2.8-fold decrease {P < 0.01) 
in ZAG mRNA levels in subcutaneous WAT. However, it led to a 4.7-fold increase (P < 
0.001) in gonadal WAT. There was a small, but not statistically significant effect on 
ZAG mRNA levels in perirenal WAT similar to gonadal WAT. Similar patterns were 
observed for ZAG protein levels in subcutaneous and perirenal WAT, as a slight decrease 
was observed in the former and a slight increase in the latter. However, the results were 
not statistically significant (P > 0.05) (Figure 4.9).
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Figure 4.8 Effects of high-fat diet on ZAG mRNA levels
S ' 6 -
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Three W AT depots were dissected from mice fed with low- and high-fat diet and total 
RNA was extracted. Real-time PCR was used for relative quantification of ZAG mRNA 
levels. Results are expressed relative to the expression levels in the low-fat diet fed group 
for each depot and are presented as means ±  SE (bars) for 7-8 mice. Subc, subcutaneous; 
gon, gonadal; peri, perirenal. **P  < 0.01, ***/> <  0.001 compared to normally fed group 
for each depot and normalized to P-actin (unpaired Student’s t- test).
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Protein samples were extracted from subcutaneous and perirenal WAT o f mice fed with 
low- and high-fat diet. Western blotting followed by densitométrie analysis was used for 
quantification o f ZAG protein levels. Results are expressed as means ±  SEM (bars) for 5 




The effects o f fasting and feeding a high-fat diet on the expression o f various adipokines 
in rodent adipose tissue, including leptin and adiponectin, has been reported previously 
(Zhang et al., 2002; Lopez et al., 2003; Bertile &  Raclot, 2004). It has been 
demonstrated that the degree to which adipose tissue secreted factors are affected by such 
changes in the diet may vary depending on several factors, the most important being the 
duration o f the dietary change (Bertile &  Raclot, 2004; Lopez et al., 2005). Regional 
variations within WAT in response to changes in the nutrient supply have also been 
demonstrated (Sugden et al., 1994; Einstein et al., 2005). The current study is the first to 
examine the site-specific effect o f fasting and high-fat diet on ZAG expression in mouse 
adipose tissue.
Fasting is characterised by changes in fuel availability and in adipose tissue lipid content. 
During food deprivation carbohydrate reserves are exhausted, resulting in protein sparing 
with increased lipid mobilization providing the main energy fuel for the needs o f the 
organism (Goodman et al., 1980). ZAG is a lipid-mobilising factor, strongly induced in 
WAT o f M AC 16 tumour-bearing mice, a cancer cachexia model, characterised by fat 
depletion (Bing et al., 2004). In vivo administration o f ZAG to mice induces a rapid 
reduction in body fat and increases serum free fatty acid levels (Hirai et al., 1998). Based 
on that, it could be assumed that ZAG would be increased in adipose tissue during food 
deprivation.
However, the present study has demonstrated that I6h fasting induced a significant 
reduction in ZAG mRNA levels in epididymal WAT o f mice, a similar trend being 
observed for subcutaneous, perirenal and mesenteric WAT. The more pronounced 
decrease in ZAG gene expression in epididymal WAT would be in line with the 
indication that the mobilization of intra-abdominal fat pads is greater during fasting 
(Sugden et al., 1994). This response is not however consistent with a local role for ZAG 
in lipid mobilization in adipose tissue. However, ZAG expression was substantially 
increased both in BAT and liver samples o f the same animals. This observed response of
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ZAG to fasting may suggest that the overall production o f ZAG is increased during food 
deprivation.
In the present study, 16h fast led to a decreased ZAG expression in WAT. Since ZAG is 
lipolytic in a full-grown animal, its decreased expression at times o f food deprivation may 
be assumed to be part o f an energy saving mechanism present in WAT as an initial 
response to fasting. A similar response to 16h fasting in adipose tissue has previously been 
reported for growth hormone (GH) (Korhonen &  Saarela, 2005), another lipolytic factor 
(Harper, 1973).
The present study shows that I6h fasting decreased the body weight o f the mice by as 
much as 8g. There was also a significant reduction in the net weight o f the epididymal 
and perirenal depots, although not as a proportion to total body weight. Although the 
effect o f fasting on body composition was not determined, it could be assumed that the 
weight reduction is largely due to decreased gut contents (food and faeces) and only 
secondarily due to WAT utilization. So it might be possible that the reduction of fat mass 
is not a direct factor for the decreased ZAG expression in WAT in response to fasting, 
which might be due to other changes occurring in the body in response to fasting, such as 
insulin resistance (Schwartz et al., 1997). Further studies would be necessary to 
demonstrate whether the response is reversed by longer food deprivation, when WAT 
utilization would be more substantial.
In contrast to its decreased expression in WAT, ZAG was upregulated in BAT o f fasted 
animals, possibly due to the high degree o f sympathetic activity in the tissue during 
fasting (Giordano et al., 2005). However, as discussed later in Chapter 4, studies on the 
regulation o f ZAG in 3T3-L1 adipocytes, indicate that the sympathetic system may play 
at best a small role in the regulation of ZAG expression.
As part o f the present study, the effect o f fasting on leptin and adiponectin mRNA levels 
was also explored. As previously demonstrated (Trayhurn et al., 1995; Zhang et al., 
2002), leptin mRNA levels were acutely and substantially decreased in all WAT depots 
tested in fasted mice. Leptin expression was also downregulated in the BAT o f fasted
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animals. The response o f leptin to fasting is due to the whole body energy conservation 
evoked by food deprivation. Although the same would be expected in the case o f 
adiponectin, both previous data and the results presented in the current study show the 
complex response to fasting. Reports available on the effects o f fasting on adiponectin 
expression in WAT are not consistent. At first it was shown that adiponectin is decreased 
in perirernal WAT as a result o f short-term fasting (Zhang et al., 2002), although it was 
later shown that short-term fasting has no significant effect on adiponectin levels in WAT 
and that a decrease in its levels is only observed in subcutaneous and epididymal WAT 
after long-term food deprivation (5-7 days), when body lipid content nears exhaustion 
and the main energy is provided from protein utilization, suggesting that adiponectin 
may be involved in the adaptive response to long-term fasting (Bertile &  Raclot, 2004). 
However, in the present study, similarly to the initial studies, adiponectin was 
significantly reduced in subcutaneous WAT after I6h fasting; however, its levels were 
increased in perirenal WAT and BAT. The possibility that the expression of adiponectin 
in BAT is differentially regulated compared to WAT has been previously raised (Zhang et 
al., 2002). Although no conclusion can be made from the current observations, the data 
may suggest that there is a significant depot difference for adiponectin in response to 
16h-fasting and some further analyses are needed.
The high fat diet induced a site specific response o f ZAG expression in WAT. While 
ZAG mRNA levels were significantly downregulated in subcutaneous WAT, at the same 
time a substantial increase in its levels was observed in epididymal WAT and a similar 
trend was noticed in perirenal WAT. As previously discussed in more detail in Chapter 3, 
there are major differences among WAT depots, in particular between subcutaneous and 
visceral fat. In terms of the effects o f changes in the diets, it has previously been reported 
that visceral fat is not biologically static and is probably regulated by nutrients (Einstein 
et al., 2004). Furthermore, it is important to mention that the observed effects could be 
due to the lipid composition o f the specific diet and different dietary lipids intake may 
possibly have a different effect.
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In Chapter 3, it was shown that ZAG expression is reduced in WAT o f genetically obese 
rodents, suggesting that it might be regulated by the increased adipogenesis occurring in 
the obese state. The mice used in the present study were kept for 12 weeks on a high fat 
diet and by the end o f that period, a substantial increase in their body weight was 
observed. However, ZAG exhibits a different pattern o f expression in genetic models o f 
obesity as opposed to obese models as a result o f changes in the diet. This finding might 
suggest that ZAG is sensitive to the component o f the diet, such as fat content. 
Furthermore, it suggests that this effect depends on the anatomical location, possibly due 
to the different characteristics o f WAT depots.
In conclusion, the current study provides information on the regulation o f ZAG in 
mouse WAT and BAT by alterations in the diet. Inconsistent with its potential role in 
lipid mobilization in WAT, ZAG was downregulated in epididymal WAT of fasted mice, 
although its expression increased in BAT and liver. ZAG exhibited a depot specific 
response to high-fat diet. Taken together, these results suggest that ZAG expression in 
WAT is sensitive to diet alterations.
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Chapter 5
ZAG expression in 3T3-L1 adipocytes: Regulation by 
hormones, inflammatory cytokines and prostaglandins
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5.1 Introduction
In Chapters 3 and 4, a number o f in vivo studies were conducted to explore the function 
of ZAG in adipose tissue. It was shown that ZAG is expressed in white adipose tissue, its 
mRNA and protein levels being equal in mature adipocytes and stromal vascular fraction 
of murine WAT depots. It was further demonstrated that ZAG expression is reduced in 
obesity, while ZAG exhibits differential patterns o f expression in response to diet 
alterations in rodents. Another approach to studying the regulation o f a certain gene is in 
vitro cell culture systems.
In contrast to in vitro studies, in in vivo studies the full physiological response to a 
stimulus can be seen and certain investigations, such as fasting or cold exposure can only 
be conducted in vivo. However, a key disadvantage o f in vivo studies is that the exact 
cause leading to an effect cannot be easily isolated and identified as a certain stimulus 
may be acting directly or indirectly via downstream mediators. This can be resolved by in 
vitro studies, where a stimulus is directly applied to the cells o f interest and thus any 
effect seen most likely results from their interaction.
In the present study, 3T3-L1 adipocytes, a widely employed murine clonal cell line, were 
used. These provide a unique model for insulin-sensitive primary fat cells, as under 
defined conditions they can be converted to fully differentiated adipocytes, characterized 
by increased insulin receptor number and induction o f adipogenic specific proteins 
(Grako et al., 1994). In contrast to primary culture systems, these cells are easier to 
maintain, and at an unlimited supply, as long as they are passaged and stored correctly.
ZAG has recently been shown to be expressed in 3T3-L1 adipocytes. As part o f that 
study, it has been reported that ZAG gene expression in 3T3-L1 adipocytes is increased 
by dexamethasone, thus suggesting a role for glucocorticoids in its regulation, and by 
BRL37344, a selective P3-adrenoreceptor agonist (Bing et al., 2004).
The aim o f the current study was to identify further key agents that play a role in the 
regulation o f ZAG gene expression in 3T3-L1 adipocytes. In the first part o f this study,
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the expression o f ZAG gene in these adipocytes was further investigated and the day of 
maximum ZAG expression post-differentiation was identified. Subsequently, adipocytes 
were treated with several important groups o f agents, known to modulate the expression 
of several adipokines. The agents included catecholamines, inflammatory agents, 
interleukins and peripheral hormones, and their effects on ZAG expression in the system 
were assessed.
In the second part, the effect o f prostaglandins on ZAG expression in 3T3-L1 adipocytes 
was investigated. As discussed in detail in Chapter 1, prostaglandins (PGs) are lipid- 
derived autacoids generated by sequential metabolism of arachidonic acid by the 
cyclooxygenase (COX) and prostaglandin synthase enzymes. Prostaglandins have been 
implicated in a broad array o f diseases, such as cancer, inflammation and hypertension 
and exert their effects by activating rhodopsin-like seven transmembrane spanning G 
protein-coupled receptors (GPCRs), which include eight members (DP, EP1-4, FP, IP 
and TP) and a recently identified ninth receptor, the chemoattractant receptor 
homologous molecule expressed on Th2 cells (CRTH2). Very importantly, 
prostaglandins are known to be synthesized and released within WAT (Shillabeer et al., 
1998; Fain et al., 2002; Bell-Parikh et al., 2003; Jowsey et al., 2003). There are no reports 
on the effects o f prostaglandins on ZAG expression; however it has been observed that 
arachidonic acid has a stimulatory effect on ZAG mRNA levels in SGBS human 
adipocytes (Bao, personal communication); and prostaglandins on the other hand have 
been shown to affect a number o f other adipokines including adiponectin, leptin, MCP- 




3T3-L1 cells were maintained and cultured as previously described in section 2.4. Briefly, 
cells were obtained from the American Type Culture Collection (Manassas, USA) and 
cultured at 37°C in a humidified atmosphere of 5% C 0 2/95% air. The cells were 
maintained in culture medium containing the following: DM EM  with 25 mM glucose, 1 
mM pyruvate, 4.02 mM L-alanyl-L-glutamine and 10% v/v FCS. Differentiation o f the 
cells was initiated 2 days after confluence by incubation for two days in induction 
medium that consisted of culture medium with additional 10% FCS, 1 pM 
dexamethasone, 0.5 mM IBMX, and 2 pM insulin. The adipocytes were then kept in 
feeding medium, which was subsequently changed every 2 days. Differentiation o f cells 
into adipocytes was confirmed by the visualized accumulation o f lipid droplets.
The cells were maintained for up to 15 days post-differentiation and sampled every day, 
or for seven days after which time specific agents were added. The cells were pre­
incubated at 7 days after differentiation for 24 h either with feeding medium (containing 
insulin and FCS), insulin-free medium (for the study on the effect o f insulin), or FCS- 
free medium (for the studies on the effects o f TN F-a, IL-6, LPS and Prostaglandins). 
Control cells were also pre-incubated with the same media.
Cells were then treated with media containing each of the specific agents at two different 
dose levels (‘low’ and ‘high’). The control cells had no agents added. Agents used were; 
rosiglitazone (100 nM &  1 pM), noradrenaline (100 nM &  1 pM), isoprenaline (100 
nM &  1 pM), BRL 37344 (100 nM &  1 pM), insulin (1 pM &  10 pM), leptin (100 nM 
& 2 pM), adiponectin (0.5 pg/ml &  2 pg/ml), LPS (10 ng/ml &  100 ng/ml), IL-6 (1 
ng/ml &  25 ng/ml), TN F-a (5 ng/ml &  100 ng/ml), PG D 2 (50 pM &c 100 pM), PGI2 
(50 pM  &  100 pM), PGJ2 (7.5 pM &  25 pM), AI2-PGJ2 (7.5 pM &  25 pM) and 15d- 
PGJ2 (25 pM &C75 pM). The concentrations used were derived from other studies in the 
Obesity Biology Unit. Between four and six individual wells in cell culture plates were 
treated with each agent or used as controls; different batches o f cells were used for each
138
set o f experiments. After 24 h cells were harvested, lysed in Trizol reagent, and stored at - 
80°C until further analysis.
To investigate the dose dependent effect o f A12-PGJ2, PGE2 and PGF2a on ZAG 
expression, cells were incubated for 24h with different concentrations (0-100 pM) of 
these agents.
5.2.2 RT-PCR and real-time PCR
Total RNA was extracted from tissues using Tri-Reagent as previously described in 
section 2.5. RNA was then treated using a DNA-free kit (section 2.5.3) and quantified 
using a BioPhotometer (section 2.5.4). RNA was reverse-transcribed using the Reverse-iT 
First Strand Synthesis kit (section 2.6.1) and the patterns o f gene expression were 
analysed by RT-PCR (section 2.6.2). mRNA levels were assessed by real-time PCR 
(section 2.7) using a qPCR Core Kit and a ABI Prism 7700 machine, while for the 
prostaglandins treated samples a Mx3005P Stratagene machine was used.
5.2.3 Statistical analysis
Data are expressed as mean values ±  SE. Comparisons between two groups were assessed 
by Student’s ¿-test, while for differences among more than two groups they were analysed 
by one-way ANOVA coupled with Bonferroni’s r-tests, as previously described in section 
2.9. P  < 0.05 was considered as statistically significant.
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5.3 Results
5.3.1 ZA G  gene expression in 3T3-L1 cells
Although the expression of ZAG in 3T3-L1 cells has previously been demonstrated (Bing 
et al., 2004), it was important to establish its detailed expression pattern in the cells both 
pre- and post-differentiation before assessing the regulation o f ZAG gene expression. 
ZAG gene expression was examined in 3T3-L1 cells by RT-PCR (Figure 5.1) and 
although the signal was relatively low, ZAG mRNA was detected at all time points tested 
before and after the induction o f differentiation. The expression o f resistin, known to be 
expressed in adipocytes post-differentiation (Haugen et al., 2001), was tested in the same 
samples as a reference point and a strong signal was detected from day 2 after induction 
of differentiation and thereafter.
In order to identify a suitable time point for treating the cells with the agents, a time 
course o f the relative mRNA levels o f ZAG in 3T3-L1 adipocytes pre- and post­
differentiation was established. As shown in Figure 5.2, there are no significant 
differences in ZAG mRNA levels at the different time-points, as well as pre- and post­
differentiation. Therefore, the subsequent studies on the regulation of ZAG in 3T3-L1 
adipocytes were conducted at day 8 post- differentiation, by which time lipid droplets are 
well established and molecular markers characteristic o f fat cells are expected.
5.3.2 Regulation o f ZA G  gene expression in 3T3-L1 adipocytes
At day 8 post- differentiation, cells were treated with various specific agents and the 
regulation of ZAG gene expression in 3T3-L1 adipocytes was investigated using real-time 
PCR to quantify the relative ZAG mRNA levels. These agents can be grouped into the 
following categories, according to their properties; sympathetic agents, peripheral 
hormones, rosiglitazone, inflammatory regulators and prostaglandins.
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Figure 5.1 Time course of ZAG gene expression in 3T3-L1 adipocytes
Days post-differentiation
3T3-L1 cells in culture were collected at various time points pre- and post- induction of 
differentiation into adipocytes. RNA was examined by RT-PCR to detect gene expression 
of ZAG (35 cycles) and resistin (25 cycles) over the time course. Differentiation was 
induced at day 0. -T , no template control; -R, no RT control.
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Figure 5.2 Time course of ZAG mRNA levels in 3T3-L1 adipocytes
4 1
-2 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
T im e (days)
3T3-L1 cells in culture were collected at various time points pre- and post- induction of 
differentiation into adipocytes. RNA was extracted and examined by real-time PCR to 
determine ZAG relative mRNA levels over the time course. Differentiation was induced 
at day 0. Results are given as single value/means.
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5.3.2.1 Effects o f sympathetic agonists on ZAG gene expression
The first set o f experiments was aimed to investigate the effects o f sympathetic mediators 
on the regulation o f ZAG gene expression. Adipocytes were treated at two dose levels of 
each o f noradrenaline, isoprénaline and BRL 37344. Treatment with noradrenaline at 
either low or high doses had no effect on ZAG mRNA level (Figure 5.3A). The addition 
of isoprénaline led, however, to a statistically significant increase in ZAG mRNA level 
(-2.5-fold) at both low and high doses (P < 0.01) (Figure 5.3B). Finally, the addition o f a 
p3-adrenoreceptor agonist, BRL 37344, induced a statistically significant response (-3- 
fold) only at the low dose (P < 0.05) (Figure 5.3C).
5.3.2.2 Effects o f peripheral hormones and rosiglitazone on ZAG gene 
expression
The aims o f the following experiments were to examine the effects o f insulin, 
adiponectin, rosiglitazone and leptin on ZAG mRNA levels in 3T3-L1 adipocytes.
As shown in Figure 5.4A, insulin had no effect on ZAG mRNA levels. Adiponectin on 
the other hand induced a statistically significant dose-dependent increase in ZAG mRNA 
levels, with the effect o f the high dose being a 5-fold elevation (P < 0.01) (Figure 5.4B).
The largest increase in ZAG mRNA levels was observed with rosiglitazone, which 
resulted in a 3.5-fold and 5-fold increase at the low and high doses respectively (P < 
0.001) (Figure 5.5A). To assess the specificity o f the effect o f rosiglitazone on ZAG 
expression in 3T3-L1 adipocytes, mRNA levels o f two other adipokines, adiponectin and 
IL-6, were measured. Adiponectin mRNA levels were increased significantly at the low 
and high doses (both -2 .5-fold) {P < 0.01 and P < 0.05) (Figure 5.5B), while IL-6 
showed a trend o f a dose-dependent reduction, although the changes were not statistically 
significant (P>  0.05) (Figure 5.5C).
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Figure 5.3 Effect of noradrenaline, isoprénaline and BRL 37344 on ZAG 
mRNA levels in 3T3-L1 adipocytes
Cells were harvested at day 8 after the induction o f differentiation and were incubated for 
24 h in a medium containing noradrenaline (NA; A), isoprenaline (Iso; B) and BRL 
37344 (BRL; C) (LD, low dose; H D , high dose). No reagent was added to the medium 
of control cells. NA LD, 100 nM; NA H D , 1 pM; Iso LD, 100 nM; Iso H D , 1 pM; 
BRL LD, 100 nM, BRL HD, 1 pM. ZAG mRNA levels, measured by real-time PCR, are 
expressed relative to controls. Results are given as means ±  SE (bars) for groups o f 5-6. *P  
< 0.05, **P  < 0.01 compared with controls and normalised to p-actin.
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Cells were harvested at day 8 after the induction of differentiation and were incubated for 
24 h in a medium containing insulin (Ins; A) and adiponectin (adipo; B) (LD, low dose; 
HD, high dose). No reagent was added to the medium of control cells. Ins LD, 1 pM ; 
Ins HD, 10 pM; Adipo, 0.5 pg/ml, adipo HD, 2 pg/ml. ZAG mRNA levels, measured 
by real-time PCR, are expressed relative to controls. Results are given as means ±  SE 
(bars) for groups o f 5-6. *P  < 0.05, **P  < 0.01 compared with controls and normalised to 
P-actin.
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Figure 5.5 Effect of rosiglitazone on ZAG mRNA levels in 3T3-L1 adipocytes
Cells were harvested at day 8 after the induction o f differentiation and were incubated for 
24h in a medium containing rosiglitazone (LD, low dose, 100 nM; HD, high dose, 1 
|iM). N o reagent was added to the medium o f control cells. ZAG (A), adiponectin (B) 
and IL-6 (C) mRNA levels, measured by real-time PCR, are expressed relative to 
controls. Results are presented as means ±  SE (bars) for groups o f 5-6. *P  < 0.05, **P  < 
0.01 compared to controls and normalised to P-actin.
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Leptin induced a statistically significant reduction in ZAG mRNA with low and high 
dose, (both -5-fold, P <  0.01) (Figure 5.6A). The effect o f leptin on ZAG expression was 
compared with that on adiponectin and IL-6. Leptin induced a 1.7-fold reduction in 
adiponectin levels at the lower dose (P < 0.01), a similar effect being observed at the high 
dose (P < 0.05) (Figure 5.6B), and similarly a 2.5-fold reduction in IL-6 mRNA levels at 
the higher dose (P < 0.01) (Figure 5.6C).
5.3.2.3 Effects o f inflammatory regulators on ZAG gene expression
In this set o f experiments, the effects o f LPS, IL-6 and T N F a  on ZAG mRNA levels 
were investigated. All three agents are known for their pro-inflammatory nature in 
adipocytes. As shown in Figure 5.7, ZAG mRNA levels in 3T3-L1 adipocytes were 
unaffected by any o f these agents at either o f the two dose levels used.
5.3.3 Regulation o f ZAG  gene expression by prostaglandins in 3T3-L1 
adipocytes
5.3.3.1 Effects ofPG D 2 and J 2-series prostaglandins on ZAG gene expression
Addition o f PG D 2 did not affect ZAG gene expression at either the low and high doses 
(Figure 5.8). As previously noted, in culture medium, PGD2 can spontaneously be 
converted to PGJ2 and the latter to its metabolites A12-PGJ2 and 15d-PGJ2. Thus, the 
possible effect o f each o f the prostaglandin derivatives o f PG D 2 on ZAG gene expression 
was explored. The high doses used for both PGJ2 and A12-PGJ2 induced a significant 
increase in ZAG mRNA levels by -3- {P < 0.05) and 23-fold respectively (P < 0.001). 
15d-PGJ2 induced a -19-fold (P < 0.001) increase in ZAG mRNA levels at the low dose, 
its levels declining to those o f the control group with the high dose (Figure 5.8).
Considering the substantial effect o f A12PGJ2 on ZAG mRNA levels at the high 
concentration, an extended dose-response study was undertaken with this prostaglandin 
with doses ranging from 1 to 100 pM o f A12PGJ2 being used. ZAG mRNA levels in 3T3-
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Figure 5.6 Effect of Leptin on ZAG mRNA levels in 3T3-L1 adipocytes
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Cells were harvested at day 8 after the induction o f differentiation and were incubated for 
24h in a medium containing leptin (LD, low dose, 100 nM; H D , high dose, 2 pM). No 
reagent was added to the medium of control cells. ZAG (A), adiponectin (B) and IL-6 
(C) m RNA levels, measured by real-time PCR, are expressed relative to controls. Results 
are presented as means ±  SE (bars) for groups o f 5-6. *P  < 0.05, **P  < 0.01 compared to 
controls and normalised to P-actin.
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Cells were harvested at day 8 after the induction of differentiation and were incubated for 
24h in a medium containing lipopolysacharide (LPS; A), Interleukin-6 (IL-6; B) and 
tumour-necrosis factor-alpha (TNF-a; C) (LD, low dose; H D , high dose). No reagent 
was added to the medium of control cells. LPS LD, 10 ng/ml; LPS H D , 100 ng/ml; IL-6 
LD, 1 ng/ml ; IL-6 H D , 25 ng/ml; TN F-a, 5 ng/ml, TN F-a H D , 100 ng/ml. ZAG 
mRNA levels, measured by real-time PCR, are expressed relative to controls. Results are 
given as means +  SE (bars) for groups o f 5-6. There were no significant differences (P > 
0.05).
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Figure 5.8 Effect of PGD2 and J 2 - series prostaglandins on ZAG mRNA levels
in 3T3-L1 adipocytes
Cells were harvested at day 8 after the induction of differentiation and were incubated for 
24h in a medium containing PG D 2, PGJ2, A12-PGj2 and 15d- PGJ2 (LD, low dose; HD, 
high dose). No reagent was added to the medium o f control cells. PGD2 LD, 50 pM; 
PGD2 H D , 100 pM ; PGJ2LD, 7.5 pM ; PGJ2 HD, 25 pM; A12-PGJ2LD 7.5 pM , A12- 
PGJ2 H D , 25 pM; 15d- PGJ2 LD, 25 pM; 15d- PGJ2H D , 75 pM. TAG mRNA levels, 
measured by real-time PCR, are expressed relative to controls. Results are given as means 
± SE (bars) for groups o f 5-6. *P  < 0.05, **P  < 0.01, ***P  < 0.001 compared to controls 
and normalised to P-actin.
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LI adipocytes were significantly increased with treatment o f A12-PGj2 and the increase 
was dose-dependent. There was a 5-fold increase in ZAG mRNA levels at 1 pM, the 
highest response being observed with 75 pM when the increase was -90-fold (figure 5.9).
5 3 3 .2  Effects o f PGE2, PGF2a and PG h on ZAG gene expression
Since a pilot study had indicated that both PGE2 and PGF2a have an inhibitory effect on 
ZAG expression in 3T3-L1 adipocytes (data not shown), an extended dose-response 
study was undertaken to explore the effect o f these prostaglandins in detail. In both 
experiments, cells were treated with PGE2 and PGF2aat doses varying from 10 nM to 100 
pM. PGE2 significantly reduced ZAG mRNA levels with a concentration of 100 nM and 
above, and the biggest effect was seen at a dose o f 100 nM, which induced a 20-fold 
reduction in ZAG mRNA levels (P <  0.001) (Figure 5.10).
To further assess the specificity o f PGE2 on ZAG expression, its effect on adiponectin and 
IL-6 mRNA levels were also examined. As demonstrated in Figure 5.11, PGE2 led to a 
significant gradual decrease in adiponectin mRNA levels with a concentration of 300 nM 
and above, while it induced a significant increase in IL-6 mRNA levels with a 
concentration o f 3 pM and above.
PGF2a induced a significant reduction in ZAG mRNA levels with a concentration o f 100 
nM and above, the biggest effect being observed at a dose o f 3 pM which induced a 30- 
fold decrease (P < 0.001) (Figure 5.12). Finally, the effect o f PGI2 on ZAG mRNA levels 
was investigated. PGI2 had no significant effect on ZAG mRNA level neither at the low 
or high doses used (Figure 5.13).
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Figure 5.9 Dose response of A12-PGj2 on ZAG mRNA levels in 3T3-L1
adipocytes
A12-PGJ2 Concentration (yM)
Cells were harvested at day 8 after the induction o f differentiation and were incubated for 
24h in a medium containing different doses o f A12-PGj2 . No reagent was added to the 
medium o f control cells. ZAG mRNA levels, measured by real-time PCR, are expressed 
relative to controls. Results are given as means ±  SE (bars) for groups o f 4. *P  < 0.05, **P  
< 0.01, ***P  < 0.001 compared to controls and normalised to P-actin.
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Figure 5.10 Dose response of PGE2 on ZAG mRNA levels in 3T3-L1
adipocytes
Cells were harvested at day 8 after the induction o f differentiation and were incubated for 
24h in a medium containing different doses o f PGE2 . No reagent was added to the 
medium o f control cells. ZAG mRNA levels, measured by real-time PCR, are expressed 
relative to controls. Results are given as means ±  SE (bars) for groups o f 5-6. **P  < 0.01, 
***P  < 0.001 compared to controls and normalised to P-actin.
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Cells were harvested at day 8 after the induction o f differentiation and were incubated for 
24h in a medium containing different doses o f PGE2 . No reagent was added to the 
medium of control cells. Adiponectin (A) and IL-6 (B) mRNA levels, measured by real­
time PCR, are expressed relative to controls. Results are given as means ±  SE (bars) for 
groups o f 5-6. *P  < 0.05, **P  < 0.01 compared to controls and normalised to P-actin.
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Figure 5.12 Dose response of PGF2a on ZAG mRNA levels in 3T3-L1
adipocytes
Cells were harvested at day 8 after the induction o f differentiation and were incubated for 
24h in a medium containing different doses o f PGF2a. No reagent was added to the 
medium o f control cells. ZAG mRNA levels, measured by real-time PCR, are expressed 
relative to controls. Results are given as means ±  SE (bars) for groups o f 5-6. *P  < 0.05, 
**P  < 0.01, ***P  < 0.001 compared to controls and normalised to P-actin.
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Figure 5.13 Effect of PGI2 0 1 1 ZAG mRNA levels in 3T3-L1 adipocytes
Cells were harvested at day 8 after the induction o f differentiation and were incubated for 
24h in a medium containing PGI2 (LD, low dose; H D , high dose). No reagent was 
added to the medium o f control cells. PGI2 LD 50 pM , PGI2 H D , 100 pM. ZAG 
mRNA levels, measured by real-time PCR, are expressed relative to controls. Results are 




In Chapter 3, it was demonstrated that both ZAG mRNA and protein are expressed in 
mouse white adipose tissue. Furthermore, it was shown that mature adipocytes express 
the ZAG gene and protein, consistent with a previous report o f ZAG gene expression in 
human adipocytes (Bao et al., 2005). This is further evidence that ZAG is an adipokine 
and could have a local autocrine/ paracrine effect on white adipose tissue and ZAG 
produced locally could also contribute to the circulating level o f the protein. However, 
from the data presented in this chapter, it is evident that in contrast to what has been 
demonstrated in human adipocytes, and unlike other adipokines such as resistin, ZAG in 
murine adipocytes is not a marker o f adipocyte differentiation, as it is expressed at similar 
levels in the fibroblastic 3T3-L1 preadipocytes. This is in line with results presented in 
Chapter 3, where it was demonstrated that ZAG is equally expressed in mature 
adipocytes and stromal vascular fraction of murine white adipose tissue depots, as a large 
portion o f the stromal vascular fraction consists o f preadipocytes.
There is little information on the regulation o f ZAG expression in mouse adipose tissue, 
although a previous study has suggested that in 3T3-L1 adipocytes, both dexamethasone 
and a p3-adrenoreceptor agonist (BRL 37344) have a stimulatory effect on ZAG mRNA 
levels (Bing et al., 2004). Studies conducted in this chapter focused on identifying key 
factors, known to modulate the expression of several adipokines, which may also regulate 
ZAG expression in murine adipocytes. The data presented in this study indicates that a 
number o f hormones and factors can modulate ZAG mRNA levels in 3T3-L1 adipocytes. 
At the same time the current study was being conducted, a study on the regulation of 
ZAG gene expression on SGBS cell strain, a model o f human adipocytes, was published 
(Bao et al., 2005). A number o f factors were also identified in that study; comparisons 
between the two models are mentioned here, when appropriate.
Noradrenaline, an a- and p- adrenoreceptor agonist, had no effect on ZAG gene 
expression. On the other hand, isoprenaline, a P- adrenoreceptor selective agonist and 
BRL 37344, a selective p3-adrenoreceptor agonist, both induced an increase in ZAG
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mRNA levels in adipocytes. These results suggest that the sympathetic system may play 
some role in the regulation of ZAG expression, especially via p3-adrenoreceptors, which 
are the dominant receptor type in the stimulation o f lipolysis in rodent adipose tissue 
(Arch, 2001). However, given the small size o f these effects, the SNS is unlikely to be a 
major player in the regulation o f ZAG expression.
One o f the more substantial effects on ZAG gene expression was obtained with 
rosiglitazone, a selective PPARy agonist, which induced a 5.5-fold increase in ZAG 
mRNA levels at the high dose. Its effect on ZAG paralleled its stimulatory effect on 
adiponectin mRNA, while having the opposite effect on IL-6, as previously reported 
(Lagathu et al., 2003), indicating that the PPARy nuclear receptor is involved in the 
regulation of ZAG synthesis. A number of studies have previously demonstrated that 
PPARy ligands regulate the expression of several adipokines by suppressing those linked 
to insulin resistance and inflammatory response, such as resistin (Haugen et al., 2001), 
T N Fa (Sigrist et al., 2000) and IL-6 (Lagathu et al., 2003), while stimulating 
adiponectin (Maeda et al., 2001), an insulin-sensitizing and anti-inflammatory adipokine. 
Since rosiglitazone has anti-inflammatory properties, upregulation o f ZAG gene 
expression in murine adipocytes by rosiglitazone observed in the current study and a 
previous report using human SGBS adipocytes (Bao et al., 2005) may suggest that ZAG 
might have an anti-inflammatory role in adipose tissue. Rosiglitazone’s stimulatory effect 
on ZAG gene expression might also suggest a role for ZAG in insulin sensitivity, however 
further investigations would be necessary to substantiate this. The observation that pro- 
inflammatory agents, such as LPS, IL-6 and T N F a had no effect on ZAG mRNA levels 
in murine adipocytes might suggest that rosiglitazone acts directly to increase ZAG 
expression and not via the regulation o f pro-inflammatory cytokines.
In the present study, it was shown that in 3T3-L1 adipocytes treated with adiponectin, 
ZAG was increased by 6-fold. Adiponectin, along with its other effects, has an anti­
inflammatory action which includes the inhibition of N FkB activation (Ouchi et al., 
2000). In contrast to many adipokines, adiponectin gene expression in adipose tissue and 
the circulating levels o f the protein fall in obesity (Matsuzawa, 2005). The observation
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that adiponectin has a stimulatory effect on ZAG gene expression in adipocytes might be 
suggestive o f ZAG’s anti-inflammatory role in adipose tissue and it is further evidence 
that there might be a functional link between the two adipokines, as it has been 
previously reported that overexpression of ZAG in 3T3-L1 adipocytes leads to an increase 
in adiponectin mRNA levels, thus suggesting a possible role for ZAG in body weight 
regulation (Gohda et al., 2003). Furthermore, since adiponectin falls in obesity, this 
might explain, at least in part, the reduction in ZAG mRNA level in WAT depots o f 
obese rodents.
Finally, leptin led to the most marked decrease in ZAG mRNA levels in 3T3-L1 
adipocytes. Similarly leptin induced a decrease in both adiponectin and IL-6 mRNA 
levels. Leptin is induced in obesity, its levels increasing with the degree o f adiposity. Both 
in vivo and in vitro studies have shown that ob gene expression is reduced by 
catecholamines (Hardie et al., 1996; Trayhurn et al., 1998), the effect occurring primarily 
through the P3-adrenoreceptors (Giacobino, 1996; Trayhurn et al., 1996). Its regulation 
in adipocytes is thus opposite to what seems to be the case for ZAG and thus 
administration o f leptin induces a decrease in ZAG gene expression. This might be a 
further explanation for the reduction in ZAG in obese rodents.
The results o f the second part o f this study have demonstrated that ZAG gene expression 
is largely modulated by key prostaglandins. PGD 2 had no significant effect on ZAG 
mRNA levels in 3T3-L1 adipocytes. In solution, PG D 2 spontaneously breaks down to 
PGJ2 (Straus &  Glass, 2001). Although the former did not induce a significant increase in 
ZAG gene expression, the latter induced a 4-fold increase in ZAG mRNA levels. 
Depending on the conditions, PG j2 is converted further to yield AI2-PGj2 and 15d-PGj2 
(Straus &c Glass, 2001). Both these metabolites have strong stimulatory effects on ZAG 
gene expression (figure 5.8). Thus, while PGD 2 does not have a direct effect on ZAG gene 
expression, derivatives, particularly A12-PGJ2, potently stimulate expression.
PGD 2 has been shown to stimulate lipolysis in adipocytes via a mechanism involving the 
elevation of cAMP levels through activation of adenylate cyclase (Kather &  Simon,
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1979), this effect being mediated through its DP receptor. 15d-PGj2 is a high affinity- 
endogenous ligand for PPARy nuclear receptor and it actually represents the highest 
affinity natural ligand for PPARy identified so far (Straus &C Glass, 2001). A12-PGj2 also 
binds to PPARy, although with considerably lower affinity than 15d-PGj2 (Forman et al., 
1995). This further supports the data presented in the first part o f this chapter, where it 
was demonstrated that the PPARy agonist rosiglitazone induced a dose-dependent 
increase in ZAG mRNA levels. Furthermore, 15d-PGj2 is a potent anti-inflammatory 
agent that represses the expression o f a number of inflammatory response genes, 
including iNOS, T N F a and COX-2 genes. It also inhibits the transcription factors 
N FkB and AP-1; and inhibits NFicB-mediated transcriptional activation by PPARy- 
dependent and independent mechanisms. There is also evidence that it functions as a 
physiological negative feedback regulator o f prostaglandin synthesis, as o f the 
inflammatory mediator PGE2.via inhibition of COX-2 synthesis (Straus &  Glass, 2001). 
It is therefore likely that the observed stimulatory effect o f 15d-PGj2on ZAG expression 
occurs via PPARy activation, but its anti-inflammatory role may also be involved.
The strong stimulatory effect o f PGJ2, AI2-PGJ2 and 15d-PGj2, however, is in contrast 
with the response to PGE2 and PGF2a, which had a strong inhibitory effect on ZAG 
expression even at very low doses. However, little is known about the functions o f these 
prostaglandins in adipose tissue. Very interestingly, PGE2 has been found to act as an 
antilipolytic-hypertrophic agent promoting terminal differentiation o f preadipocytes, 
while PGI2 may act as an adipogenic-hyperplastic effector. Thus it has been proposed 
that both contribute to the development o f adipose tissue mass (Vassaux et al., 1992 a &  
b). Furthermore, PGE2 has been shown to stimulate leptin secretion in rodent adipose 
tissue and in mature adipocytes (Fain et al., 2000). Similar observations have been made 
in the heart, where it has been demonstrated that PGE2 and PGI2 act as inhibitory 
modulators o f p-adrenergic receptor-stimulated cardiac lipolysis (Ruan et al., 1996). 
Thus, the anti-lipolytic properties o f these prostaglandins could possibly be responsible 
for the inhibition of ZAG gene expression in adipocytes treated with these prostaglandins. 
The downregulation of ZAG by PGE2 might also be attributed to the possible role o f this 
prostaglandin as an inflammatory mediator (Straus &  Glass, 2001). The up regulation o f
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IL-6, an inflammatory regulator in adipose tissue, by PGE2 further supports this 
suggestion.
As aforementioned, it has been known for some time that adipocytes can synthesize 
prostaglandins (Shillabeer et al., 1998), with PGE2, 6-keto-PGFia (the natural metabolite 
of PGI2), PGF2a and 15d-PGj2 being secreted by 3T3-L1 adipocytes (Borglum et al., 
1999). Similarly, PGD 2 is expressed in both 3T3-L1 adipocytes and human adipose 
tissue (Jowsey et al„ 2003) and both PGI2 and PGE2 are secreted by isolated human 
adipocytes, although their expression is higher in the stromal vascular fraction (Fain et al., 
2002). Thus WAT, either mature adipocytes, or other cells in the tissue, such as 
macrophages and preadipocytes, produce the prostaglandins that affect ZAG gene 
expression in 3T3-L1 adipocytes.
Finally, it should be noted that the concentrations o f PG D 2 and the J 2 series PGs used in 
the present study were based on recent studies demonstrating the effects o f prostaglandins 
on a number of adipokines on 3T3-L1 cells (Bullo et al., 2005; Peeraully et al., 2006). 
Physiological concentrations o f PGs in the body fluids are found to be in the pico- 
nanomolar range, their levels rise considerably under pathological conditions reaching the 
micromolar range at the site o f damage (Herschman et al., 1997). In the case o f PG D 2 
and PG J2, however, the fact that there is a fall in their initial concentrations during 
culture because o f their conversion to their metabolites has to be taken into 
consideration. However, their synthesis was found to be increased in the late phases o f 
inflammation (Gilroy et al., 1999).
In conclusion, in the present study, a number o f key factors regulating ZAG expression in 
3T3-L1 adipocytes were identified. Briefly, it has been demonstrated that rosiglitazone, 
isoprenaline, and adiponectin have a stimulatory effect on ZAG gene expression, while 
leptin inhibits its expression in 3T3-L1 adipocytes. According to their properties, 
prostaglandins exert different, but potent, effects on ZAG gene expression. While ZAG 
gene expression is strongly induced by PG j2-series prostaglandins, pro-inflammatory 
prostaglandins PGE2 and PGF201 inhibit its expression in the murine adipocytes. O f
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course, the effects o f these factors have only been studied at the mRNA levels in this 
study and further analysis o f the secretion o f the protein by adipocytes would provide 
stronger evidence o f the regulation o f ZAG in WAT.
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Chapter 6
Postnatal development of ZAG in rodent adipose tissue
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6.1 Introduction
In Chapter 3, it was shown that ZAG is expressed in both adult mouse and rat adipose 
tissue, as both the mRNA and protein were detected in all WAT depots as well as in 
BAT. Quantitative analysis also showed that ZAG is mainly expressed in the internal 
WAT depots. When, however, the physiological functions o f a gene are studied, it is 
important to establish the time at which its system first becomes functional in the young 
animal and how this changes during early postnatal life. This is particularly so as adipose 
tissue itself undergoes a number of major morphological and metabolic changes (Herrera 
&  Amusquivar, 2000). There are also suggestions from the study o f other adipose tissue 
factors, such as leptin and resistin, that the distribution of a particular factor in different 
depots might also undergo changes during early development (Rayner et al., 1997; Oliver 
etal., 2001a, b; Oliver et al., 2003).
Rats are a good model for studies on the postnatal development o f factors relating to 
adipose tissue and this is mainly due to two reasons. The first is that in the rat the 
development o f white adipose tissue occurs mainly after birth. At day 1 after birth, white 
fat is barely detectable, usually solely in the subcutaneous area and not internally. 
However, rats rapidly lay down fat stores during the suckling period, while internal fat 
depots appear in tiny amounts, only to expand after weaning, around day 21 
(Greenwood &  Hirsch, 1974; Cryer &  Jones, 1978). The second reason for using the rat 
as a model is that BAT is well developed in newborn rats, where it is present throughout 
neonatal and adult life (Dessolin et al., 1997). Rats are preferable to mice as the WAT 
depots are inevitably much smaller in mice and especially at these early stages they are not 
substantial enough to sample.
The metabolism of rat adipose tissue during the time course o f postnatal development 
undergoes some major changes. Briefly, these can be grouped into the suckling period 
that usually lasts until day 21 after birth (weaning), the period o f highest hyperplasia 
between birth and 40 days after birth, which is followed by a period o f highest cell 
hypertrophy occurring between 40 and 80 days after birth due to the intense increase in
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both LPL activity and lipogenesis (Herrera &  Amusquivar, 2000). In the early suckling 
period, the high-fat and low-carbohydrate diet present in milk (l4 .8g fat/lOOg milk) 
contributes to the marked hyperketonaemia normally present in both humans and rats 
during this time, since nonesterified fatty acids are the major precursors for ketone body 
synthesis (Williamson, 1998). Immediately after birth, and less intensively during 
suckling, the rate o f lipolysis has been shown to be enhanced (Gruen et al., 1980). 
During the first hours after birth, this appears to be regulated by catecholamine release, 
resulting in cAMP production and increased protein kinase C  activity (Kimura et al., 
1983). Later, during suckling, enhanced lipolysis is most possibly caused by an enhanced 
sensitivity to lipolytic hormones, and a decreased plasma insulin/ glucagon ratio (Issad et 
al., 1987; Marcus et al., 1988). Moreover, LPL activity, which is representative o f the 
tissue’s capability to take up circulating triglycerides, peaks at mid-suckling (Ramirez et 
al., 1998), thus contributing to the enhanced rate o f cell proliferation observed at this 
period. Finally, the suckling period is characterised by a very low lipogenic activity 
(Smith &  Kaplan, 1980).
Weaning at day 21, which is the switch from a high-fat to a high-carbohydrate (the 
animals gradually consume lab chow from day 18) diet is characterised by many 
metabolic changes in rat adipose tissue. LPL activity declines around weaning, only to 
increase again at 30-40 days o f age (Cryer &  Jones, 1978; Ramirez et al., 1998). 
Furthermore, lipogenic activity rapidly increases during this period. Because o f these 
changes, from weaning up to around 40 days after birth, although the number of 
adipocytes is still increasing, they start to be filled up with fat. Finally, lipolysis, which 
declines as the suckling period advances, slightly peaks after weaning to decline afterwards 
(Gruen et al., 1980).
Finally, rat foetal liver contains a high level o f LPL activity, which increases after birth. 
This activity declines with age, but still remains higher in the liver o f the suckling rat 
than after weaning, when it declines to undetectable levels (Llobera et al., 1979; Ramirez 
et al., 1998). Since changes in liver LPL activity in the newborn rat are accompanied by 
changes in the hepatic content o f triglycerides, circulating triglycerides and ketone bodies
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(Grinberg et al., 1985), it has been proposed that in the suckling neonate, long chain 
fatty acids derived from milk lipids are channelled to liver due to its LPL, and such a 
change possibly contributes to the high ketogenic capacity o f that organ during the 
suckling period (Herrera &  Amusquivar, 2000).
Little is known about the occurrence and roles o f different adipokines at the early stages 
of adipose tissue development, leptin being the only adipokine whose fetal and early 
postnatal development both in WAT and BAT have been documented (Dessolin et al., 
1997; Rayner et al., 1997). In this study, the ontogenic pattern o f ZAG gene and protein 
expression during postnatal development up to day 32, is reported in different WAT 
depots (subcutaneous, perirenal, gonadal), BAT and liver in rats. The expression pattern 
of leptin in rat adipose tissue during this period is also studied as a reference. 
Furthermore, the ontogenic patterns o f adiponectin, the neurotrophin N G F, and the 
inflammatory factors IL-6 and MCP-1 during early postnatal development in the rat are 
explored, in order to provide reference points and to gain further information on the 
physiological role o f these adipokines. Each o f these adipokines has been linked to body 
weight control, obesity, insulin sensitivity, as well as inflammation in adipose tissue 
(Prins, 2002; Wood &  Trayhurn, 2006). Thus the present study provides information on 
the expression patterns o f ZAG and the aforementioned adipokines in different WAT 
depots during early postnatal development in the rat, thus providing a greater insight into 




For the purposes o f this study, two sets o f experiments were carried out. In the first 
experiment, the aim was to explore whether ZAG is expressed in rat WAT and BAT in 
the first 24 hours after birth, or if  not when it first appears in the early postnatal period. 
For this experiment four female wistar rats were sacrificed at days 1, 3, 5 and 10 after 
birth and liver, BAT and WAT depots were dissected as soon as they were sufficient to 
sample. After having established that ZAG was expressed in rat WAT and BAT from day 
1 postnatally, the aim was to explore the detailed ontogenic pattern o f ZAG expression in 
the early postnatal period. In the second extended experiment, five female rats were 
sacrificed at each o f the following time points, days 1, 3, 5, 7, 10, 13, 21, and 32 
postnatally and again liver, BAT and WAT depots were dissected. Rats were kept under 
controlled environmental conditions (20-24°C; 12h:12h light:dark cycle) and were 
sacrificed between 10:00 and 11:00 h at the allocated days. Since their stomachs were 
invariably full, they were considered to be in the fed state. All animals used for each 
experimental cycle shared the same genetic background and were kept in mixed sex 
litters.
Animals were sacrificed by cervical dislocation and according to the regulations for 
animal treatment o f the University o f Liverpool. As soon as the tissues were dissected, 
samples were weighed, snap frozen in liquid nitrogen and stored at -80°C until further 
analysis.
6.2.2 RT-PCR and real-time PCR
Total RNA was extracted from tissues using Tri-Reagent as previously described in 
section 2.5. RNA was then treated using a DNA-free kit (section 2.5.3) and quantified 
using a BioPhotometer (section 2.5.4). RNA was reverse-transcribed using the Reverse-iT 
First Strand Synthesis kit (section 2.6.1) and the patterns o f gene expression were
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analysed by RT-PCR (section 2.6.2). mRNA levels o f expression were assessed by real­
time PCR  (section 2.7) using the qPCR Core Kit and a Stratagene Mx3005 instrument.
6.2.3 Western blotting
Protein was extracted from tissues using Tri-Reagent after the RNA had been removed 
for total RNA extraction, as previously described in section 2.8.1. The protein 
concentration o f samples was determined using the BCA method (section 2.8.2) and 10 
pg o f protein were mixed with equal volumes o f loading buffer and separated by 
electrophoresis on 10% SDS-polyacrylamide gels (section 2.8.3). Immunoblotting was 
then performed as described in section 2.8.4 by using an anti-mouse ZAG monoclonal 
primary antibody at a 1:1000 dilution, followed by incubation with a goat anti-mouse 
secondary antibody conjugated to horseradish peroxidise at a 1:1000 dilution. 
Densitometric analysis was carried out as previously described in section 2.8.6 and gels 
were stained with Ponceau S to confirm equal loading (section 2.8.5.2).
6.2.4 Statistical analysis
Data are expressed as mean values ±  SEM. Comparisons between two groups were 
assessed by unpaired Student’s ¿-test, while differences among more than two groups were 
analysed by one-way ANOVA coupled with Bonferroni’s i-tests, as previously described 
in section 2.9. Differences were considered as statistically significant when P < 0.05.
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6.3 Results
6.3.1 ZAG expression in the early postnatal period
An initial study was conducted in order to explore whether ZAG is expressed in rat 
neonates in the first 24 hours after birth or if not when it first appears. Experiments were 
also carried out in the liver as a further reference point on ZAG’s availability in the body. 
For this, ZAG mRNA and protein expression were studied using RT-PCR and western 
blotting respectively, in the liver, BAT and WAT depots o f 1, 3, 5, and 10 day old female 
rats. Liver and BAT were available from day 1, whereas subcutaneous and gonadal were 
sufficient to sample at days 3 and 5 respectively.
Both ZAG mRNA and protein were expressed in liver and BAT postnatally at day 1 
onwards, and in subcutaneous and gonadal at all days tested (Figures 6.1A&B). Further 
to ZAG, the expression of leptin and adiponectin mRNA was studied as a reference. 
Consistent with what has previously been reported for leptin (Rayner et al., 1997), it was 
expressed in adipose tissue from day 1 and although not quantified, its expression was 
clearly increasing with time (Figure 6.2A). The adiponectin gene was also found to be 
expressed at all time points tested (Figure 6.2B).
Although RT-PCR indicated that the ZAG gene is expressed in all sites tested postnatally, 
as soon as they are sufficient to be sampled, the signal intensity varied between time 
points, suggesting that the expression o f ZAG changes postnatally. Thus real-time PCR 
was used and some initial results showed an interesting pattern o f ZAG mRNA and 
protein expression postnatally (data not shown). It thus led to the studies on the 
postnatal ontogenic pattern o f ZAG gene and protein expression in a more extensive 
manner.
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(A) Gene expression o f ZAG in liver (a), subcutaneous WAT (b), gonadal WAT (c) and 
BAT (d) from 1, 3, 5 and 10-days old rats were examined by RT-PCR; PCR was 
performed at 30 cycles for ZAG and 23 cycles for (3-actin (B) Protein expression of ZAG 
in BAT and gonadal WAT depots o f the same animals were examined by western 
blotting. —T , no template control; BAT, interscapular brown adipose tissue
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Figure 6.2 Gene expression of leptin and adiponectin in WAT depots and
BAT of rat neonates
A.
day 1_______  _______day 3______  day 5_______  d ay  10 -T
Gene expression o f leptin (A) and adiponectin (B) in subcutaneous WAT (a), gonadal 
WAT (b) and BAT (c) from 1, 3, 5 and 10-days old rats were examined by RT-PCR; (1) 
at 30 cycles for leptin; and (2) at 28 cycles for adiponectin; lpl cDNA was used as a 
template; -T, no template control
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6.3.2 Total body weight and adipose tissue depots during early 
postnatal development
In order to establish the pattern of ZAG expression postnatally a larger scale study was 
designed. Groups o f five female rats were sacrificed at days 1, 3, 5, 7, 10, 15, 21 and 32 
after birth. Weaning was initiated at day 21, with rats having ad libitum access to lab 
chow from day 18. As shown in Figure 6.3, their total body weight increased very 
rapidly, with the greatest increase being observed between days 21 and 32, when their 
weight almost doubled. In this study, only a tiny amount o f subcutaneous WAT could be 
sampled at day 1, with increased amounts thereafter, while the perirenal and gonadal 
depots could only be sampled from days 5 and 7 respectively. This again demonstrates 
that after birth the amount o f subcutaneous fat increases rapidly, while it takes longer for 
the internal fat depots to develop. The amount o f BAT, on the other hand, reached its 
peak at day 15 but gradually decreased thereafter (Figure 6.3). As a percentage o f total 
body weight (Figure 6.4), both perirenal and gonadal WAT depots steadily increased 
rapidly although not so abruptly, to reach maximum values at day 21. In contrast, BAT 
gradually declined in terms of relative weight from day 5 onwards.
6.3.3 ZAG expression patterns in adipose tissue postnatally
Real-time PCR results (Figure 6.5) revealed no differences in ZAG mRNA levels between 
different time points in the case o f the subcutaneous depot. On the other hand, ZAG 
mRNA levels in gonadal WAT were significantly decreased at day 21 and thereafter, the 
same being observed in the perirenal depot at day 32. Interestingly, ZAG mRNA levels in 
BAT continually declined from day 3 onwards.
The levels o f ZAG protein expression (Figure 6.6) in subcutaneous (A), perirenal (B), 
gonadal (C) and BAT (D) were then analysed at days 7, 21 and 32 using western 
blotting. Similar to what was observed for mRNA levels, protein expression levels 
declined in all depots with time, including in the subcutaneous site. Interestingly, in 
perirenal WAT and BAT, ZAG levels o f protein expression were lowest at day 21.
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Figure 6.3 Developmental changes in body weight and weight of adipose
tissue depots in rat neonates
A. Total body weight B. Perirenal weight
Total body weight was measured following sacrifice, while individual depots were 
weighed after dissection. Results are presented as means ±  SE (bars) for five rats at each 
time point. *P  < 0.05, **P  < 0.01, ***P  < 0.001 compared to day 1 for total body weight 
and BAT, day 5 for perirenal and day 7 for gonadal WAT (one-way ANOVA).
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Figure 6.4 Developmental changes in weight of WAT depots and BAT relative























For total body weight, rats were weighed after being sacrificed, while individual depots 
were weighed after dissection. Perirenal WAT (A), gonadal WAT (B) and BAT (C) 
weights are presented relative to total body weight [tissue (g)/ body weight (g)]. Results 
are presented as means ±  SE (bars) for five rats at each time point. *P  < 0.05, **P  < 0.01, 
***P  < 0.001 compared to day 1 for total body weight and BAT, day 5 for perirenal and 






























Figure 6.5 ZAG gene expression in adipose tissue depots of neonatal rats
A. Subcutaneous B. Perirenal
C. Gonadal
Adipose tissue depots were dissected from rats at each time point and total RNA was 
extracted. Real-time PCR was used for the relative quantification o f ZAG mRNA levels. 
Results are expressed relative to the ZAG mRNA levels in each depot at day 1 postnatally 
or day 5 for perirenal and day 7 for gonadal WAT and are presented as means ±  SE (bars) 
for 4-5 rats. *P <  0.05, **P <  0.01 and * **P <  0.001 (one-way ANOVA).
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Protein samples were extracted from adipose tissue depots dissected from neonate rats at 
age o f 7, 21 and 32-days old and then were analysed by western blotting followed by 
densitométrie analysis. Representative blots are shown and results are presented as means 
±  SE (bars) for 4-5 rats at each time point. *P  < 0.05, **P  < 0.01 and * **P  < 0.001; 
results are relative to ZAG protein expression at day 7 (one-way ANOVA). < 0.05, nP 
< 0.01; results are comparisons between days 21 and 32 (unpaired Student’s 7-test).
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6.3.4 Postnatal expression o f ZAG in the liver o f rat neonates
As previously mentioned, the liver is the main site o f ZAG production in the body. 
Indeed from day 1 ZAG mRNA levels in the liver were significantly higher than in 
subcutaneous WAT, and the difference was increased with time (Figure 6.7A). The 
patterns o f ZAG expression in the liver postnatally were further studied in greater detail. 
As shown in Figure 6.7B, contrary to the expression pattern in adipose tissue, ZAG 
mRNA levels in the liver were gradually increased, reaching a 10-fold increase by day 32 
compared to day 1.
6.3.5 Expression patterns o f several adipokines in adipose tissue 
postnatally
As a reference to ZAG and in order to further explore how the metabolic changes 
occurring in adipose tissue during early postnatal development affect the expression of 
adipokines, the expression patterns o f several adipokines were analysed using real-time 
PCR. mRNA levels o f leptin, adiponectin, NGF, MCP-1 and IL-6 were analysed in 
subcutaneous, perirenal, and gonadal WAT and in BAT o f newborn rats at days 1, 3, 5, 
7, 10, 21 and 32 postnatally.
6.3.5.1 Gene expression pattern o f leptin in rat adipose tissue during postnatal 
development
As aforementioned, leptin was evident in adipose tissue at day 1 after birth and thereafter 
(Figure 6.2). As shown in Figure 6.8, leptin mRNA levels in subcutaneous WAT were 
gradually increased from day 1 onwards; reaching a peak at day 15, when they were 
almost 250-fold higher than at day 1, and then slightly declined at days 21 and 32. In 
perirenal WAT, leptin mRNA levels gradually increased, reaching a peak at day 32, being 
20-fold higher than at day 1. In gonadal WAT, however, there were no statistically 
significant changes in expression levels until day 32, at which point leptin mRNA levels 
were 5-fold higher than at day 7. Finally, in BAT leptin expression was significantly 
increased at all time points compared to day 1, and peaked at day 10 with a 20-fold 
higher level.
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Figure 6.7 ZAG gene expression in the liver of rat neonates
(A)
(B)
Liver was dissected from rats at each time point and total RNA was extracted. Real-time 
PCR was used for (A) the comparison between ZAG mRNA levels in subcutaneous 
WAT and liver at days 7 and 32 postnatally (unpaired Student’s r-test); and (B) the 
relative quantification o f ZAG mRNA levels in the liver o f neonate rats up to day 32. 'P  
< 0.05, "P  < 0.01, "  P < 0.01. Results are expressed relative to the ZAG mRNA levels in 
subcutaneous WAT (A) or liver at day 1 postnatally (B) and are presented as means ±  SE 
(bars) for 4-5 rats (one-way ANOVA).
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Adipose tissue depots were dissected from rats at each time point and total RNA was 
extracted. Real-time PCR was used for the relative quantification o f leptin mRNA levels. 
Results are expressed relative to the leptin mRNA levels in each depot at day 1 postnatally 
or day 5 for perirenal and day 7 for gonadal WAT and are presented as means ±  SE (bars) 
for 4-5 rats. *P <  0.05, **P <  0.01 and * **P <  0.001 (one-way ANOVA).
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6.3.5.2 Gene expression pattern o f adiponectin in rat adipose tissue during 
postnatal development
The pattern o f expression of adiponectin in WAT depots and BAT postnatally was 
similar to that o f leptin (Figure 6.9). In the subcutaneous depot, adiponectin mRNA 
levels were increased significantly from day 3 relative to day 1, reaching a 5-fold increase 
at day 15, while at days 21 and 32 the levels fell again. In the perirenal depot there was a 
gradual increase in adiponectin levels, peaking at day 32 (8-fold higher compared to day 
1), while in the gonadal depot, adiponectin levels were significantly suppressed at 
weaning but increased again at day 32. Finally, in BAT there were no changes in the 
levels o f  adiponectin expression throughout the early postnatal development.
6.3.5.3 Gene expression pattern ofN G F in rat adipose tissue during postnatal 
development
N G F was evident in adipose tissue at day 1 postnatally and thereafter. As shown in 
Figure 6.10, no changes were observed in N G F mRNA levels in subcutaneous and 
perirenal WAT until day 32, when the expression levels were significantly suppressed. 
There was a small increase in N G F mRNA at day 21 compared to day 7 in gonadal 
WAT. In BAT, N G F levels were significantly reduced at day 7, 21 and 32 relative to day 
1.
6.3.5.4 Gene expression pattern ofM CP-1 in rat adipose tissue during 
postnatal development
MCP-1 was also expressed at day 1 after birth and thereafter. As shown in Figure 6.11, 
there were no fluctuations in MCP-1 mRNA levels in the subcutaneous depot until day 
21, while it was significantly reduced at day 32. However, in perirenal WAT MCP-1 
mRNA levels were significantly increased at days 10, 15 and 32, when they peaked. 
Weaning though led to downreguladon ofM CP-1 in the gonadal depot, which was also 




















































Figure 6.9 Adiponectin gene expression in adipose tissue depots of neonatal
rats
A. S u bcutaneou s
d l  d3 d 5  d7 d io  d l5  d 2 l  d32
B. P erirenal
d 5  d7 d 10 d 15  d21 d32
C. G o n ad a l D. B A T
Adipose tissue depots were dissected from rats at each time point and total RNA was 
extracted. Real-time PCR was used for the relative quantification of adiponectin mRNA 
levels. Results are expressed relative to the adiponectin mRNA levels in each depot at day 
1 postnatally or day 5 for perirenal and day 7 for gonadal WAT and are presented as 










































Figure 6.10 N G F  gene expression in adipose tissue depots of
neonatal rats
A. Subcutaneous B. Perirenal
C. G onadal D. BAT
Adipose tissue depots were dissected from rats at each time point and total RNA was 
extracted. Real-time PCR was used for the relative quantification o f N G F mRNA levels. 
Results are expressed relative to the N G F mRNA levels in each depot at day 1 postnatally 
or day 5 for perirenal and day 7 for gonadal and are presented as means ±  SE (bars) for 4- 
5 rats. *P <  0.05, * *P <  0.01 and * **P <  0.001 (one-way ANOVA).
*
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Figure 6.11 M CP-1 gene expression in adipose tissue depots of neonatal rats
A. Subcutaneous B. Perirenal
C. Gonadal D. BAT
Adipose tissue depots were dissected from rats at each time point and total RNA was 
extracted. Real-time PCR was used for the relative quantification o f MCP-1 mRNA 
levels. Results are expressed relative to the MCP-1 levels in each depot at day 1 
postnatally or day 5 for perirenal and day 7 for gonadal and are presented as means ±  SE 
(bars) for 4-5 rats. *P  < 0.05, **P  < 0.01 and ***P  < 0.001 (one-way ANOVA).
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6.3.5.5 Gene expression pattern o fIL -6  in rat adipose tissue during postnatal 
development
Finally, IL-6 was also evident in adipose tissue at day 1 after birth and thereafter. As 
shown in Figure 6.12, mRNA levels were increased at days 10 and 15 in subcutaneous 
and perirenal. In the latter, however, the level peaked at day 32 (100-fold). At days 21 
and 32, the levels were also increased in the gonadal depot. In BAT, IL-6 mRNA levels 
were significantly downregulated from day 3 onwards.
6.3.6 Comparison o f ZAG mRNA levels in different adipose depots at 
days 1, 21 and 32 postnatally
Although RT-PCR analysis has shown that ZAG is present from day 1 postnatally in all 
sites tested, it has been shown that there are some differences in the levels o f its expression 
among different sites. There is also some evidence that this pattern may change at 
different stages during postnatal development. To address this point, the ZAG mRNA 
levels were compared at days 1 in BAT and subcutaneous WAT at days 7 as it is the first 
time points at which all four depots were enough to sample, and 32, as this is when some 
of the major changes had previously been observed not only in ZAG expression pattern 
but also in the other adipokines. Very interestingly, as shown in Figure 6.13, at day 1, 
ZAG m RNA levels were higher (18-fold) in subcutaneous WAT compared to BAT. At 
day 7 and 32, ZAG was still significantly more abundant in the subcutaneous depot 
compared to the other depots.
Although no major differences were observed in ZAG mRNA levels at different time 
points during the early stages o f development, some interesting patterns were observed in 
the case o f leptin (Figure 6.14) and adiponectin (Figure 6.15) during the same 
experiment. At day 1 postnatally, leptin mRNA levels were significantly higher in BAT 
(12-fold) compared to subcutaneous WAT. By day 7 however, the levels were higher in 
subcutaneous (10-fold) compared to perirenal WAT, while still quite high in BAT. This 
pattern was completely changed by day 32, when leptin mRNA was more abundant in 
the internal WAT depots.
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Figure 6.12 IL -6  gene expression in adipose tissue depots of neonatal rats
A. Subcutaneous B. Perirenal
C. G onadal D. BAT
Adipose tissue depots were dissected from rats at each time point and total RNA was 
extracted. Real-time PCR was used for the relative quantification o f IL-6 mRNA levels. 
Results are expressed relative to the IL-6 mRNA levels in each depot at day 1 postnatally 
or day 5 for perirenal and day 7 for gonadal and are presented as means ±  SE (bars) for 4- 
5 rats. *P <  0.05, * *P <  0.01 and * **P <  0.001 (one-way ANOVA).
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Figure 6.13 Depot differences in ZAG gene expression in adipose tissue of
neonatal rats
Samples from four adipose tissue depots o f neonatal rats at days 1, 7 and 32 were 
analysed by real-time PCR for the relative quantification of ZAG mRNA levels. Results 
are expressed relative to ZAG mRNA levels in BAT (day 1 &  7) or peri (day 32) and are 
presented as means ±  SE (bars) for 5 rats. Subc, subcutaneous; peri, perirenal; gon, 
gonadal; BAT, interscapular brown adipose tissue. aP  < 0.01 vs Subc; aIP  < 0.001 vs subc; 
h,P  < 0.001 vs subc, C,P  < 0.05 vs subc; *2/ > < 0.001 vs subc, h2P < 0.001 vs subc, c2P < 0.01 
vs subc (Student’s r-test for comparisons between 2 groups and one-way ANOVA for 
comparisons between two or more groups).
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Figure 6.14 Depot differences in leptin gene expression in adipose tissue of
neonatal rats
Samples from four adipose tissue depots o f neonatal rats at days 1, 7 and 32 were 
analysed by real-time PCR for the relative quantification o f leptin mRNA levels. Results 
are expressed relative to leptin mRNA levels in subc (day 1 &  32) or peri (day 7) and are 
presented as means ±  SE (bars) for 5 rats. Subc, subcutaneous; peri, perirenal; gon, 
gonadal; BAT, interscapular brown adipose tissue. “P < 0.01 vs BAT; alP < 0.001 vs BAT; 
P  < 0.001 vs subc; clP  < 0.05 vs subc; < 0.05 vs peri, P < 0.01 vs gon; b2P < 0.05 vs 
gon (Student’s i-test for comparisons between 2 groups and one-way ANOVA for 
comparisons between two or more groups).
187
The observations made on adiponectin were similar to those made on leptin. Although at 
day 1, adiponectin mRNA levels were equal in BAT and subcutaneous WAT, at day 7 
the concentration in the latter was increased by 3-fold. At day 32, however, adiponectin 
mRNA levels were 20-fold higher in gonadal and 7-fold in perirenal WAT compared to 
BAT.
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Figure 6.15 Depot differences of adiponectin gene expression in adipose tissue
of neonatal rats
</)
BAT Subc BAT Peri Gon Subc BAT Subc Peri Gon
day 1 day 7 day 32
Samples from four adipose tissue depots o f neonatal rats at days 1, 7 and 32 were 
analysed by real-time PCR for the relative quantification o f adiponectin mRNA levels. 
Results are expressed relative to adiponectin mRNA levels in BAT at each time point and 
are presented as means ±  SE (bars) for 5 rats. Subc, subcutaneous; peri, perirenal; gon, 
gonadal; BAT, interscapular brown adipose tissue. aIP  < 0.05 vs subc; hIP  < 0.05 vs subc, 
C,P  < 0.05 vs subc; P  < 0.05 vs gon, h2P  < 0.05 vs peri, P  < 0.01 vs gon; c2P  < 0.05 vs gon 
(Student’s ¿-test for comparisons between 2 groups and one-way ANOVA for 
comparisons between two or more groups).
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6.4 Discussion
Little is known so far about the onset o f the ZAG system in adipose tissue and its role in 
the early stages o f postnatal development. The studies described here demonstrate that 
ZAG, both mRNA and protein, is expressed in subcutaneous WAT and BAT o f one-day 
old rats, this being the point at which WAT can in practice be sampled from the 
subcutaneous region, the major fat depot during the suckling period. A signal for ZAG 
mRNA was also detected in perirenal and gonadal WAT as soon as they were large 
enough to be sampled postnatally. Moreover ZAG mRNA was expressed from day 1 
postnatally in the liver. As previously discussed, the metabolism o f rat adipose tissue 
during the time course o f early development undergoes some major changes (Herrera &  
Amusquivar, 2000). The strong signal observed for ZAG mRNA and protein expression 
from day 1 postnatally suggests that the glycoprotein might play a role in the regulation 
of adipose tissue metabolism from the early stages o f postnatal development.
The extensive study o f the ontogenic pattern of ZAG expression in subcutaneous, 
perirenal and gonadal WAT revealed that there are no substantial changes during 
suckling in ZAG levels in WAT, the expression not being affected by the rapid 
accumulation o f fat, primarily subcutaneously, during this period. Furthermore, as later 
discussed, ZAG expression is higher during suckling than post-weaning. As previously 
discussed (section 6.1), immediately after birth and throughout suckling, the rate o f 
lipolysis is enhanced (Gruen et al., 1980). ZAG is a lipid-mobilising factor, which 
stimulates lipolysis in mature adipocytes in vitro (Todorov et al., 1998), while 
administration o f ZAG to mice induces a rapid reduction in body fat and increases serum 
free fatty acid levels via the activation o f hormone-sensitive lipase through increased 
intracellular cAMP levels (Hirai et al., 1998). Immediately after birth, and until lactation 
is fully established, usually after 2-3 days, the mobilisation o f lipids via lipolysis is 
essential for the maintenance o f life. During this period, there is a rapid change from 
carbohydrate to lipids as the major energy source (Fisher, 1976). This enhanced lipolytic 
activity appears to be regulated by catecholamine release, resulting in cAMP production 
and increased protein kinase C  activity (Kimura &  Warshaw, 1983; Bahnsen et al.,
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1984). Thus ZAG might play a role in the regulation o f lipolysis at this early stage o f 
postnatal life.
Consistent with previous reports (Rayner et al., 1997), lepdn production, assuming that 
mRNA levels reflect rates o f production, on the other hand dramatically increased in 
subcutaneous WAT, peaking at day 15. A gradual increase in leptin levels was also 
detected in the perirenal depot, although at a smaller scale. Since leptin is involved in the 
regulation o f energy balance, these results support its potential to play this role from early 
in postnatal life. Adiponectin showed similar patterns, although to a smaller extent.
It was shown in Chapter 3 that in the adult mouse there are marked differences between 
depots in the relative contribution to total ZAG production in adipose tissue, the mRNA 
and protein levels being much higher in the internal depots (omental and perirenal) than 
in subcutaneous tissue. In contrast, as demonstrated in this chapter, in the suckling 
period, the subcutaneous fat appears to be the key source o f ZAG o f the adipose tissues 
tested. The same was observed for leptin, as previously demonstrated (Rayner et al., 
1997) and adiponectin. Although in adult rodents visceral fat appears metabolically more 
active and the expression of most adipokines is significantly upregulated compared to 
subcutaneous WAT, it seems that this is not the case in the early suckling period; at this 
time the subcutaneous depot is the main site o f adipokines production. However, as 
discussed in the next paragraphs, this pattern o f expression changes considerably during 
the post-weaning period, by which point the mass o f visceral fat has substantially 
increased.
Weaning, the switch from a high-fat to a high-carbohydrate diet revealed a site-specific 
effect in the expression o f the adipokines examined. ZAG mRNA levels in gonadal WAT 
were reduced compared to both day 1 and day 15, while protein levels were reduced in 
subcutaneous WAT compared to day 7 and were at their minimum in the perirenal 
depot. These changes in ZAG expression as a result o f a change in the diet suggest that 
ZAG could be sensitive to nutritional changes, as also suggested in Chapter 4, where 
ZAG was shown to exhibit a depot specific reaction in response to high-fat diet, its
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mRNA levels increasing in epididymal while being reduced in subcutaneous WAT o f the 
high-fat diet fed group. Furthermore, they also suggest that the decrease o f ZAG 
synthesis could be due to the metabolic changes occurring in WAT during this period, 
the main one being a rapid increase in lipogenic activity, as previously discussed (Gruen 
et al., 1980). The observation that the reduction in protein levels in subcutaneous and 
perirenal sites was not accompanied by a similar change in mRNA levels is most probably 
caused by post-transcriptional effects.
By day 32, animals have settled into the high-carbohydrate diet initiated at weaning, and 
lipogenesis is increased, adipocytes being filled with fat as a result (Herrera &  
Amusquivar, 2000). Furthermore, by this point, internal fat depots have considerably 
increased in size as opposed to the suckling period, when the subcutaneous depot is the 
main W AT site. As a result o f these morphological and metabolic changes, substantial 
changes were observed at day 32 in the expression of the tested adipokines particularly in 
internal depots. ZAG levels, both in perirenal and gonadal WAT were highly reduced, as 
revealed by mRNA and protein analysis. A slight increase in ZAG protein levels in 
perirenal WAT and BAT might link to a small peak in lipolytic activity o f adipose tissue 
shortly after weaning (Gruen et al., 1980).
Both leptin and adiponectin on the other hand show a different pattern. They were both 
increased in perirenal and gonadal depots, the latter being their main WAT production 
site at this stage as shown from the depots comparisons. Indeed, after weaning, there 
seems to be a rapid switch from subcutaneous to internal adipose tissue as the main 
source o f leptin and adiponectin, which is evident by day 32. This is the same pattern of 
differential expression that has previously been observed in Chapter 3 and reported for 
leptin in adult mice (Hardie et al., 1996). ZAG, however, at this stage is still mainly 
expressed in subcutaneous WAT. However, it would be assumed that there is a switch 
later on during development as in 10-week old mice it is mainly expressed in omental 
and perirenal depots. Studies covering a longer period of postnatal development would 
make it possible to further explore this.
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IL-6, MCP-1 and N G F have been linked to body weight control, obesity and insulin 
sensitivity, as well as inflammation in adipose tissue (Prins, 2002; Wood &  Trayhurn,
2006). There have been no reports so far on their expression in adipose tissue during 
early postnatal development. The current study demonstrates that all three are expressed 
in W AT o f rat neonates from day 1 o f life. During suckling there were only small 
changes in the mRNA levels in all three WAT depots tested, the effects being depot 
specific, including an increase in MCP-1 mRNA levels in perirenal WAT at days 10 and 
15 and in IL-6 mRNA levels in both subcutaneous and perirenal WAT at days 10 and 15 
compared to day 1. In adult rodents, IL-6 has been reported to be implicated in 
stimulating lipolysis (Path et al., 2001), being mainly synthesized by visceral fat (Fried et 
a l,  1998). According to the present data, though, IL-6 might also be involved in the 
regulation o f lipolysis occurring during suckling, as indicated by an increase in its mRNA 
levels at day 10 and 15 in subcutaneous and perirenal WAT depots. The same was 
observed in response to weaning, which had only small depot-specific effects in the 
expression of the adipokines in WAT. The most dramatic effects on the expression of the 
three adipokines were however observed at day 32 postnatally.
Interestingly at day 32, N G F mRNA is suppressed in subcutaneous and perirenal WAT, 
although not altered in the gonadal depot, its main production site in adult mice 
(Peeraully et al., 2004). Furthermore, MCP-1 is also suppressed in the subcutaneous, but 
increased in perirenal WAT, while a substantial increase in IL-6 production in the latter 
was observed. Although no depots comparisons were carried out for these adipokines, the 
present data suggests that as for leptin and adiponectin, they are mainly synthesized by 
visceral WAT at that stage o f postnatal development. So at this stage, it is likely that most 
o f the adipokines start showing the patterns found in adult rodents, thus accounting for 
the high metabolic activity observed in internal depots o f adult rodents compared to 
subcutaneous WAT (Kelley, 2004). However, not all o f the observed changes in mRNA 
levels during early postnatal development could be explained in relation to the function 
o f these adipokines in rat WAT at this stage.
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The heterogeneity o f WAT and the differences between different depots, as previously 
discussed in Chapter 3 are thus evident in the current study as well. Although WAT 
undergoes major metabolic changes during early postnatal development, these probably 
affect specific depots in different degrees. Such differences may also be related to regional 
differences in the production o f adipose-derived factors, as previously reported 
(Mohamed-Ali, 1998), which also change during the course o f postnatal development, as 
specifically shown in the case o f leptin and adiponectin in this study.
Apart from WAT, BAT also plays an important role in the early postnatal development, 
especially soon after birth as it is the site o f non-shivering thermogenesis. This study 
demonstrates that ZAG is expressed in BAT o f rats by/or soon after birth. The mRNA 
and protein levels are at their peak at day 1, but fell significantly thereafter. O f all 
adipokines tested, ZAG’s reduction in BAT from day 3 onwards was the most dramatic, 
indicating that ZAG may have a role in the metabolic activities o f BAT at or soon after 
birth. Furthermore, ZAG has been shown to increase UCP-1 expression in mouse BAT 
(Bing et al., 2002) and in primary cultured brown adipocytes (Sanders &  Tisdale, 2004).
In addition to ZAG, the other five adipokines tested were expressed in BAT at day 1 
postnatally. Leptin, whose presence in BAT in rat neonates has previously been reported 
(Dessolin et al., 1997), gradually increased in BAT, peaked at day 10, and started 
declining thereafter. Very interestingly, depot difference analysis revealed that leptin 
synthesis is higher in BAT at day 1 compared to subcutaneous WAT. However, as 
mentioned above, by day 7, leptin expression in subcutaneous WAT is higher than in 
BAT. No changes were observed in adiponectin mRNA levels in BAT throughout the 
early postnatal development. On the other hand, similarly to ZAG, N G F, MCP-1 and 
IL-6 mRNA levels in BAT started decreasing during suckling, this being most dramatic 
at weaning. The increasing levels o f leptin in BAT throughout early stages o f postnatal 
development may support a previous suggestion that BAT thermogenesis may be 
involved in the control o f food intake in neonates. It was suggested that both in humans 
and rats a feeding episode occurs during an episode o f increased sympathetic nervous 
system activity that stimulates BAT thermogenesis and increases body temperature; BAT
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thermogenesis being important in the control o f meal size, relating it to thermoregulatory 
needs (Himms-Hagen, 1995 a &  b).
Finally, the fact that ZAG is mainly produced in the liver o f adult mice was further 
supported in the current study, as it was shown that from the very early stages o f 
postnatal development, there is a significant difference between ZAG mRNA levels in the 
liver and subcutaneous WAT. Contrary to what was observed in adipose tissue, ZAG 
mRNA levels in the liver were gradually increased during the early stages o f postnatal 
development, peaking at day 32 (-10-fold compared to day 1). This might indicate that 
levels o f circulating ZAG would also increase, although further studies on serum 
circulating levels are needed to clarify this notion.
In conclusion, ZAG is expressed in WAT and BAT o f rat neonates from day 1 
postnatally (or earlier), the subcutaneous depot being its main site o f production within 
adipose tissue. Its ontogenic pattern o f expression may be linked or contribute to the 
metabolic changes occurring within the tissues at different phases o f postnatal 
development. An interesting observation is that in contrast to most adipokines tested, 
ZAG levels are higher in WAT during the suckling period than after weaning, suckling 
being characterised by low lipogenic and high lipolytic activity within the depots, the 
reverse being the case after weaning. These results may suggest that ZAG might 
contribute to the high lipolytic and low lipogenic activity which characterises WAT 






Adipose tissue is now considered as a major endocrine organ, and more than fifty adipose 
tissue secreted factors, known as adipokines, have been identified so far, their number 
continually increasing. As already discussed in Chapter 1 (section 1.4), adipokines have 
numerous functions and are involved in a broad range of physiological conditions. 
However, many o f the functions and underlying mechanisms are still unknown. The 
complexity o f adipose tissue studies is due to the diversity o f the roles o f these factors and 
the fact that in a number of cases they are not specific to adipose tissue. In order to 
establish the secretory function o f adipose tissue, the key challenge after identifying a new 
secreted factor is to establish its role and to assess how its production is regulated with 
alterations in adiposity and energy flux, present in conditions such as obesity, fasting, and 
cachexia. ZAG, a lipid-mobilising factor, has been recently identified as a novel 
adipokine, the protein being secreted by human adipocytes (Bao et al., 2005). The 
studies in this thesis were thus designed to further explore ZAG function and regulation 
in adipose tissue using both in vivo (rodent models) and in vitro (3T3-L1 adipocytes) 
approaches.
7.2 Previous work
Little is known o f ZAG expression in adipose tissue and previous studies exploring the 
expression o f ZAG in rodents using northern blotting analysis, which is effective for the 
analysis o f highly expressed genes, had failed to detect ZAG mRNA in adipose tissue 
(Ueyama et al., 1992). However, RT-PCR and real-time PCR are much more sensitive 
methods for detecting an mRNA and it was shown in 2004 by Bing and co-workers that 
the ZAG  gene is actually expressed in mouse adipose tissue and murine adipocytes (Bing 
et al., 2004). That study formed the basis for the development o f the current work in 
different directions, as it was the first evidence that ZAG could have a local (possibly 
paracrine) role in adipose tissue. For example, since ZAG was detected in all major 
adipose tissue depots as part o f that study, it was o f interest to explore the possibility that 
there might be significant differences in the levels o f  its expression among specific depots,
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the same being the case for differences in ZAG levels in mature adipocytes and the 
stromal vascular fraction of these depots, both at the mRNA and protein level.
Studying ZAG expression and regulation in adipose tissue is significant for an additional 
reason. As discussed in detail in chapter 1, ZAG is identical to lipid-mobilising factor 
(LMF) and administration o f ZAG purified from the urine o f patients with cancer, leads 
to a significant decrease in body fat o f both normal and ob/ob mice as it increases fat 
breakdown while it does not affect muscle mass (Hirai et al., 1998). This lipolytic effect is 
mediated through the P3-adrenoreceptor (Russell et al., 2002). This led to the suggestion 
that ZAG could be a possible treatment for obesity (Tisdale, 2003), a chronic low-grade 
inflammatory state with considerable health consequences (Trayhurn &  Wood, 2004). 
Since the main obesity phenotype is the expansion of fat at different sites, understanding 
of the role o f ZAG in adipose tissue and in lipid metabolism could provide further 
insight into its function and potential. Studies so far have provided evidence that ZAG is 
involved in the induction of lipolysis in adipose tissue, but that ZAG could also exert its 
effects by inhibiting lipogenesis.
7.3 Current study
The studies presented in Chapters 3, 4, 5, and 6 were carried out in order to explore the 
expression and regulation o f ZAG in adipose tissue, both under normal and 
pathophysiological conditions. For this reason, two main approaches were used: in vivo 
studies in mice and rats, and in vitro studies using 3T3-L1 adipocytes. Following 
collection o f samples, both mRNA and protein levels were examined using real-time PCR 
and western blotting respectively. It would be expected in such a study to also measure 
circulating levels o f the protein o f interest. However, an Enzyme Linked Immunosorbant 
Assay (ELISA) kit for ZAG has not yet been commercially available and it was not one o f 
the aims o f this thesis to develop one. Although, it was initially attempted to assess 
changes in circulating levels by western blotting, these trials were not successful, as a 
number o f non-specific bands were detected on the blots, even at very low concentrations
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of protein, making it very hard to distinguish ZAG and particularly making it impossible 
to measure the intensity o f these bands by densitométrie analysis.
Furthermore, adipose tissue is not the main synthesis site for ZAG in the body, and 
adipose tissue most probably contributes a low percentage o f circulating ZAG. This is 
evident by previous studies which failed to detect ZAG in adipose tissue, but also by the 
current study. As discussed in Chapter 6, the difference between ZAG expression in the 
subcutaneous WAT and the liver (which is its main synthesis site) is very high from the 
early stages o f postnatal development. This sometimes has made studies on adipose tissue 
rather challenging, especially when studying a condition in which ZAG expression was 
suppressed, or when a certain agent applied to the adipocytes in vitro led to its 
downregulation. This is also likely to be the main reason for variation in some studies 
and lack of statistical significance, although a certain trend was evident. Availability o f 
larger groups o f samples could have possibly solved this problem.
In the following paragraphs, the main findings o f this thesis are summarised, together 
with mention o f some initial results from experiments which have not been presented in 
the Results Chapters. In addition, in most cases, ZAG expression was studied in reference 
to other adipokines, primarily leptin. Lepdn was mainly used as it is the most studied 
adipokine and its regulation under most conditions has been extensively examined, both 
in humans and rodents. In all cases, the results obtained for leptin were consistent with 
those already described by previous studies. These included the highest levels o f leptin 
being in mouse epididymal WAT, the adipocyte-specific expression, the acute 
downregulation by fasting, the increase in genetic models o f obesity and the increasing 
levels during early postnatal development. Other adipokines were also studied in certain 
experiments, such as adiponectin and IL-6, as both have established roles in metabolic 
regulation, insulin sensitivity and inflammation.
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7.4 ZAG expression in adipose tissue
It has been shown in the current study that ZAG is expressed in rodent liver, 
subcutaneous WAT and BAT from day 1 postnatally and in all other WAT depots as 
soon as they become sufficient to be sampled. Whether ZAG is also expressed prenatally 
has not been addressed yet, although it would be very interesting to explore whether it is 
expressed in the fetus. However, rodents would not be an ideal model for a study of that 
kind, as WAT depots develop primarily postnatally. Quantitative analysis during early 
postnatal development revealed that in WAT, weaning at day 21 induced a reduction in 
ZAG mRNA and protein levels, suggesting that ZAG could possibly be involved in early 
adipose tissue mass development. Furthermore, throughout early postnatal development, 
subcutaneous WAT appears to be the main adipose tissue site o f ZAG synthesis. 
However, as revealed from the experiments described in Chapter 3, in the adult mouse 
ZAG is most highly expressed in visceral fat, particularly omental. This is in line with the 
previous observation that rates o f lipolysis are higher in omental WAT, which is also 
characterised by high levels o f P3-adrenoreceptors; ZAG having been suggested to exert its 
lipolytic effect through this type o f receptor (Russell et al., 2002). There thus seems to be 
a switch at some point during development from high levels o f ZAG in subcutaneous to 
high levels in visceral fat. This is also the case for leptin, as has previously been reported 
(Rayner et al., 1997), and adiponectin, although in these cases the changes happen soon 
after weaning.
There is an ongoing debate and intensive research on what the differences in the 
expression levels o f most adipokines in different fat sites mean and whether this is 
associated with regional variations o f adipocyte function. Apart from morphological 
variations, different depots exhibit different metabolic characteristics, this differential 
expression o f adipokines being the major one. Furthermore, differences have been 
reported between species. For example, in the case o f leptin, although in adult rodents 
leptin is preferentially expressed in epididymal WAT, as also shown in the results 
presented in Chapter 3, in humans leptin levels are higher in subcutaneous compared to 
omental WAT (Masuzaki et al., 1995; van Harmelen et al., 1997; Zhang et al., 1999). It
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has been suggested that this regional variation in the expression o f leptin might play a 
role in controlling the size o f different fat depots (Montague et al., 1997; van Harmelen 
et al., 1997). In contrast, from some recent findings in our group, it has been shown that 
in the dog, although leptin is expressed in all major WAT sites, there are no specific 
inter-depot differences in its expression levels (Ryan, personal communication). Another 
well established difference between subcutaneous and visceral depots, as shown by both 
in vivo and in vitro investigations, is the regional variations in the lipolytic activity o f 
adipose tissue sites, the rate o f lipolysis being higher in the visceral, especially the omental 
region. The lipolytic Pi, 2 , 3  adrenoreceptors are most active in the visceral fat cells, while 
the antilipolytic insulin receptors, a 2 adrenoreceptors and adenosine receptors are most 
active in the subcutaneous adipocytes (Arner, 1995). However, the physiological 
significance o f these differences is still not fully understood. A study carried out on 
preadipocytes isolated from the stromal vascular fraction of adipose tissue in order to 
explore whether regional variations in adipocyte function are primary events or effects o f 
external factors derived from the circulation, suggested that omental and subcutaneous 
adipocytes might originate from precursor cells that are genetically different or that are 
programmed differentially by the surrounding tissue before their differentiation (van 
Harmelen et al., 2002).
Although for a factor to be classified as an adipokine, it does not have to be exclusively 
expressed in adipose tissue, it has to be established that it is expressed and secreted by 
mature adipocytes. In the initial study, ZAG had been detected by RT-PCR both in the 
mature adipocytes and stromal vascular fraction o f epididymal WAT. In the study 
described in Chapter 3, it was shown using quantitative analyses (real-time PCR and 
western blotting), that ZAG is equally expressed in the two fractions o f subcutaneous, 
epididymal and perirenal WAT. This means that other cells contribute to ZAG levels in 
WAT and indeed ZAG has previously been detected using immunohistochemical analysis 
in many types o f endothelial and epithelial cells (Tada et al., 1991). It would be 
interesting to further determine ZAG expression in the different types o f cells present in 
the stromal vascular fraction of adipose tissue depots; for example, whether it is expressed 
in the macrophages.
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In contrast to other adipokines, such as leptin and resistin, mouse ZAG may not function 
as a marker o f adipocyte differentiation. This is evident both by the presence o f ZAG in 
the WAT stromal vascular fraction, as a major part o f it consists o f undifferentiated or 
immature adipocytes, as well as by the data presented in Chapter 5, where it was shown 
that in 3T3-L1 cells the ZAG gene was expressed both pre- and post-differentiation. 
Contrary to that observation, a recent study in SGBS human cells has shown that ZAG is 
a marker o f early adipocyte differentiation (Bao et al., 2005). This might be attributable 
to the difference between mouse and human, as the homology between the two species is 
not particularly high and only reaches about 60%, apart from regions important in lipid 
metabolism where the similarity is 100%.
The present study also demonstrates that ZAG, both mRNA and protein, is expressed in 
mouse and rat BAT, an important site o f lipid utilization. As discussed in Chapter 1, 
BAT contributes to the regulation o f energy homeostasis through UCP-1, which 
uncouples mitochondrial respiration, thus generating heat (Ricquier &  Bouillaud, 2000). 
It has been shown that ZAG promotes lipid utilization via upregulation of BAT UCP-1 
mRNA and protein expression in normal mice (Bing et al., 2002) and in primary 
cultured primary adipocytes (Sanders &  Tisdale, 2004) stimulating oxygen uptake by 
isolated BAT (Hirai et al., 1998). The observation that ZAG expression is higher in rat 
BAT at day 1 postnatally, its levels being significantly reduced thereafter, could suggest 
that ZAG might have a role in the metabolic activities o f BAT at or soon after birth.
7.5 Regulation of ZAG expression in adipose tissue
The first pathophysiological condition to be studied was obesity and as demonstrated in 
Chapter 3, ZAG levels are reduced in genetic models o f obesity (ob/ob mouse and fa /fa  
rats). This is consistent with a recently published study, where it was shown that ZAG is 
reduced in obese women (Dahnlman et al., 2005). It is thus likely that there is a link 
between obesity and reduced ZAG expression and as previously discussed, this could be 
attributed to numerous reasons, such as the increased degree o f lipogenesis and the 
extensive loss o f p3 adrenoreceptors in WAT in both genetic and dietary obesity in mice
202
(Boschman, 2001). The downregulation of ZAG in obesity could also be partly explained 
by the fact that administration o f leptin in 3T3-L1 adipocytes induced a reduction in 
ZAG mRNA levels, while adiponectin had the opposite effect, as shown in Chapter 5. 
However, in the study on ob/ob mouse, it was only possible to analyse the mRNA levels, 
while ZAG protein was not measured due to limited samples. Further protein analysis 
would show whether these changes are also observed at the protein level.
In addition to obesity, whether diet has a role in the modulation o f ZAG expression in 
adipose tissue was examined. As described in Chapter 4, ZAG expression was studied in 
two different types o f nutritional manipulation. In the first case, animals were fasted for 
16 hours, while in the second, mice were fed a high-fat diet for 12 weeks. However, as 
shown in Chapter 5, a clear pattern in the changes o f ZAG expression as a result o f 
dietary changes failed to be established. ZAG mRNA levels in WAT were reduced as a 
result o f short-term fasting, although a similar change was not observed in protein levels. 
This observation appears to argue against a local role in lipid mobilization. In contrast, 
ZAG mRNA levels were significantly increased both in BAT and liver o f the same 
animals as a result o f food deprivation. Although it has been proposed in Chapter 5 that 
this could be a result o f an initial energy conservation mechanism, further experiments 
would be necessary to prove whether this is the case. These could include experiments in 
animals fasted for a longer period, as well as experiments in which re-feeding would 
follow the fasting period. Furthermore, since after 16 hours, the loss observed in total 
body weight is mostly due not to actual loss o f fat, the decrease observed in ZAG mRNA 
levels could actually be because o f another primary effect o f fasting.
On the other hand, a high-fat diet induced a depot-specific response in ZAG mRNA 
levels, the levels reducing in subcutaneous while increasing in epididymal WAT. The fact 
that ZAG is sensitive to changes in the diet is supported by the observation in Chapter 6 
that ZAG mRNA and protein levels in all WAT depots tested reduced as a result o f 
weaning; weaning represents a switch from a high-fat diet characteristic o f milk to a high- 
carbohydrate diet. This sensitivity to dietary alterations is further illustrated by the fact 
that although after 12 weeks, the animals kept on a high-fat diet were obese, the effects
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observed were not the same as in WAT depots from genetically obese models. However, 
in all cases, other mechanisms are involved, so using the current data it is not possible to 
fully explain the observed changes in ZAG levels.
The observation that adiponectin induces ZAG gene expression in vitro might be 
suggestive o f ZAG’s anti-inflammatory role in adipose tissue. Indeed, there is some 
further evidence arising both from studies described in this thesis and the parallel studies 
in human adipocytes that ZAG is involved in the inflammatory response, its effect being 
most probably anti-inflammatory. Firstly, ZAG levels are reduced in adipose tissue depots 
o f genetic models o f obesity. Since obesity is now recognised as a low-grade inflammatory 
state, mainly due to the elevated circulating levels o f several markers o f inflammation, 
such as T N F a and acute-phase proteins (Trayhurn &  Wood, 2004), it is possible that 
similarly to adiponectin, which is known to be reduced in obesity and has an established 
anti-inflammatory role, ZAG may also have anti-inflammatory properties.
Furthermore, as shown in Chapter 5, 15d-PGJ2, a potent anti-inflammatory agent, 
strongly induces ZAG gene expression, while both PGE2 and PGF2ot, which act as 
inflammatory mediators (Straus &  Glass, 2001), inhibit its expression in 3T3-L1 
adipocytes in a dose dependent manner. The observation that PGE2 induces IL-6, an 
inflammatory regulator in adipose tissue, further supports this suggestion. However, both 
the pro-inflammatory cytokines T N F a  and IL-6 did not affect ZAG mRNA levels in 
3T3-L1 adipocytes, although the former induced a significant dose-dependent decrease in 
human SGBS cells (Bao et al., 2005). Similarly, LPS administration to the 3T3-L1 
adipocytes had no effect. In contrast, studies in WAT samples from mice treated with 
LPS for 4 hours showed a significant decrease in ZAG mRNA levels in epididymal and 
perirenal WAT, while there was no change observed in ZAG levels in WAT o f mice 
treated with LPS for 12 hours, and thus a connection failed to be established (Tzanavari, 
unpublished observations). A role for ZAG as an anti-inflammatory agent in adipose 
tissue is further supported by the finding that rosiglitazone, a selective PPARy agonist, 
has a stimulatory effect on ZAG gene expression; this also indicates that the PPARy 
nuclear receptor is involved in the regulation o f ZAG synthesis.
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Apart from rosiglitazone, A12-PGJ2 and 15d-PGJ2, the two metabolites o f PGJ2, have 
strong stimulatory effects on ZAG gene expression. While 15d-PGJ2 is the highest 
affinity natural ligand for PPARy identified so far, A12-PGJ2 also binds PPARy, but with 
a much lower affinity (Forman et al., 1995). The reasons for the different effects of 
prostaglandins on ZAG expression in adipocytes could be attributed to their various 
functions identified so far and their involvement in many pathophysiological conditions. 
The main finding, however, o f this work is that prostaglandins are key regulators o f ZAG 
gene expression in adipose tissue and have the greatest effects on its levels identified in the 
studies carried out for this thesis. The effects o f prostaglandins on different adipokines 
have just recently started being explored and so far it has been reported that 
prostaglandins influence the expression o f some key adipokines as well, including 
adiponecdn, IL-6, MCP-1 and N G F (Bullo et al., 2005; Peeraully et al., 2006). The 
regulation of ZAG by prostaglandins seems worth further exploration by studying in the 
first instance ZAG levels in the media o f the adipocytes and then by conducting a time- 
course analysis o f their effects on ZAG expression.
One of the problems encountered during the work presented in this thesis was with the 
quantification o f protein levels from western blots and as a result, in a few studies, such as 
fasting, the changes observed at the mRNA level were not mirrored by protein analysis, 
especially when changes were not substantial. One reason for that could be due to the fact 
that real-time PCR is a much more sensitive technique than western blotting. Secondly, 
although for mRNA analysis five to eight samples were used for each group, four to five 
samples were usually used for protein work (for practical reasons). Finally, these 
variations could be due to post-transcriptional events or time lag in mRNA levels leading 
to changes in protein and differential roles o f secretion. In all cases however, equal 
protein loading was confirmed by Ponceau S staining.
7.6 Future work
The work presented in this thesis has laid the foundations for future studies. Some have 
already been mentioned above as they would complete already constructed experiments,
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such as assessing the changes in ZAG circulating levels in all the animal models, as well as 
in the media from adipocytes treated with different agents. Furthermore, and as 
aforementioned, interesting information on ZAG expression and regulation in adipose 
tissue would be provided by studies on primary adipocytes, as they would show whether 
the inter-depots differences in ZAG expression observed in Chapters 3 and 4 are primary 
events. A further issue is that as demonstrated in Chapter 3, ZAG is equally expressed in 
mature adipocytes and the stromal vascular fraction of WAT depots, consisting of 
preadipocytes and a number o f other cell types, including macrophages. Considering that 
ZAG could be an inflammation-related adipokine, it is important to further explore the 
relative importance o f both fractions in ZAG regulation in the obese state.
It has been discussed in Chapter 1 (section 1.2.1.5) that knockout mice have so far been 
useful tools in the study o f adipose tissue, as in the case o f PO M C and M C3R knockout 
models (Butler &  Cone, 2003). The construction of a knockout mouse in vivo or RNA 
silencing in vitro could provide useful information on the function o f ZAG in adipose 
tissue and the organism as a whole.
In many occasions, and as has also been shown in Chapter 5, where it was demonstrated 
that both leptin and adiponectin have an effect on ZAG expression, these factors affect 
one another. Similarly, ZAG stimulates the expression o f adiponectin in transfected 3T3- 
L1 cells (Gohda et al., 2003). This, as well as other similarities observed between the two 
adipokines, suggests a functional relation between them. Furthermore, although there are 
numerous such observations in the literature, it is worth mentioning that T N F a has, for 
example, been shown to have major effects on the expression o f many adipokines in 
adipocytes (Wang &C Trayhurn, 2006), the same being the case for prostaglandins (Bullo 
et al., 2005). Thus, in order to be able to unfold the complexity o f the endocrine 
function of adipose tissue, it is crucial to try and understand the relations between 
different adipokines.
Furthermore, it has previously been shown that there is a 10-fold increase in ZAG 
mRNA levels in white adipose tissue of MAC 16 adenocarcinoma bearing mice, a widely
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used model for studying cancer cachexia, compared to control mice (Bing et al., 2004). 
Cachexia also characterises other pathophysiological conditions, including AIDS and 
sepsis. It was observed while carrying out the work described here that ZAG mRNA 
levels were 20-fold higher in the epididymal WAT o f a sepsis model mouse, in which 
sepsis was induced by faecal material injection (Tzanavari, unpublished observations). 
However, these results have not been presented here, as they suggested that ZAG 
expression could also be induced due to stress (injection) and further work to explore 
whether this is the case has not been carried out yet due to time restrictions. It would, 
however, be very interesting to further investigate this.
Finally, so far, all evidence on ZAG expression and regulation in adipose tissue comes 
from studies in rodents and humans. Considering the differences among different species, 
useful information could also be provided from studies on ZAG regulation in adipose 
tissue of other species. Companion animals, especially the dog, have started being used in 
adipose tissue research due to the increasing occurrence o f obesity in these animals. It has 
recently been shown that several key adipokines, including leptin, adiponectin, PAI-1 
and IL-6, are expressed in canine adipose tissue and dog mature adipocytes (Eisele et al., 
2005). Very recently and as part o f some studies conducted in our group on the dog, 
ZAG has been detected by RT-PCR in all major dog WAT depots (Ryan &  Tzanavari, 
unpublished observations).
7.7 Concluding remarks
In conclusion, the work presented in this thesis has provided key information on the 
regulation and possible role o f ZAG in adipose tissue, as certain aspects that could 
contribute to its regulation were examined for the first time. The findings presented 
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